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Abstract 
Research suggests that consumption of slow release or low glycaemic index (LGI) 
carbohydrates is beneficial in patients with heart disease, diabetes and insulin resistance, 
and has a role in reducing obesity. In this thesis, I investigated whether ingestion of a LGI 
compared with a high GI (HGI) diet, provides benefits over and above those of traditional 
healthy eating and weight loss on coronary heart disease (CHD) risk, and whether this 
dietary intervention facilitates weight maintenance after weight loss. 
Two groups of subjects at risk of CHD, were advised to follow a diet which met healthy 
eating and weight loss requirements but differed in GI for 12 weeks. The LGI group 
reduced their 24-hour and overnight glucose profiles. Similarly, men at risk of CHD were 
asked to follow the same dietary manipulation over a 6-month period, and the LGI 
compared with the HGI group had reductions in total cholesterol and insulin resistance and 
on 24-hour blood pressure. Arterial compliance, another CHD risk factor, was also 
assessed; however, further measurements are needed before drawing conclusions. 
A third study in people who had recently lost weight and were then randomised to a HGI 
or LGI diet, suggested that in the setting of a healthy eating diet, manipulating diet GI does 
not have an effect on body weight maintenance. However, the LGI group compared with 
the HGI group consumed less energy than their estimated requirements over a 4-month 
period, which may be due to the satiating effects of the LGI diet. Nevertheless, since this 
was a pilot study, a bigger sample size is required for further exploration of these findings. 
The results of this thesis suggest that a LGI diet reduces CHD risk over and above that 
achieved by healthy eating and weight loss. Likely mechanisms include improvements in 
insulin sensitivity and glucose profile. In the setting of a healthy eating diet, however, 
manipulating diet GI does not seem to provide an extra benefit on body weight 
maintenance. Further data collection is necessary while future work should include 
assessment of changes in arterial compliance, postprandial lipid metabolism and appetite- 
regulating gut peptides following long-term consumption of a LGI compared with a HGI 
diet and an exploration towards identification of GI biomarkers. 
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1.0 Brief Overview of Introduction 
Dietary carbohydrates (CHO) are an essential energy and nutrient provider with significant 
effects on satiety and insulin sensitivity as well as on risks of coronary heart disease 
(CHD) and obesity development. The classification of CHO and their dietary roles are 
discussed in Section 1.1. CHO-containing foods may be classified according to the blood 
glucose response they produce following ingestion; termed 'Glycaemic Index' (GI) 
(Section 1.2). Foods containing slowly digested CHO are termed low GI (LGI) and those 
containing quickly digested CHO are termed high G1 (HGI). There is a positive correlation 
between the postprandial glucose and insulin responses of foods and their GI (Section 
1.2.1). The factors determining a food's GI are discussed in Section 1.2.2 while the 
application of GI to mixed meals is discussed in Section 1.2.3. The mechanisms by which 
manipulating dietary GI may affect glucose and cholesterol metabolism are presented in 
Section 1.2.4. Section 1.3 introduces the Glycaemic Load (GL) defined as the product of 
GI and amount of CHO of a food, while Section 1.4 presents insulin, the main hormone 
controlling CHO metabolism and its principal actions. 
Since one of the aims of this thesis was to investigate the role of dietary GI on CHD risk, 
CHD is introduced in Section 1.5. The main CHD risk factors as well as methods of CHD 
risk assessment are discussed in Sections 1.5.1-1.5.4. Recommendations on CHD 
prevention and how diet, exercise and dietary GI manipulation may affect CHD risk are 
presented in Section 1.5.5. Arterial compliance, which is one of the CHD risk factors 
assessed in this thesis, is introduced in Section 1.6 and methods of assessment are also 
discussed. A finiher aim of this work was to investigate how manipulating dietary GI 
affects weight maintenance following weight loss, thus in Section 1.7.1-1.7.4, obesity, its 
prevalence, causes and consequences are introduced. Section 1.7.5 deals with obesity 
treatment including weight loss and maintenance. In Section 1.7.6, the available evidence 
linking GI and obesity is presented. An introduction to appetite and CHO-based feeding 
models are presented under Sections 1.8-1.8.1 while studies linking appetite and GI are 
discussed in Section 1.8-2. The hypothesis and aims of this thesis are presented in Sections 
1.9 and 1.10. 
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1.1 Dietary Carbohydrates 
1.1.1 Definition of Carbohydrates 
Carbohydrates (CHOs) or 'hydrates of carbon' are chemical compounds of carbon, 
hydrogen and oxygen only, in the ratio of Cn(H20)nq the basic unit of which is 
monosaccharide (a single sugar unit) (Bender 1997). 
1.1.2 Carbohydrate Classification 
CHOs are classified based on their molecular size (degree of polymerisation (DP)), into 
sugars (DP 1-2), oligosaccharides (DP 3-9) and polysaccharides (DP 10+) (Table 1.1). 
Further subdivision can be made on the basis of monosaccharide composition (Joint 
FAO/WHO Expert Consultation 1998). Depending on their gastrointestinal handling, 
CHOs can be referred to as 'glycaemic CHOs' i. e. CHOs that are digested and absorbed in 
the small intestine and cause a rise in blood glucose (e. g. free sugars, maltodextrins and 
starch) and 'non-glycaemic' CHOs, i. e. those (or their components) that are not absorbed 
in the small intestine and therefore move down to become fermented in the colon with the 
production of short chain fatty acids (SCFA), methane and hydrogen gas. Examples of the 
latter are resistant starch, non-starch polysaccharides and sugar alcohols (Englyst & 
Englyst 2005). 
Table 1.1: Carbohydrate Classification (adapted from (Joint FAO/WHO Expert 
Consultation 1998) DP = degree of polymerisation 
Class (DP) Subgroup Examples 
Sugars (1-2) Monosaccharides Glucose, galactose, fructose 
Disaccharides Sucrose, lactose, trehalose 
Polyols Sorbitol, mannitol 
Oligosaccharides Malto-oligosaccharides Maltodextrins; 
(3-9) Other oligosaccharides Raffmose, stacchyose, fructo- 
oligosaccharides 
Polysaccharides Starch Amylose, amylopectin, modified 
(>9) starches 
Non-starch Cellulose, hemicellulose, pectins, 
polysaccharides hydrocolloids 
3 
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1.1.3 Resistant Starch 
Resistant starch (RS), an example of a non-glycaemic CHO is defined as 'starch and starch 
degradation products not absorbed in the small intestine of healthy humans' (Englyst & 
Cummings 1990). A suggested classification of RS is as follows: physically enclosed 
starch e. g. within intact cell structures (RSI) in foods such as bulgur wheat, legumes and 
pumpernickel bread, RS2 which is starch resistant to amylolytic digestion because of its 
compact unbranched nature such as amylose, retrograded amylose (RS3) formed by the 
cooling of gelatinised high-amylose starch, and modified starches (RS4) (Englyst & 
Cummings 1990; Englyst et al. 1992). 
1.1.4 Dietary Fibre 
Trowell defmed dietary fibre as 'the cellular walls of plants that are resistant to hydrolysis 
by the enzymes of man' (Trowell 2006). However, the non-digestibility of the plant cell 
walls will vary from person to person and will be affected by food storage, cooking, 
chewing, ripeness and the presence of other foods (Cummings & Stephen 2007). The 
United Nations' Food and Agriculture Organisation (FAO) and the World Health 
Organisation (WHO) Scientific Update meeting on CHOs in human nutrition in July 2006 
agreed that the definition of dietary fibre should be more clearly linked to health. Thus, the 
following deflnition was proposed: 'dietary fibre consists of intrinsic plant cell wall 
polysaccharides'(Cummings & Stephen 2007). Non-starch polysaccharides (NSPs) are 
4macromolecules consisting of a large number of monosaccharides (glucose) residues 
joined to each other by glycosidic linkages' (IAU-IUPAC Joint Commission on 
Biochemical Nomenclature 1982) which comprise of a mixture of many molecular forms, 
of which cellulose, a straight chain 0 1-4-linked glucan (DP 103-106) is the most widely 
distributed. The plant cell wall polysaccharides can be determined using the enzymatic- 
chemical method. This method is designed to remove all starch and thus measures NSP as 
the sum of chemically identified NSP constituent sugars (Englyst et al. 1994). The 
advantage of measuring NSP is that it is not in itself created or destroyed by normal food 
preparation or storage techniques and thus it is a consistent indicator of plant cell-wall 
material. Any added preparations of NSP will also be measured (Englyst et al. 2007). 
Dietary fibre may also be measured using the enzymatic-gravimetric method, which is 
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based on the 'indigestibility' approach (AOAC 2007; Englyst et al 2007). This aims to 
measure the sum of indigestible polysaccharides and lignin, and in practice includes RS, 
the amount of which may be affected by food processing and the addition of RS 
preparations, as well as non-CHO materials such as lignin and food processing artefacts 
such as Maillard reaction products (Englyst et al 2007; Tuohy et al. 2006). The dietary 
fibre reported in this thesis refers to that measured using the enzymatic-chemical method. 
1.1.5 Soluble and Insoluble Fibre 
The terms soluble and insoluble fibre are based on the fractional extraction of NSP which 
can be controlled under laboratory conditions by changing the pH of solutions (Joint 
FAO/WHO Expert Consultation 1998). In the initial understanding of the properties of 
dietary fibre, these terms proved very useful, allowing a simple division of NSPs into those 
that were soluble and had effects on glucose and lipid absorption in the small intestine 
(Lairon 1994), and those that were insoluble and thus more slowly and incompletely 
fermented and had more pronounced effects on bowel habit (Cummings 1997). However, 
their physiological differences are not always so distinct; for example, much insoluble fibre 
is completely fermented and not all soluble fibre has effects on glucose and lipid absorption 
and moreover, their separation is dependent on the conditions of extraction (Asp et al. 
1992; Cummings & Stephen 2007). It should be noted that a lot of the earlier work was 
done on isolated gums or extracts of cell walls whereas fibre exists together mostly in intact 
plant cell walls (Cummings & Stephen 2007). 
1.1.6 Carbohydrate Intake Recommendations and Dietary Roles 
The FAO/WHO Expert Consultation on CHOs in human nutrition, recommend that CHOs 
provide at least 55% of total energy intake from a variety of sources and that excessive 
intake of sugars which compromise micronutrient density should be avoided (Joint 
FAO/WHO Expert Consultation 1998). The FAO/WHO consultation endorses that the 
bulk of CHO-containing foods consumed should be rich in NSP and with a low GI (Joint 
FAO/WHO Expert Consultation 1998). 
5 
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The dietary roles of CHOs are shown in Table 1.2. Their most important role is to provide 
energy, thus CHO-containing foods are the staple foods in most countries (Joint 
FAO/WHO Expert Consultation 1998) with significant effects on satiety (Blundell et al. 
1994). Additionally they are an important vehicle for protein intake and a source of B 
vitamins and minerals (calcium, magnesium, potassium, phosphorus, selenium, 
manganese, zinc and iron) (Joint FAO/WHO Expert Consultation 1998). In particular, 
wholegrain CHO foods are important sources of fibre, vitamin E, antioxidants and 
phytoestrogens, found in their bran and germ components (Anderson et al. 2000). The 
fructose and glucose CHO moieties contribute to protein glycosylation and possibly the 
ageing process (McDonald 1995). 
In heart disease prevention, CHOs may have both a direct role by improving insulin 
sensitivity and glucose tolerance (Wolever 2003), and an indirect role by displacing other 
nutrients such as fat (Joint FAO/WHO Expert Consultation 1998). Foods based on CHO 
are usually, but not always, less energy dense than high fat foods which can limit energy 
intake and reduce the risk of obesity (Stubbs et al. 2001) and thus the associated co- 
morbidities including heart disease. However, the effectiveness of high CHO, low fat diets 
in heart disease prevention has been questioned (Willett 2000), since replacing saturated fat 
with CHOs causes reductions in total cholesterol and low density lipoprotein (LDL) 
cholesterol but also in high density lipoprotein (HDL) cholesterol and thus minimal change 
in the ratio of total cholesterol to HDL cholesterol (Mensink & Katan 1992). The effect of 
cholesterol on CHD is discussed in Section 1.5.3.5. 
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Table 1.2: Roles of Dietary Carbohydrates (adapted fi-orn (Curnmim4s et al. 1997) 
Energy Provision 
Enhancement of Satiety 
Blood Glucose and Insulin Control 
Protein Glycosylation 
Bile acid Dehydroxylation 
Laxative 
Through Fermentation: Hydrogen/Methane Production 
Increase in Microbial Biomass 
Control of Colonic Epithelial Cell Function 
Selective Stimulation of Microbial Growth (e. g. Bifidobacteria) 
1.2 Glycaemic Index 
The GI is a numeric classification of CHO foods based on their glycaernic response i. e. the 
rate of CHO absorption (Jenkins et al. 1981). It is derived in 1-ij, o from the blood glucose 
2-hour incremental area under the curve (IAUC) following consumption of a portion of the 
tested food containing 50g available CHO compared to a 50g CHO portion of a standard 
food (glucose or white bread) taken by the same subject (Jenkins et al 1981; Joint 
FAO/WHO Expert Consultation 1998). Available CHO is the surn of available sugar, 
starch, oligosaccharides and maltodextrins and excludes dietary fibre (Barclay et al. 2005). 
GI is defined as: (Joint FAO/WHO Expert Consultation 1998) 
GI = (lAUC for test food containing 50g available CHO)/ 
(lAUC 50g standard food) x 100 
Where IAUC = Incremental Area Under the Curve (i. e. area above fasting concentrations) 
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There is a direct correlation between the food's glycaernic and insulinaernic response, also 
referred to as Insulin Index, calculated in the same way as the GI by using the 2-hour 
postprandial insulin IAUC rather than the glucose IAUC (Bomet et al. 1987). 
1.2.1 Glycaernic Index Classification 
CHO-containing foods can be ranked according to their glucose response as low, medium 
or high GI although the cut-off values are arbitrary. The most widely acceptable 
classification is as follows: 
low GI: 5 55 e. g. lentils, beans, oats, pasta, apples 
medium GI = 56-69 e. g. seeded breads, sweet potato, basmati rice and 
high GI ý: 70 e. g. white or wholemeal bread, baked potato, arborio, rice 
(Foster-Powell et A 2002) 
1.2.2 Factors Determining a Food's Glycaemic Index 
The GI of a food is determined by a complex interaction of factors, including the physical 
and chemical properties of foods, the rate of CHO digestion, the rate of gastric emptying, 
the presence of other nutrients or anti-nutrients, the insulin response elicited by the food, 
and others; such that the GI reflects the combined effect of all the properties of a food or 
meal that influence and rate of influx and removal of glucose from the circulation (Englyst 
& Englyst 2005; Wolever 2006). Hence, a GI value is an in vivo measurement and does 
not always correlate with in vitro measurements of glycaemic response since the latter 
cannot fully account for all the factors that determine a GI value (Brand-Miller & Holt 
2004). It should also be noted that not all the food factors or mechanisms that determine 
the glycaemic response to a food or meal are equally beneficial to health. 
Starting with sugars, glucose, a monosaccharide, is rapidly digested (Cummings et al 1997) 
and is used as the reference food and assigned a GI of 100, whereas sucrose and lactose 
(disaccharides) have a lower GI because of their fructose and galactose moieties 
respectively, which are removed rapidly by the liver from the portal blood and enter the 
peripheral circulation in only small amounts (Gannon et al. 2001; Nuttall et al. 2000). The 
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reduced GI of dairy products is probably a combination of their lactose content and their 
protein content, since milk proteins stimulate insulin release which results in lowering of 
blood glucose concentrations (Nilsson et al. 2004). 
The GI of starchy foods is influenced by the physical and chemical properties of the starch 
granules. Starch is composed of the linear, compact-structured 1,4-cc-linked glucose chains 
(amylose) and the highly branched 1,4; 1,6-cc-linked glucose chains (amylopectin). The 
proportions of amylose and amylopectin in starchy foods are variable and can be altered by 
plant breeding. CHOs with a high amylose content yield less glucose molecules on 
hydrolysis (Bjorck & Liljeberg-Ehnstahl 2003) and thus have a lower GI than those with a 
high amylopectin content (Englyst & Englyst 2005; Miller et al. 1992). For example, 
different kinds of rice vary widely in amylose and amylopectin ratios (Kennedy et al. 2003) 
which largely explains the wide range of GI values of this starchy food (Foster-Powell et al 
2002). Whole grains, when largely intact, have a low GI, the main mechanism being the 
botanical encapsulation of starch and/or the limited extent of starch swelling leading to a 
reduced rate of amylolysis (Bjorck & Liljeberg-Elmstahl 2003). For example kernel-based 
breads are usually characterised by a low GI (LiIjeberg & Bjorck 1994). However, 
wholegrain products contain a variable proportion of intact grains. Additionally, food 
processing, such as milling of whole grains, may destroy the cell wall structure which 
would normally have a structural role in maintaining the integrity of the cells, and this may 
increase the rate of starch hydrolysis (Bjorck & Liljeberg-Ehnstahl 2003) and thus GI. 
Naturally encapsulated starch also accounts for which beans and lentils remain largely 
intact until they reach the large bowel where they undergo fermentation and thus the rate of 
hydrolysis is slowed and GI is lowered. On the other hand, some polysaccharides, for 
example, those present in instant potato, result in a high glycaemic response because of 
their rapid and near complete digestion and absorption in the small intestine (Venn & 
Green 2007). 
Food processing, the cooking method and duration also affect the food's glycaemic 
response. Processing and cooking lead to hydration of the starch granules i. e. 
gelatinisation and disruption of the starch structure (Collings et al. 1981; Colonna et al. 
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1992), while storage can result in formation of RS which is more resistant to enzymic 
hydrolysis (Englyst et al 2005). For example, by parboiling cereals such as rice and bulgur 
wheat (cracked wheat) their GI value is reduced (Jenkins et al. 1986) while when boiled 
potato is allowed to cool, such as in a potato salad, its GI is lowered probably due to the 
formation of RS (Englyst & Cummings 1987). Changing the temperature and duration of 
cooking can also reduce the GI; for example, low-temperature, long-duration baking 
promotes growth of crystalline amylose (annealing) (Eerlingen et al. 1993) and increases 
the RS content of breads made using high-amylose wholegrain barley flours. The 
combination of these baking conditions and the high amylose flour results in a reduced 
glycaemic response (Akerberg et al. 1998). In addition to the effect of processing, porridge 
made from rolled oats has a lower GI than that made from processed quick-cooking oats 
also because of its content of the viscous fibre P-glucan which forms gelatinous gels in the 
stomach. This results in delayed gastric emptying and limits enzymatic hydrolysis in the 
small intestine by restricting access to the food bolus (Jenkins et al. 1978). Adding guar 
gum to foods also has the same effect when present in sufficient quantities (Tappy et al. 
1996). However, it should be noted that the GI of a food cannot be predicted from its fibre 
content (Jenkins et al. 1983), for example the GI of wholemeal bread and white wheat 
bread is very similar (Foster-Powell et al 2002). 
The presence of anti-nutrients such as phytic acid, lectins and tannins reduces the rate of 
food digestion (Thompson et al. 1984; Yoon et al. 1983), while fat and protein also modify 
the glycaemic response of a food (Chapter 1, Section 1.2.3). Other factors also affect the 
GI of a food. For example, organic acids such as those present in sour-dough breads, 
reduce the rate of gastric emptying and may be one of the mechanisms for their low 
glycaemic response (LiIjeberg & Bjorck 1998). Table 1.3 gives a summary of the main 
factors determining the food's GI. 
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Table 1.3: Main Factors Determining a Food's Glycaemic Index 
(adapted from (Jenkins et al. 2002a) 
Factors affecting the rate of digestion (i. e. enzyme susceptibility): 
Processing and storage (e. g. milling of whole grains, cooling and re-heating potato) 
Cooking method and duration affects degree of hydration (boiling pasta, parboiling rice) 
Particle size and food form (e. g. tabouli, couscous, pasta; affected partly by chewing) 
Food matrix and chemical structure (e. g. legumes) 
Starch structure and properties (e. g. content of amylose and amylopectin) 
Presence of viscous water soluble fibre (e. g. oats) 
Presence of retrograded starch (i. e. recrystallisation of starch molecules) 
Factors that may delay the gastric emptying rate: 
Presence and amount of fat and protein 
Presence of viscous soluble fibre acting as a physical barrier to starch digestion 
Presence of retrograded starch 
Presence of antinutrients, enzyme inhibitors, phytates, lectins, tannins 
1.2.3 The Glycaernic Index of Mixed Meals 
The addition of fat to a meal lowers its GI by increasing the viscosity of the intestinal 
contents and delaying gastric emptying (Collier et al. 1984; Cooke 1975), while the 
addition of protein induces the secretion of gastric inhibitory polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) which increase the amount of insulin secreted (Nuttall et 
al. 1984), but may also prevent glycolytic enzymes from digesting the CHO (Bomet et al 
1987). This has led to concerns regarding the applicability of GI in mixed meals (Xavier 
Pi-Sunyer 2002). However, even for mixed meals, the relative GI response of one meal to 
another does not change. For example, a meal containing lentils will still have a lower GI 
than a meal containing white bread (Wolever & Jenkins 1985a; Wolever et al. 1985b). It is 
of note that some of the studies questioning the use of GI in mixed meals either used an 
inappropriate methodology for GI calculation (Hollenbeck et al. 1988), or large amounts of 
fat (Henry et al. 2006), or assigned possibly incorrect GI values to foods (Flint et al. 2004). 
This discrepancy was resolved in a recent study where the mixed meals' CHO content and 
GI together explained about 90% of the variation in the mean glycaemic response while 
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protein and fat had negligible effects (Wolever et al. 2006). Furthermore, in a previous 
study of mixed meals varying widely in energy, CHO, fat and protein, 85% and 90% of the 
postprandial glucose and insulin response respectively were explained by the amount and 
GI of the meal CHO (Wolever & Bolognesi 1996a). 
1.2.4 Possible Mechanisms of Action of Low Glycaernic Index 
Foods 
As discussed in Section 1.2.2, a number of factors determine a food's GI. Similarly, since 
there is a wide variety of LGI foods, the mechanisms through which they exert their action 
are also multiple and depend on their physical properties and composition. Moreover, not 
all mechanisms are known and a number of foods or food groups may exert their effects 
through a combination of mechanisms. Some examples of ways LGI foods may exert their 
actions are given below while the effects of HGI foods are also discussed. 
LGI foods characterised by slow glucose release such as lentils and pasta result in a slower 
and more consistent insulin release which may also affect postprandial lipid handling. The 
effects of reducing glucose release were shown by reproducing this effect either by sipping 
a glucose drink as opposed to taking it in one go, or by increasing the frequency of an 
isocaloric meal, processes that led to reductions in glucose and insulin responses as well as 
C-peptide and GIP concentrations (Jenkins et al. 1990; Jenkins et al. 1992). The reduction 
in insulin release and long-term improvement in insulin sensitivity attributed to LGI foods 
has also been shown to cause a prolonged suppression of free fatty acids (FFAs) and 
triacylglycerol (TG) concentrations and improve glucose handling during the next meal 
(Jenkins et al 1992), termed the 'second meal effect' (LiIjeberg & Bjorck 2000). Thus 
slow glucose release may have metabolic implications for the postprandial period of both 
the current and the subsequent meal. 
The high content of water soluble or viscous fibre, characteristic of some LGI foods such 
as oats, barley and rye is one of the mechanisms by which these foods result in delayed 
gastric emptying and a slower rate of digestion and thus a reduced postprandial glycaemic 
and insulinaemic response (Jenkins et al. 2000). Moreover, soluble fibre causes impaired 
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bile acid and cholesterol reabsorption from the ileum (Jenkins et al. 1993). Additionally, 
the reduction in insulin secretion which has been shown to occur following consumption of 
LGI foods (Ostman et al. 2006; Wolever & Mehling 2002), may lead to a lower insulin- 
stimulated 2-hydroxy-2-methylglutaryl-CoA (HMG-CoA) reductase activity, which is the 
rate limiting enzyme in cholesterol synthesis (Rodwell et al. 1976) resulting in cholesterol 
reduction. A meta-analysis of 67 trials found that isolated fibre sources (pectin or guar 
gum) or fibre enriched ingredients (oat bran or psyllium) reduce LDL cholesterol but have 
no effect on HDL cholesterol or TG concentrations (Brown et al. 1999). 
LGI foods such as beans and lentils, which escape digestion in the small bowel and 
undergo colonic fermentation result in the production of SCFAs (acetic acid, propionic 
acid and butyric acid) which have a range of metabolic effects (Cummings & Macfarlane 
1991; Jenkins et al. 1987a; Jenkins et al. 1998). Butyric acid plays a major role in 
colonocyte metabolism (Topping & Clifton 2001), acetic acid is the primary substrate for 
hepatic fatty acid and cholesterol synthesis (Wolever et al. 1989), whereas propionic acid 
inhibits enzymes involved in the cholesterol synthesis pathway (Rodwell et al 1976) and 
redistributes cholesterol from plasma to liver in animals (Illman et al. 1988). Thus the 
ratio of acetic acid to propionic acid produced from fermentation determines the effect of 
colonic SCFAs on blood lipids (Wolever et al. 1996b). Propionic acid supplementation in 
humans has been shown to reduce glucose concentrations and improve insulin sensitivity, 
as well as increase HDL cholesterol, thus suggesting an effect on hepatic CHO metabolism 
which possibly involved reduction of FFAs (Venter et al. 1990). Propionic acid also has 
some regulatory functions in hepatic CHO metabolism as it stimulates both 
gluconeogenesis (generation of glucose from non-sugar substrates) and glycolysis (glucose 
oxidation) in rats (Veech et al. 1986). Acetic acid i. e. vinegar may contribute to the second 
meal effect by reducing the postprandial FFA concentrations as shown both by ingestion of 
LGI foods (Brighenti et al. 2006) and also by rectal infusions of this SCFA (Wolever et al 
1989). The detrimental effects of high levels of FFAs are discussed in Chapter 1, Section 
1.5.3.2. 
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On the other hand, consumption of HGI CHOs has been hypothesised to exaggerate tile 
normal anabolic responses to eating, by causing hyperglycacnila which stimulates insulin 
and suppresses glucagon release. The high insulin-to-glucagon ratio results in a higher 
uptake of nutrients by insulln-responsive tissues and Subsequent stimulation of 
glycogenesis (generation of glycogen) and lIpogcnesIs (fatty acid production) and 
suppression of gluconeogenesis and lipolysis (fat breakdown) (Ludwig 2002). According 
to this hypothesis, two to four hours after a HGI meal, absorption of nutrients from the 
gastrointestinal tract declines, but the effects of tile high nisuln-i-to-glucagon ratio persist, 
causing a rapid fall of blood glucose often into the hypoglycaernic range. Ludwig (2002) 
suggests that this triggers the release of couritcrregulatory hormones In tile late 
postprandial phase (4-6 hours after a HGI meal) to restore euglycaen-da via stimulating 
glycogenolysis (glycogen catabolism) and gluconeogenesis as well as FFA release through 
11polysis (Jenkins et al. 1985). Diaz and colleagues, however, criticised this hypothesis, 
su(_Ygesting that there is lack of evidence to support fuel oxidation differences following 
consumption of HGI and LGI meals (Diaz et al. 2006). It must be noted though, that some 
of the studies cited in their discussion (Howe et al. 1996; Korach-Andt-6 et al. 2004; Spat-ti 
et a]. 2000) have methodological limitations, the most relevant being not testing the GI of 
the foods provided. 
1.3 Glycaemic Load 
The olycacinic load (GL) is a measure of the overall Iglycaernic Impact of the food and is 
the product of the food's GI and amount of CHO it provides. It incorporates both the 
quantity and the quality of the dietary CHO consurned as opposed to GI, which measures 
only the quality of CHO intake (Wolever 2003). Each unit of GL is equal to the glycaermc 
effect produced following the ingestion of Ig of glucose, used as a reference food. 
GL is defined as: (SaInicron et a]. 1997b) 
GL = (GI x amount of CHO)/ 100 
Brand-Miller calculated that the foods' CHO content alone explained 68% of the variance 
in GL values, whereas the GI value alone explained 49% of the variance in GL values, 
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concluding that CHO (rather than GI) is the greatest determinant of GL (Brand-Miller et al. 
2003). 
1.3.1 Glycaernic Load Classification 
The higher the GL, the greater the expected elevation in blood glucose and insulin (Foster- 
Powell et al 2002). It has been suggested to classify foods with a GL: 5 10 as low GL and 
those with a GL ý: 20 as high GL (Brand-Miller et al 2003) but this was only used for 
research purposes and may be revised in the future. 
1.3.2 Low Glycaernic Index versus Low Glycaernic Load 
Although by definition a LGI/high CHO diet or a HGI/low CHO diet can have the same 
GL, these two diets will have different metabolic effects on P-cell function (Wolever & 
Mehling 2002), insulin sensitivity (Swinburn et al. 1991), TG concentration (Wolever & 
Mehling 2003b) and FFA concentrations (Rizkalla et al. 2004), which will be mostly 
favouring the LGI/high CHO diet. To consume a moderately high CHO, LGI diet, one 
should choose LGI foods from the major CHO-providing food groups (Barclay et al 2005). 
Summary of Carbohydrates and Glycaemic Index Section 
CHOs may be classified according to their glycaemic impact following consumption, 
which is affected by their rate of absorption and the gastric emptying rate. Their glycaemic 
impact has direct and indirect effects on insulin sensitivity and cholesterol metabolism 
which may affect heart disease risk factors as discussed in Section 1.5. 
1.4 Insulin 
Insulin is the key hormone controlling CHO metabolism and is secreted in response to 
blood glucose elevation. It is an anabolic hormone, with principal effects on adipose 
tissue, muscle and liver. Its main physiological role is to stimulate the disposal of ingested 
glucose into skeletal muscle and adipose tissue and to decrease the production of glucose 
by the liver by reducing glycogenolysis and gluconeogenesis. In adipose tissue, it 
increases glucose entry and inhibits lipoprotein lipase action thus preventing lipolysis of 
stored TG (Jensen et al. 1989). The principal insulin actions are listed in Table 1.4. 
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In addition to these roles, insulin has important vascular actions that involve activation of 
the endothelial nitric oxide synthase (eNOS) pathway, thus increasing production of nitric 
oxide (NO) (a vasodilator), leading to vasodilation and increased skeletal muscle blood 
flow. Insulin also regulates vascular action through stimulation of the expression of 
vascular cell adhesion molecule (VCAM)-I on endothelium. which may participate in 
recruitment of monocytes to sites of atherosclerosis (Kim et al. 2006). Insulin also has 
multiple opposing haemodynamic actions caused by stimulating secretion of the 
vasoconstrictor endothelin-I (ET-1) from endothelium. Stimulation of sympathetic 
activity by insulin may also contribute to haemodynamic regulation. In healthy lean 
people physiological concentrations of insulin, increase noradrenaline concentrations as 
well as sympathetic nerve activity which may oppose the vasodilator effects of insulin 
(Anderson et al. 1991). Additionally, insulin stimulates renal re-absorption of sodium, 
which favours expansion of extracellular fluid volume and may lead to increased blood 
pressure (13P) (Vierhapper 1985). The multiple metabolic effects of insulin have a 
negligible net effect on BP in normal individuals. However, a shift in balance between the 
vasodilator and vasoconstrictor actions of insulin may be a contributing factor to the 
vascular pathophysiology characterising insulin resistance. The haemodynamic actions of 
insulin are shown in Figure 1.1. 
Table 1.4: Principal Actions of Insulin (modified from (Ganong 1995) 
Rapid (seconds) 
Increased transport of glucose, amino acids and potassium into insulin- sensitive cells (e. g. 
adipose tissue and muscle) 
Intermediate (minutes) 
Stimulation of protein synthesis and inhibition of protein degradation 
Activation of glycogen synthase and glycolytic enzymes 
Inhibition of phosphorylase and gluconeogenic enzymes 
Delayed (hours) 
Increase in mRNAs for lipogenic enzymes 
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Figure I. I: "aemodynamic Actions of Insulin (Kim et al 2006) 
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1.5 Coronary Heart Disease 
1.5.1 Definition and Pathogenesis 
Coronary Heart Disease (CHD) is caused by atherosclerosis or 'hardening of the arteries' 
supplying the myocardium (the muscle of the heart), in association with hypertension and 
dyslipidaemia. Atherosclerosis begins in childhood with cholesterol esters being deposited 
in macrophage foam cells in the intima of large muscular arteries (McGill 1968) and is in 
an advanced state by the time symptoms occur (Third Joint Task Force of European and 
other Societies on Cardiovascular Disease Prevention in Clinical Practice 2003). The 
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terminal event occluding the artery is usually thrombosis, occurring after plaque rupture 
and aggravated by elevated fibrinogen concentrations (Schaefer 2002). The two major 
clinical conditions of CHD are angina pectoris and myocardial infarction (MI). Angina 
results from a reduction or temporary halt in the blood flow to the myocardium. causing 
pain or discomfort in the chest which is brought on by exertion or stress. MI results from 
prolonged total occlusion of the coronary artery leading to death of part of the myocardium 
and is associated with prolonged and usually excruciating central chest pain (Mann 2000). 
At this point, it should be noted that Cardiovascular Disease (CVD) incorporates CHD, 
stroke and peripheral vascular disease. Some studies in this thesis refer to CVD rather than 
only CHD; however, stroke and peripheral vascular disease are outside the scope of this 
thesis and will not be discussed. 
1.5.2 Prevalence and Economic Cost 
CHD is the leading cause of death in the Western World and a significant source of 
disability (Murray & Lopez 1997). In the UK, it causes over 120 000 deaths a year, a rate 
that despite reductions (British Heart Foundation 2005), still remains among the highest in 
the world. CHD epidemiology is characterised by regional, socio-economic and ethnic 
differences and CHD disability has become a growing economic problem as the population 
is ageing. CHD costs the UK E1750 million a year, of which less than 1% is spent on 
primary prevention (British Heart Foundation 2005). 
1.5.3 Risk factors for Coronary Heart Disease Development 
Development of CHD is characterised by a complex interplay between synergistic 
metabolic abnormalities (Despres 2003) occurring due to genetics, obesity, physical 
inactivity, psychosocial stress, and intra-uterine growth retardation (Isomaa 2003). 
Globally, it has been estimated that 83-89% of ischaemic heart disease is attributed to 
hypertension, dyslipidaemia, high Body Mass Index (BMI), low fruit and vegetable intake, 
physical inactivity, tobacco use and high alcohol intake (Ezzati et al. 2003). The main 
heart disease risk factors are discussed in the following Sections (1.5.3.1-1.5.3.6). 
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1.5.3.1 The Metabolic Syndrome 
Reaven proposed the term 'Syndrome X' or 'metabolic syndrome' (Reaven 1988) to 
describe the clustering of metabolic and haemodynamic abnormalities associated with 
resistance to insulin-mediated glucose uptake. The metabolic syndrome is characterised by 
visceral adiposity, insulin resistance, low HDL cholesterol and a systemic pro- 
inflammatory state (Ford et al. 2002) (Table 1.5) and leads to an increase in all cause and 
cardiovascular mortality (Hu et al. 2004). Although, the syndrome was thought to identify 
substantial additional cardiovascular risk above and beyond individual risk factors (Lakka 
et al. 2002a), recently, both this and the certainty regarding its pathogenesis and its value 
as a CHD risk marker have been under debate (Kahn et al. 2005). 
There are a number of definitions of the metabolic syndrome including those of the World 
Health Organisation (Alberti et al. 1998), the US National Cholesterol Education Program 
(NCEP Adult Treatment Panel 1112001) and the European Group for the Study of Insulin 
Resistance (Balkau & Charles 1999). A new definition has recently been proposed by the 
International Diabetes Federation (IDF) allowing easy identification of patients in the 
clinical setting (International Diabetes Federation 2005) This definition is based on central 
obesity (defiried as waist measurement > 94 cin in men and > 88 cm in women) plus two of 
four additional factors, these being: raised triacylglycerols (> 1.7 mmol/1), reduced HDL 
cholesterol (<1.29 mmol/I in males or <1.03 mmol/I in females), raised BP (systolic BP > 
130 mmHg or diastolic BP > 85 mmHg) raised fasting plasma glucose (>5.6 mmol/1) or 
being on pharmaceutical treatment for any of these. For the first time, ethnicity-specific 
cut-points for central obesity were included with lower cut-offs for South-Asians than 
Europeans. Although the prevalence of the syndrome depends on its definition (Isomaa 
2003), it affects approximately 25% of the adult population (Ford et al. 2003). 
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Table 1.5: Abnormalities Associated with the Metabolic Syndrome (modified from 
(Reaven 2002) 
The Core Cluster 
Central Obesity 
Hypertriglyceridaemia 
Low HDL Cholesterol 
Small, dense LDL particles 
Exaggerated Postprandial Lipaemia 
Impaired Fasting Glucose 
Impaired Glucose Tolerance 
Type 2 Diabetes 
Insulin Resistance 
Other often Associated Features 
Microalbuminuria 
Hyperuricaemia and Gout 
Impaired Fibrinolysis and Increased Coagulability 
Elevated PAI- I 
Elevated Fibrinogen 
Increased concentrations of Von Willebrand factor 
Elevated CRP 
Impaired Endothelium-Dependent Vasodilatation 
Low Cardiorespiratory Fitness 
Fatty Liver Disease 
Polycystic Ovary Syndrome 
Increased Sympathetic Activity 
Low Heart Rate Variability 
Hypertension 
1.5.3.2 Insulin Resistance and Risk of Coronary Heart Disease 
Insulin resistance is the diminished ability of insulin to promote glucose uptake in adipose 
tissue and skeletal muscle and to suppress hepatic glucose output (Reaven 1993). The 
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pathophysiology of the metabolic syndrome is mostly hypothesised to be through insulin 
resistance in pancreatic islet P cells. In large epidemiological studies, significant 
associations were found between insulin resistance and risk and event frequency of CVD 
(Hanley et al. 2002; Yip et al. 1998), as well as hypertension (Zavaroni et al. 1999). 
FFAs are the prime candidates for the defects in glucose-dependent insulin secretion 
(Eckel et al. 2005). Elevated concentrations of FFAs, characteristic of both the insulin 
resistant and the obese state (Opie & Walfish 1963), are associated with increased risk of 
CVD (Carlsson et al. 2000). Although FFAs would normally stimulate insulin secretion, 
prolonged exposure to excessive concentrations results in falls in insulin secretion, mostly 
due to pancreatic 0 cell lipotoxicity (Yaney & Corkey 2003). FFAs compete with glucose 
and impair glucose utilisation by skeletal muscle (Boden et al. 1994; Randle et al. 1963), 
increase hepatic glucose output (Boden et al 1994) and inhibit hepatic glucose production 
by insulin (Boden et al. 2002; Ferrannini et al. 1983; lozzo et al. 2004), all of which could 
cause glucose intolerance and insulin resistance. In the long term, elevated concentrations 
of FFAs lead to impairment of glucose-stimulated insulin secretion (Carpetier et al. 1999; 
Dubois et al. 2004; Zhou & Grill 1995). 
Moreover, in insulin resistance and obesity, uptake and oxidation of FFAs in skeletal 
muscle is diminished during the post-absorptive phase (Blaak et al. 2000). The imbalance 
between uptake and oxidation may lead to net TG storage and accumulation of lipid 
intermediates within the skeletal muscle (Blaak 2003). Additionally, high concentrations 
of FFAs could lead to increased concentrations of very low density lipoprotein (VLDL) 
since FFAs are the substrates for hepatic TG secretion in VLDL; as well as increased 
concentrations of small dense low density lipoprotein (LDL) particles and apoB 
lipoprotein. All of these lipoproteins are associated with an increased risk of CHD. FFAs; 
may also directly affect epithelial and smooth muscle cell integrity (Howard & Gray 1999) 
and impair microvascular function (de Jongh et al. 2004) and could therefore predispose to 
hypertension, another correlate of insulin resistance and CHD. 
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1.5.3.3 Hyperglycaernia and Risk of Coronary Heart Disease 
The relationship between insulin resistance and hyperglycaemia is complex as one 
condition exacerbates the other. High glucose concentrations or hyperglycaemia cause 
pancreatic 0 cell toxicity thus depressing pancreatic function and leading to insulin 
resistance and its consequences discussed under Section 1.5.3.2. At the same time, insulin 
resistance leads to impaired fasting glycaemia (IFG) and/or impaired glucose tolerance 
(IGT) following glucose ingestion (Eckel et al 2005) or to Type II diabetes mellitus. 
In non-diabetic cohorts, the DECODE study in Europe suggested that IGT (defmed as 
fasting plasma glucose <7.0 mmol/l, 2-hour plasma glucose post glucose load test: 7.8-11.0 
mmol/1), rather than IFG (defmed as fasting plasma glucose: 6.1-6.9 mmol/l, 2-h glucose: 
<7.8 mmol/1) (World Health Organisation 1999) may be a better predictor of CHD (The 
DECODE Study Group 2001). Further meta-analysis confirmed this finding (Levitan et al. 
2004). However, the relationship between glucose concentrations and CHD risk seems to 
be confounded by other heart disease risk factors (The DECODE Study Group 2001) 
which are often associated with hyperglycaemia, such as obesity, insulin resistance, 
hyperinsulinaemia and hyperlipidaemia. Nevertheless, even if the relationship of 
hyperglycaemia with CHD is indirect, it is still a valuable risk marker for CHD (Unwin et 
al. 2002). Direct evidence for the importance of elevated postprandial glucose 
concentrations with regard to CHD comes from the use of an (x-glucosidase inhibitor 
which slows CHO digestion, and was shown to halve the risk of CVD events and 
hypertension in subjects with IGT (Chiasson et al. 2003) and to reduce the annual 
progression of intima-media thickness (Hanefeld et al. 2004), a surrogate marker for 
atherosclerosis. Moreover, in subjects with normal glucose tolerance who developed CHD 
disease, the severity of the disease was positively correlated with post-load glycaemia and 
HbAlc concentrations (Sasso et al. 2004). 
Hyperglycaemia itself can also lead to endothelial dysfunction, which is one of the first 
stages in the development of CHD, through oxidative stress (Giugliano et al. 1996), non- 
enzymic glycation of LDL cholesterol and clotting factors (Vlassara et al. 1994), reduced 
production/bio availability of NO and increased platelet aggregation and blood viscosity 
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(De 2000). Endothelial damage may result from advanced glycation end-products (AGE) 
deposited in the vessel wall and matrix, and the activation of inflammation (Brownlee 
1994). A further link between hyperglycaemia and risk of CHD, even in healthy subjects, 
is through high concentrations of adhesion molecules which induce inflammation in the 
endothelium leading to atheromatous lesions (Marfella et al. 2000). 
1.5.3.4 Triacylglycerols and Risk of Coronary Heart Disease 
A meta-analysis of seventeen prospective human studies showed that plasma TG 
concentration is an independent risk factor for CHD (Hokanson et al. 1996). The cause of 
hypertriglyceridaernia in insulin resistant subjects is thought to be due to an increased 
synthesis of VLDL caused by a high FFA concentration in the portal vein. Furthermore, 
the magnitude and duration of postprandial TG metabolism has been related to the 
presence and progression of atherosclerosis in both sexes (Patsch et al. 1992). The precise 
way by which postprandial TG metabolism affects the pathogenesis and progression of 
CHD has not been elucidated but it could be through the production of chylomicron 
remnants (Zilversmit 1979) which promote atherogenesis (Shaikh et al. 1991). Moreover, 
the magnitude and duration of postprandial triglyceridaernia is directly related to the 
composition and metabolic fate of LDL and HDL cholesterol (Cohn 1994). Postprandial 
hypertriglyceridaernia stimulates the formation of small dense LDL cholesterol (Karpe et 
al. 1993) and promotes the catabolism of HDL cholesterol (Patsch et al. 1987) while it also 
activates coagulation factor VII (Ruddock & Meade 1994), all of which are associated with 
increased CHD risk and mortality. 
1.5.3.5 Cholesterol and Risk of Coronary Heart Disease 
There is a strong positive association between total and LDL cholesterol and the risk of 
CHD (Smith et al. 1992) while cholesterol lowering leads to a significant reduction in 
CHD risk (Law et al. 1994). LDL cholesterol is the principal caff ier of cholesterol in the 
blood and plays a pivotal role in atherogenesis, with CHD risk progressively increasing at 
concentrations > 2.6 mmol/l (Sniderman et al. 1997). Oxidation of LDL is a major 
prerequisite for the uptake and deposition of LDL cholesterol in the artery wall (Goldstein 
et al. 1979). HDL cholesterol concentrations and CHD share an inverse relationship 
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(Assmarin et al. 1996) which is consistent with the role of HDL in tile cellular efflux and 
elimination of cholesterol from the body (Griffin 1999). The ratio of total cholesterol to 
HDL cholesterol is a better predictor of CHD than either total or LDL cholesterol alone 
(Kinosian et al. 1994). Individuals with a high total cholesterol to HDL cholesterol ratio 
are more insulin resistant, glucose intolerant and hypertriglyceridaemic than those having a 
normal ratio (Jeppesen et al. 1998). 
1.5.3.6 Blood Pressure and Risk of Coronary Heart Disease 
Blood pressure is defined as: (Poirier et al. 2006b) 
BP = CO x SVR 
where BP = Blood Pressure 
CO = Cardiac Output (i. e. heart rate x stroke volume) and 
SVR = Systemic Vascular Resistance (from small arterioles and capillaries) 
Epidernio logical evidence from one million adults has demonstrated the close relationship 
between BP (both systolic (SBP) and diastolic (DBP)) and heart disease down to a BP of 
115/75 mrnHg (Prospective Studies Collaboration 2002). Isolated systolic hypertension 
(SBP ý! 140 mmHg and DBP < 90 mrnHg) is the most common subtype of hypertension 
(Franklin et al. 2001) and arterial stiffening is its underlying cause (Nichols et al. 1992). 
Hypertension is characterized by a reduced activity of NO, a molecule with antiplatelet and 
vasodilating effects (Panza 1999), and a simultaneous increased activity of endothelin-1, an 
endothelium-derived agent with potent vasoconstrictive and pro-atherosclerotic effects 
(Cardillo et al. 1999), thus increasing CHID risk (Panza 2001). There is a direct link 
between high BP and insulin resistance, since both treated and untreated hypertensive 
patients were shown to be relatively glucose intolerant compared with individuals with 
normal BP (Jarrett et al. 1978; Lucas et al. 1985; Manicardi et al. 1986). 
Hyperinsulinaernia can raise BP through stimulation of the sympathetic nervous system, 
enhancement of sodium retention, alteration in cation transport, hypertrophy of the 
vascular smooth muscle cells, and stimulation of the renin-anglotensin-aldosterone system 
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(Kim et al 2006). Also, hypertension is most frequent in obese subjects (Stamler et al. 
1978) and obesity has negative cffects on cardiac output and peripheral vascular resistance 
(Poirier et al. 2006a) which increase CHD risk (Section 1.7.4.1) 
1.5.4 Risk Assessment for Coronary Heart Disease 
Since CHD has a multifactorial aetiology and the risk factors have a multiplicative effect, 
risk assessment should deal with the whole person, not just with isolated risk factors (Third 
Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in 
Clinical Practice 2003). Several models have been developed to estimate the 5 or 10-year 
risk of CHD in asymptornatic subjects based on different combinations of risk factors 
(Third Report of the National Cholesterol Education Program (NCEP) 2002; Conroy et al. 
2003). The Joint British Societies on Prevention of Cardiovascular Disease have recently 
developed a 10-year prospective CVD (i. e. CHD and/or stroke) risk prediction chart based 
on five risk factors: age, sex, smoking habit, systolic BP and total cholesterol to HDL 
cholesterol ratio (Wood et al. 2005). A total CVD risk ofý:: 20% over 10 years is defined 
as 'high risk' and requires professional lifestyle intervention and/or drug therapy. 
1.5.5 Prevention of Coronary Heart Disease 
1.5.5.1 Lifestyle and Dietary Modifications 
Overwhelming scientific evidence supports lifestyle modification for prevention of CHD 
since the majority of risk factors are modifiable (Third Joint Task Force of European and 
other Societies on Cardiovascular Disease Prevention in Clinical Practice 2003). Smoking, 
nutrition and physical activity have direct effects on body weight, plasma lipids, insulin 
sensitivity, BP, thrombotic tendency, cardiac rhythm, endothelial function, systemic 
inflammation, oxidative stress and homocysteine concentration (Hu et al. 2002b). British 
(Wood et al 2005), European (Third Joint Task Force of European and other Societies on 
Cardiovascular Disease Prevention in Clinical Practice 2003) and American Societies 
(Poirier et al 2006b) have set lifestyle targets for heart disease prevention. The Joint 
British Societies' Lifestyle Targets for Prevention of Cardiovascular Disease (Wood et al 
2005) are shown in Table 1.6. 
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Table 1.6: Lifestyle Targets for Cardiovascular Disease Prevention (Wood et al 2005) 
1. Do not smoke 
2. Maintain ideal body weight (BMI: 20-25 kg/m) and avoid central obesity (waist 
circumference in white Caucasians <102 cm in men and <88 cm in women, and in 
Asians <90 cm in men and <80 cm in women) 
3. Keep total dietary intake of fat to:: 00% of total energy intake 
4. Keep the intake of saturated fats to: 510% of total fat intake 
5. Keep the intake of dietary cholesterol to <300 mg/day 
6. Replace saturated fats by an increased intake of monounsaturated fats 
7. Increase the intake of fresh fruit and vegetables to at least five portions per day 
8. Consume fish and other sources of omega 3 fatty acids regularly (at least two 
servings of fish per week) 
9. Limit alcohol intake to <21 units/week for men or <14 units/wcek for women 
10. Limit intake of salt to <100 mmol/l day (<6g of sodium chloride or <2.4 g of 
sodium per day) 
Take regular aerobic physical activity of at least 30 mins per day, most days of the 
week (for example, fast walking/swimming) 
1.5.5.2 Fat Intake 
Evidence from the Seven Countries Studies first suggested that saturated fatty acids 
increase, and polyunsaturated fatty acids reduce total and LDL cholesterol (Keys et A 
1986), while in intervention trials, cardiovascular events were reduced by replacement of 
saturated by monounsaturated or polyunsaturated fats (Hooper et al. 2001b). A meta- 
analysis showed that the most effective reduction on the ratio of total cholesterol to HDL 
cholesterol occurs when trans and saturated fatty acids are replaced by cis unsaturated fatty 
acids (Mensink et al. 2003). However, replacement of saturated fats with CHO results in 
an increase in fasting TG concentrations (Mensink et al 2003). Moreover, epidemiological 
evidence suggests that regular fish consumers are at a lower risk of fatal CHD (Hu et al. 
2002a), including sudden death (Albert et al. 2002). Dietary cholesterol intake has little 
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effect on blood lipid values, although there is considerable variation in response between 
individuals (Katan et al. 1987). 
1.5.5.3 Wholegrain and Fibre Intake 
A number of prospective studies found an inverse association between wholegrain 
consumption and incidence of CHD (Jensen et al. 2004; Liu et al. 1999; Steffen et al. 
2003); with a 20-30% reduction in risk on a daily intake of ?3 servings of wholegrain food 
items (Steffen et al 2003). CHD risk is most strongly negatively associated with 
wholegrain and wholewheat bread intake (Anderson et al 2000), the bran portion of the 
fibre being the heart disease reducing constituent (Jensen et al 2004). A minor part of this 
protective effect can be explained by the cholesterol lowering effect of soluble fibre 
(Jensen et al 2004), due to its viscosity (Hallfrisch et al. 2000). Pooled results from over 
300 000 adults showed that for each lOg/day increment in total dietary fibre intake, 
coronary events reduced by 12% and coronary deaths by 19%, while for cereal fibre, the 
reduction was 25% in coronary deaths (Pereira et al. 2004a). Wholegrains might also 
reduce risk through their vitamin content e. g. Vitamin E, mineral content e. g. folate and 
trace minerals such as. copper, zinc and manganese and other substances such as phenolic 
acids, lignans and phytoestrogens, which affect glucose and insulin responses and/or 
haemostatic factors (Truswell 2002). In addition, wholegrain and fibre intake have been 
associated with lower risk of obesity (Koh-Banerjee et al. 2004) and increased insulin 
sensitivity (Liese et al. 2003). Moreover, fortification of cereal foods with folic acid 
lowers plasma homocysteine concentrations, an independent risk factor for CHD (Hankey 
& Eikelboom 1999). Both folate intake and serum folate concentration have been linked 
epidemiologically with an inverse CHD risk (Loria et al. 2000; Rimm et al. 1998). 
1.5.5.4 Fruit and Vegetable Intake 
Fruit and vegetable consumption may reduce CHD risk (Joshipura et al. 2001). One 
mechanism is through the reduction in BP caused by potassium (DASH-sodium 
collaborative research group 2001; Law & Morris 1998). The fibre content of fruit and 
vegetables is another cardioprotective factor; each 10 g increment in fruit fibre is 
associated with a 30% reduction in CHD (Jensen et al 2004). Moreover, antioxidants in 
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fi7uit and vegetables may improve insulin action by reducing lipid peroxidation in muscle 
cell membranes (Miller, III et al. 1998), which would enhance the ability of insulin to bind 
to its receptor (Caballero 1993). Randomised controlled trials showed that the same 
benefit cannot be achieved by antioxidant vitamin supplementation however (Hooper et al. 
2001 a; Medical Research Council et al. 2002). 
1.5.5.5 Alcohol Consumption 
Moderate alcohol consumption is associated with the lowest all cause mortality (Power et 
al. 1998) largely due to lower coronary mortality (Corrao et al. 2000), while binge-drinking 
is associated with a higher risk of sudden death (Britton & McKee 2000). 
1.5.5.6 Salt Intake 
High concentrations of salt intake are associated with increased cardiovascular morbidity 
and mortality in overweight people (He et al. 1999) and with increased BP across 
populations (Meneton et al. 2005). Moreover, independently of its effects on BP, a high 
salt intake also increases the left ventricle mass and stiffens conduit arteries amongst 
having other detrimental effects on the cardiovascular system (Meneton et al 2005). 
Sodium restricted diets reduce BP (Dickinson et al. 2006), left ventricular mass (Ferrara et 
al. 1984) and the stiffness of conduit arteries (Avolio et al. 1986). 
1.5.5.7 A'Prudent Diet' 
The Dietary Approaches to Stop Hypertension (DASH) diet, demonstrated that a diet that 
emphasises consumption of fruits, vegetables, wholegrain products and is low in saturated 
fat, total fat, cholesterol and sugar, substantially lowers BP (Appel et al. 1997). In the 
Nurses' Health Study (Fung et al. 2001) and the Health Professionals' Follow-up Study 
(Hu et A 2000) a 'prudent diet', characterised by higher intakes of fruit, vegetables, 
legumes, fish, poultry and wholegrains was associated with a lower CHD risk compared 
with a 'Western' diet containing higher intakes of red and processed meats, sweets, 
desserts, French fries and refined grains. It is of note that large cohort analyses have 
shown that 74% of CHD events could be potentially prevented by diet and lifestyle 
modifications (Stampfer et al. 2000). 
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1.5.5.8 Glycaemic Index and Coronary Heart Disease 
A low GI diet may reduce the risk of CHD through improvements in insulin sensitivity, 
cholesterol metabolism, thrombolytic factors and endothelial function (Augustin et al. 
2002). 
The Nurses' Health Study provided the first epidemiological evidence of an adverse effect 
of a high GL diet on CHD risk, HDL cholesterol and TG concentrations (Liu et al. 2000; 
Liu et al. 200 1). On the other hand, at a population concentration, both in the UK (Frost et 
al. 1999) and the US (Ford & Liu 2001), a LGI diet was associated with higher HDL 
cholesterol concentrations. 
The effect of a LGI diet on insulin sensitivity has been shown in several trials. A LGI diet 
was found to increase first-phase insulin release in subjects with the metabolic syndrome, 
suggesting an improvement in 0 cell function (Laaksonen et al. 2005), and in those with 
IGT, a similar diet improved insulin secretion (Wolever & Mehling 2002) and reduced 
insulin demand (Ostman et al 2006). In women with heart disease, consumption of slow 
release foods improved both in vivo insulin sensitivity (measured by the rate of fall in 
plasma glucose after an intravenous insulin injection) and in vitro insulin responsiveness of 
adipocytes (Frost et al. 1998). 
The link between GI and insulin resistance is also supported by prospective studies of men 
(Salmeron et al. 1997a) and women (Salmeron et al 1997b; Schulze et al. 2004) where 
consumption of a HGI diet predicted diabetes development, increased the risk of metabolic 
syndrome diagnosis and of insulin resistance assessed by Homeostasis Model Assessment 
(HOMA) (McKeown et al. 2004). However, prospective evidence has been inconsistent 
since in other large cohorts such as the Insulin Resistance Atherosclerosis Study (Liese et 
al. 2005) and the Inter99 Study (Lau et al. 2005), as well as in the elderly (Meyer et al. 
2000; van Dam et al. 2000), no association was found between GI and insulin sensitivity. 
The discrepancy in population groups and between prospective and experimental evidence 
could be due to the data collection methods and inaccurate estimation of dietary GI (Xavier 
Pi-Sunyer 2002), as well as genetic heterogeneity affecting gene-environment interactions 
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(Snyder et al. 2004). Also the GI values needed to achieve a preventive potential may not 
be reached in prospective studies (Liese et al 2005). 
A LGI diet has also been shown to improve the cholesterol profile. In hyperlipidaemic 
patients, consumption of a LGI diet for a month reduced TG, total cholesterol and LDL 
cholesterol (Jenkins et al. 1987c) while in men at risk of heart disease, LGI diets had more 
favourable effects on insulin, glucose and TG responses than high-monounsaturated fatty 
acid, high sucrose or HGI diets (Brynes et al. 2003a). A meta-analysis examining the 
effects of GI on lipid metabolism found that total cholesterol reduces by 0.33 mmol/I when 
GI is lowered by 22 units. However, HDL cholesterol, LDL cholesterol and TG were not 
found to significantly change by GI modification (Opperman et al. 2004). 
Nevertheless, a LGI meal led to faster clearance of intestinally derived TG-remnants (apo- 
B48 lipoproteins), which are associated with atherosclerosis (Harbis et al. 2001). 
Additionally, in obese, insulin resistant subjects, ingestion of a HGI diet led to an early and 
exaggerated postprandial accumulation of both intestinally (apoB-48) and hepatically- 
derived (apoB-100) chylomicrons, possibly due to the generated acute hyperinsulinism 
which inhibits lipoprotein lipase action and thus fat breakdown (Harbis et al. 2004). 
Another way by which a LGI diet may improve risk of CHD is through its effects on blood 
clotting. Consumption of a LGI diet dramatically lowered and even normalised PAI-I 
concentrations in Type II diabetic subjects thus improving fibrinolytic activity (Jarvi et al. 
1999). It is also possible that the HGI-induced hyperglycaernia may generate oxygen free 
radicals and cause endothelial cell dysfunction (Cosentino et al. 1997). Recently, a HGI 
diet was positively associated with two lipid peroxidation markers suggestive of high 
oxidative stress (Hu et al. 2006). However, the value of these markers in CHD risk 
assessment is not yet clear. 
Considering evidence from only randomized controlled trials (RCTs) lasting at least 4 
weeks and assessing the effect of LGI diets on CHD risk factors, a Cochrane Review 
detected only limited and weak evidence of a small reduction in total cholesterol and small 
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reduction in HbAlc with LGI compared with HGI diets. The authors concluded that the 
evidence that LGI diets reduce CHD is weak, and that well designed, adequately powered, 
long-term RCTs are needed (Kelly et al. 2004). 
1.5.5.9 Physical Activity 
Physical activity protects against heart disease development (Powell et al. 1987), by 
conferring cardiovascular fitness and reducing CHD risk factors (Thompson ct al. 2003). 
Physically active people have half the incidence of coronary artery disease (CAD) 
compared to sedentary individuals (Blair & Jackson 2001) while the relative risk of 
inactivity is similar in magnitude to that of hypertension, hypercholesterolaemia and 
smoking (Powell et al 1987). Regular exercise improves myocardial contraction and the 
heart's electrical stability and increases stroke volume thus leading to a higher maximal 
cardiac output (Bouchard 1997). Exercise also improves endothelial function leading to 
improvements in flow-mediated dilatation (Bouchard 1997), blood coagulation, 
fibrinolysis and platelet aggregation (EI-Sayed 1996), plasma viscosity (Yamell ct al. 
2000) and inflammatory markers such as C-reactive protein (CRP) (Lakka et al. 2005). 
Moreover, exercise improves the blood cholesterol profile (Leon & Sanchez 2001) by 
increasing lipoprotein lipase activity (Durstine & Haskell 1994; Leon et al. 2000) and 
contributes to BP reduction (Whelton et al. 2002), possibly by reducing insulin resistance 
(Reaven 1988). Both the chronic and the acute effects of exercise have beneficial effects 
on heart disease risk factors (Thompson et al. 2001). 
1.5.5.10 Weight Loss and Coronary Heart Disease Prevention 
The metabolic derangements of obesity such as insulin resistance, hypercholesterolaernia 
and hypertension can be reversed by weight loss; and a 10% reduction in weight should be 
the first priority in CHD prevention in the obese (Grundy et al. 2005). Moderate weight 
loss improves insulin resistance and glucose handling (Knowler et al. 2002), hypertension 
(Mertens & Van Gaal 2000), the cholesterol profile and TG concentrations (Dattilo & Kris- 
Etherton 1992) and also the clustering of heart disease risk factors (Wilson et al. 1999). 
The cardiovascular system benefits by weight loss through reductions in (amongst others) 
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blood volume, stroke volume, cardiac output, BP and subsequently left ventricular mass 
and also confers an improvement in its function (Poirier et al 2006b). 
Summary of Coronary Heart Disease Section 
CHD is the leading cause of death in our society and its development depends on many 
metabolic abnormalities for which insulin resistance is central. Lifestyle modifications 
including weight loss, healthy eating and exercise constitute the basis for prevention of this 
disease. Evidence suggests that consumption of a LGI diet improves risk of CHD, 
however further long-term research is required in this area. 
1.6 Arterial Compliance 
1.6.1 Definition of Arterial Compliance 
Compliance is the physiological property of a hollow container to change in volume as 
pressure changes. Arterial compliance, defined as AWAP, where A=Change, V=Volume 
and P=Pressure is the capacity of the arterial system to accommodate volume at a specific 
concentration of pressure (O'Rourke 1990). Large arteries can instantaneously 
accommodate the volume of blood ejected from the heart, storing part of the stroke volume 
during systolic ejection and draining the volume during diastole, thereby ensuring a 
continuous perfusion of organs and tissues. This ability of the arteries to accommodate the 
blood instantaneously is termed 'compliance' (Safar 200 1). 
1.6.2 Primary Determinants of Compliance 
Arterial compliance is dependent on many factors including physical and chemical ones. 
The three primary elements of the arterial wall determining its compliance are: 1) the ratio 
of elastin and collagen (the quantitative structural elements) (Yin 1990); 2) 
fracture/fragmentation of elastic lamellae and the cross-linking of collagen and AGE 
products (qualitative structural elements); and 3) the vasoconstrictor tone exerted by the 
smooth muscle cells by vaso-active substances like NO and endothelin (functional 
elements) (Tanaka & Safar 2005). 
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1.6.3 Arterial Compliance Assessment 
Systemic Arterial Compliance, Pulse Wave Velocity and Augmentation Index 
measurements are surrogate markers of arterial stifffiess. 
1.6.3.1 Models of the Arterial System 
Before explaining the methods used in assessing arterial compliance, the models used to 
simulate the impedance of the arterial system are described as they provide the basis for 
understanding how assessment of the arterial system is carried out. 
The Windkessel model was the first suggested model. It treats the circulation as a central 
elastic reservoir consisting of the large arteries i. e. aorta and its major arteries, into which 
the heart pumps, and from which blood travels to the tissues through relatively nonelastic 
conduits i. e. the peripheral arteries e. g. radial and brachial (O'Rourke 1982). BP has two 
functions in this model: the conduit function, which on the basis of a pressure gradient 
supplies blood to peripheral tissues and organs, and the cushioning function which is able 
to dampen the pressure oscillations that result from intermittent ventricular ejection (Safar 
et al. 2003). However, this model is seriously limited to extreme conditions of stiffness. 
A more realistic model of the arterial system is a simple tube with one end representing the 
peripheral resistance and the other end, receiving blood in spurts from the heart. When a 
wave is generated by cardiac activity, it travels along the wall of the tube toward the 
periphery and is reflected back at points of biffircation in the periphery. A pressure wave 
at any point along the tube is a resultant of incident and reflected waves. When the tube 
wall is stiff, as in the hypertensive or elderly, wave travel is fast, and the reflected wave 
merges with the systolic part of the forward wave, causing a high pressure in systole and a 
low pressure in diastole throughout the tube (O'Rourke et al. 2002). The generation of 
pressure waves in the actual arterial system is described below (Section 1.6.3.2). 
1.6.3.2 Pressure Waves 
The contraction of the left ventricle and the ejection of blood into the ascending aorta 
generates a pressure wave which travels along the arterial wall throughout the body (Asmar 
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1999a). The forward travelling pressure wave may be reflected at all points of structural 
and/or functional discontinuity of the arterial tree (mainly located in the distal arteries at 
the branching origins of arterioles) (Safar et a] 2003), sometimes rellerred to as 'points of 
impedance mismatch' (Nichols & O'Rourke 1998b). From these points ot'discontinUlty, it 
reflected wave is generated that travels backward tov,, ard tile ascending aorta. The final 
pressure wave is analysed as the surn tip or superposition of the fiorward and reflected 
pressure waves which are in constant interaction alomý the arterial circuit (()'Rourke et al. 
1992, Safar et al 2003), and its amplitude and shape arc determined by the timing between 
the two component waves. The timing of the forward and reflected waves depends on 
pulse Wave Velocity (PWV) (Chapter 1, Section 1.6.4.2), the travelling distance of the 
pressure waves and the duration of ventricular ejection (Safar et al 2003). 
1.6.3.3 Pulse Wave Velocity 
Pulse Wave Velocity (PWV) represents the propagation velocity of the pulse wave transit 
between two major arteries e. g. carotid-radial or carotid-femoral (Colin 2006a). It is 
determined by the time delay between the foot of pulse pressure waves recorded at two 
different sites after measuring the distance between those two sites. The velocity is 
calculated using the formula: L, 
Velocity = D/T 
where D= distance travelled by the pulse between the two recording sites, tile proximal 
and the distal, and is measured in metres and 
T= transit time needed by the forward wave to travel from one site to the other, and is 
determined by the time delay between tile two corresponding recorded forward waves 
(Asi-nar 1999b). 
Propagation of the pulse is determined by the elastic and geometric properties of the 
arterial wall and the viscosity of the contained fluid Le. blood. Since blood is a relatively 
incompressible fluid, its density is constant, thus the energy propagation occurs 
predominantly along the walls of the arteries and not through the blood. 
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PWV can be mathematically represented by the Bramwell-11111 equation (Bramwell &, I fill 
1922) as: 
PWV = ýAPN/AV. p ni/s 
where AP and AV are the changes in pressure and volume, 
V baseline volume and 
p blood viscosity 
PWV is used as a surrogate measure of arterial compliance and it is negatively associated 
NvIth compliance i. e. higher PWV corresponds to lower elasticity. It reprcscnts only the 
state of the arterial segment measured thus the carotid- femoral PWV (thoracic-abdominal) 
is a measure of the stiffiess of the aorta i. e. the central circulation, while carotid-radial 
PWV assesses peripheral compliance. Central PWV correlates well Nvith cardiovascular 
mortality and morbidity (Cohn 2006b). 
1.6.3.4 Augmentation Index 
Augmentation Index (Al) allows estimation of the effect of the reflected wave oil tile 
amplitude of the pulse pressure (PP) wave (Rajkumar et al. 2000) (Figure 1.2). The 
forward wave depends on the lefi ventricular ejection and the arterial stiffiess whereas the 
reflected wave is related to arterial stiffness and tile potential sites of wave reflection. It 
should be noted that the left ventricular load and corollary blood flow are determined by 
the BP of the central aorta rather than the brachial BP (Oliver & Webb 2006). In 
compliant arteries, such as in young people, the reflected wave returns fi-orn the distal 
arterial compartment during diastole thus augmenting DBP and corollary artery filling. 
This is termed PP amplification (Nichols & O'Rourke 1998a). In less distellsible arteries, 
such as in arteriosclerosis or hypertension, there is a faster propagation of tile pulse wave 
along the arterial wall and a more rapid backward wave, which arrives during systole and 
not diastole, thus boosting SBP and increasing cardiac load. Such an earlier return of wave 
reflection results in an augmentation of aortic and ventricular pressures during systole and 
reduces aortic pressure during diastole (Safar et al 2003). The measured Al is higher ill 
this case. Al is not simply a surrogate measure of PWV since the former is also affected 
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by tile intensity of wave reflection, which in turn is determined by tile diameter and 
elasticity of small arteries and arterioles (Oliver & Webb 2006). 
Augmentation Index is defined as: 
Al = (AP/PP) x 100 
where AP - the difference between the late systolic peak and the 1110-systolic peak and 
PP = Pulse Pressure or the amplitude of the pulse wave 
where DBP = Diastolic Blood Pressure 
AP = Difference between the inflection point and peak systolic pressure 
SBP = Systolic Blood Pressure 
Pi Augmentation Index 
PP Pulse Pressure 
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1.6.3.5 Systemic Arterial Compliance 
Systemic Arterial C'ornphance (SAC') IS a Measure Of \vhole body compliance. The 
distension of an artery (change in diameter) during a cardiac cycle depends on the elastic 
characteristics of the vessel wall (and the surrounding tissues) and the local PP according 
to I curvilinear relationship (Nichols & O'Rourke 1990). The slope ofthis relationship can 
be expressed by the Compliance (C) defined as the absolute Chan(ICS In V0111111C f0llOWII1g 
changes in pressure as shown liclow. A higher SAC Indicates better compliance. 
C= AV/AP (CM3 rnn-iHg-1) 
whcre AV systolic-diastolic changes in volurne ofan artcrial segnicia and 
AP = change in pressure (i. e. the Pulse Pressure) 
Details of the procedures used to measure PWV, Al and SAC can be found in Chapter 2, 
Section 2.17. 
1.6.4 Physiological Consequences of Reduced Arterial Compliance 
Reduced arterial compliance leads to increased SBP and myocardial oxygen demand, 
reduces DBP and ejection fraction and increases the left ventricular load thereby inducing 
left ventricular hypertrophy and increasing cardiac workload (Westerhof & O'Rourke 
1995). Moreover, since tile BP and duration of the diastole largely determine myocardial 
blood supply (Watanabe et al. 1995), a decrease in DBP can compromise coronary 
perfiision resulting in subendocardial ischaernia (Satar 1989). Improvement in arterial 
compliance has been shown to reduce left ventricle mass and afler load, subsequently 
reducing cardiac morbidity and mortality (Balcher et al. 1999). 
The most evident changes of reduced compliance are elastin fragmentation and 
calcification and increase in collagen content in the arteries (Yin 1990) which occur with 
ageing and hypertension. Other changes include fibrosis and medial smooth muscle cell 
necrosis of the arterial wall (Masawa et al. 1994). Arterial compliance decreases, amongst 
other ways, with ageing (Bulpitt et al. 1999), hypertension (Safar & London 1994), glucose 
intolerance, impaired fasting glucose (van Popele et al. 2006) and insulin resistance (Henry 
et al. 2003; Schram et al. 2004), metabolic syndrome parameters (Li et al. 2005; Safar et al. 
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2006b; van Popele et al. 2000) and obesity (Toto-Moukouo et al. 1986), especially 
increased accumulation of visceral adipose tissue (Sutton-Tyrrell et al. 2001; Wildman et 
al. 2003). These and other factors that reduce compliance such as certain diseases and 
smoking, and factors that improve it are shown in Figure 1.3. The list is rapidly expanding 
with ongoing research and it is outside the scope of this thesis to discuss each condition or 
factor in detail. More details of the link between arterial compliance and CHD are given in 
the following Section. 
Figure 1.3: Factors Affecting Arterial Compliance 
Examples of factors that worsen arterial 
compliance: 
Ageing 
Genetic factors e. g. race 
Metabolic syndrome 
Disease e. g. diabetes, heart disease, peripheral 
vascular disease, end-stage renal disease, 
hypertension, auto-immune diseases e. g. 
Takaysus disease 
Obesity 
Inactivity 
Smoking 
Menopause 
Compliant III Non-compliant II Compliant 
Artery I 'I Artery I+- 'I Artery 
Examples of factors that improve arterial 
compliance: 
Pharmacotherapy e. g. antihypertensives, 
statins; 
Hormone replacement therapy 
Exercise 
Diet e. g. soy, omega-3 fatty acids, 
antioxidant vitamins 
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1.6.5 Arterial Compliance and Coronary Heart Disease 
Arterial compliance is becoming recognised as another modifiable CHD risk factor (Cohn 
et al. 1995; Stamler et al. 1993; Syeda, et al. 2003) and an independent predictor of CHD 
and stroke even after adjustment for atherosclerosis (Mattace-Raso et al. 2006). 
The link between reduced arterial compliance and CHD is still not completely -understood 
but it might be through insulin resistance, characterised by hyperinsulinaemia and 
hyperglycaemia. Hyperinsulinaemia may lead to arterial stifffiess by promoting 
endothelial dysfiinction, oxidative stress, vascular smooth muscle cell growth and 
stimulation of the sympathetic nervous system (Eckel et al. 2002). Additionally, 
hyperinsulinaemia may also lead to proliferation of smooth muscle cells and an increase in 
collagen production (Avena et al. 1998; Ruiz-Torres et al. 1998). 
As previously discussed (Chapter 1, Section 1.5.3.2), FFAs are the prime candidates for 
insulin resistance (Eckel et al 2005). In overweight, hypertensive patients, concentrations 
of postprandial FFAs and TG are abnormally raised (Brynes et al 2003a). In these patients, 
there is also an increased vascular (x-adrenergic activity and tone (Egan et al. 1987). FFAs 
may link insulin resistance with reduced arterial compliance by inhibiting NO production 
(the main vasodilator) through impairing eNOS activity (Egan et al. 1996), by increasing 
oxidative stress (Egan et al. 1999) and by activating proinflammatory signals with 
opposing actions to NO (Kim et al 2006). Moreover, high concentrations of FFAs have 
been shown to directly inhibit glucose transport by causing mitrochondrial dysfunction 
(Lowell & Shulman 2005), which in turn uncouples oxidative phosphorylation, leading to 
increased generation of reactive oxygen species (ROS). FFAs also lead to oxidative stress 
by stimulating NADPH oxidase to produce ROS, which then scavenge NO-producing 
peroxinitrite and lead to endothelial cell damage (O'Donnell & Freeman 2001). 
Additionally, increased concentrations of ROS activate proinflammatory cytokines further 
exacerbating insulin resistance and vascular endothelium dysfunction (Kim et al 2006). 
The insulin resistant state which is thought to be the link between low arterial compliance 
and increased risk of CHD, is also characterised by hyperglycaernia, which may result in 
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the formation of cross-links in collagen fibres by non-enzymatic glycation, thereby 
decreasing the distensibility of the arterial wall (Rutter et al. 2003). In studies where 
medication that inhibits the formation or breaks down cross-links of AGE products, was 
administered arterial stiffness was prevented or reduced (Cantini et al. 2001; Kass et al. 
200 1 a). 
In the obese all of the above may be exacerbated, as obesity is characterised by high 
concentrations of leptin (Singhal et al. 2002) and proinflammatory cytokines such as 
Interleukin-6 QL-6) and PAI- I (Yasmin et al. 2004) and reduced production of detoxifying 
enzymes, such as peroxisome pro liferator-activated receptor y (PPARy) (Furukawa et al. 
2004), which enhance the lipotoxic effects of FFAs and the impaired glucose metabolism 
in skeletal muscle and cause further endothelial dysfunction. 
All of these pathophysiological mechanisms link insulin resistance as well as obesity with 
reduced arterial compliance and CHD (Safar et al. 2006a). LGI foods may improve arterial 
compliance through improvements in insulin sensitivity and reduction in FFA and glucose 
concentrations. 
Summary of Arterial Compliance Section 
Arterial Compliance is becoming a recognised and modifiable CHD risk factor. 
Compliance is the change in pressure over the change in volume. Assessment of arterial 
compliance can be carried out by measuring the forward and reflected waves generated 
along the arterial tree and the speed of travel between two major arteries. 
1.7 Obesity 
1.7.1 Definition of Obesity 
Obesity is defmed by a Body Mass Index (BMI) (calculated as weight (kg) divided by 
height squared (mý), above 30 kghný, and overweight is defmed as BMI > 25 kg/lr? 
(Garrow & Webster 1985). Obesity is a state brought about by positive energy balance 
over a prolonged period of time. In practice most of the excess weight reflects excess fat 
accumulation, mainly in adipose tissue. 
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1.7.2 Prevalence and Economic Cost of Obesity 
Obesity is now an epidemic with more than I billion people being overweight and at least 
300 million being clinically obese worldwide (World Health Organisation 2003). In the 
UK, 42% of men and 32% of women are overweight and 25% of men and 20% of women 
are obese (Ruston et al. 2004). Obesity accounts for 2-7% of total health care costs in 
developed countries (World Health Organisation 2003) while in the UK, treating the 
complications of obesity costs the NHS over half a billion pounds per year (Boum 2001). 
1.7.3 Causes of Obesity 
Obesity, a condition where body fat is in excess, is fundamentally caused by a chronic 
imbalance between the amount of energy eaten as food and the energy expended by the 
body. Obesity is commonly believed to result from excessive fat and sugar consumption 
and a sedentary lifestyle (Ludwig 2000; World Health Organisation 2003). WHO 
attributes this kind of lifestyle to economic growth, modemisation, urbanisation and 
globalisation of food markets as well as less physically demanding work (World Health 
Organisation 2003). WHO/FAO have pulled together evidence from epidemiological, 
experimental and intervention studies on the dietary factors that may affect the risk of 
obesity (Table 1.7) (World Health Organisation/Food and Agriculture Organisation 2003). 
Ecological analyses have shown a positive association between intake of fat and the 
prevalence of obesity (Bray & Popkin 1998) attributed to high fat hyperphagia (Stubbs et 
al. 1995) and passive overconsumption with an inadequate down regulation of 
consumption to match the increased energy density of the food consumed (Stubbs et al. 
1996). The concentration of education or socio-econon-& status are inversely related to 
inappropriate food choices and the prevalence of obesity (James et al. 2001). It appears 
that the human body easily tolerates positive energy balances, leading to weight gain 
(Blundell & Gillett 2001). 
Other than environmental influences, the 2004 update of the human genome coding, 
identified more than 600 genes, markers and chromosomal regions which have been 
associated or linked with human obesity phenotypes (Perusse et al. 2005) while twin, 
adoptee and family studies found genetics to account for 67% of the variance in adiposity 
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(Maes et al. 1997). However, the rapid increase in obesity prevalence in a genetically 
stable population conf= the important influence of the environment (British Nutrition 
Foundation 1999). 
Table 1.7: Dietary Factors that may Influence the Risk of Obesity (World Health 
Organisation/Food and Agriculture Organisation 2003) 
Evidence Decreases risk No 
relationship 
Increases risk 
Convincing Regular physical activity Sedentary lifestyle 
High dietary NSP intake High intake of energy-dense 
foods 
Probable Home and school Heavy marketing of energy- 
environments supporting dense foods and fast-food 
healthy food choices for outlets 
children Adverse social and economic 
Breast feeding conditions 
High sugar drinks 
Possible Low-glycaemic index Protein Large portion sizes 
foods content High proportion of food 
of the diet prepared outside the home 
'Rigid restraint and/or periodic 
disinhibition' eating patterns 
Insufficient Increased eating Alcohol 
frequency 
1.7.4 Consequences of Obesity 
Obesity is a condition with multiple organ specific manifestations, physical, psychological, 
social and medical consequences (Lean 2000). Ultimately obesity can kill (Lean 2000) 
through secondary and multiple metabolic effects which conspire leading to cardiovascular 
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disease, diabetes, stroke, certain forms of cancer, respiratory diseases, infertility and 
psychological disorders (World Health Organisation 2003). 
1.7.4.1 Obesity and Coronary Heart Disease 
It is well established that obesity, especially central obesity, increases the risk of CHD 
exponentially and independently of other factors (National Institutes of Health 1998). 
Around 5% of deaths from CHD in the UK are directly attributable to obesity (The United 
Kingdom Parliament 2004). Obesity has a direct effect on heart disease, causing or 
contributing to cardiac pathology through metabolic complications such as 
hyperlipidaernia, hypertension and hypercoagulation, and it also exaggerates the effect of 
these risk factors (Lean 2000). The major determinant of the metabolic complications is 
increased waist circumference (Nieves et al. 2003), which is a stronger predictor of CHD 
development than weight (Lakka et al. 2002b), and is associated with accerelated 
progression of carotid atherosclerosis (Lakka et al. 2001). Excess adipose tissue leads to 
overproduction of proinflammatory cytokines (Kershaw et al. 2004) such as Tumor 
Necrosis Factor-cc, IL-6, C-Reactive Protein and resistin which can lead to atherogenesis 
(Pickup et al. 1997; Stcppan & Lazar 2002). On the contrary, adiponectin, another 
cytokine also produced by adipocytes, has anti-inflammatory properties and enhances 
insulin sensitivity (Nawrocki & Scherer 2004) but its concentrations are reduced in the 
metabolic syndrome (Matsuzawa et al. 2004). Lcptin, the production of which is 
upregulated in obesity, has been shown to predict cardiovascular events independent of 
traditional risk factors (Wallace et al. 2001). 
1.7.5 Management of Obesity 
1.7.5.1 Weight Loss 
Obesity is managed through diet, exercise, tackling behavioural and psychological factors, 
through pharmacotherapy, and by surgery as a last resort. A 10% intentional weight loss in 
obese patients confers many benefits including reductions of more than 20% in total 
mortality, 30% or more in diabetes-related deaths and 10-30% in blood lipids (SIGN 
1996). Nevertheless, the global trend of increasing obesity prevalence indicates that the 
current prevention and treatment strategies are failing (British Nutrition Foundation 1999). 
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Only three anti-obesity agents are licensed for use in the UK. These are: orlistat (a 
gastrointestinal lipase inhibitor that reduces fat absorption), sibutramine (a monoamine- 
reuptake inhibitor that reduces appetite and increases thermogenesis) and the recently 
available rimonabant (a cannabinoid receptor antagonist that reduces appetite). These 
medications cause an additional 3-5% weight loss compared with placebo but are limited in 
their use by high attrition rates and lack of long-term morbidity and mortality data (Padwal 
& Majumdar 2007). 
1.7.5.2 Weight Loss Maintenance 
Body weight homeostasis is achieved by the balance between energy intake and energy 
expenditure. In order to sustain the benefits of weight loss both on total mortality and 
obesity-related morbidity, body weight maintenance needs to be achieved. Although there 
is a strong consensus that a weight loss of 5-10% of body weight confers many metabolic 
benefits, currently there is no consensus on the definition of weight maintenance following 
weight loss. Expert Committees have addressed this issue (Stevens et al. 2006). The US 
Clinical Guidelines on the Evaluation and Treatment of Overweight and Obesity in Adults 
have defined successful weight maintenance after weight loss as a weight regain of < 3kg 
in 2 years and a sustained reduction in waist circumference of at least 4 cm (NIH 1998). 
The US Institute of Medicine defined weight loss maintenance as losing at least 5% of 
body weight, or reducing BMI by at least I unit, and keeping weight below this minimum 
amount for at least I year (Institute of Medicine 1995). A systematic review found that the 
long term success rate of weight maintenance (all of initial weight loss or over I lkg) for a 
period of 3-14 years was only 15% (Ayyad & Andersen 2000); active follow up being 
associated with better success rate (19%) than passive follow up (10%). Other studies 
found success rates to be between 15-21% depending on the definition used (McGuire et 
al. 1999). 
Strategies used by those who successfully maintained their body weight include: control 
over the pattern of food intake and food items selected, self-monitoring, regular weight 
monitoring, consumption of a low-energy, low-fat diet, eating breakfast, a consistent eating 
pattern, high concentrations of daily physical activity and catching 'slips' before they turn 
44 
Chapter 1: Introduction 
into larger regains (Klem et al. 1997; Wing & Hill 2001; Wing & Phelan 2005). More 
initial weight loss, social support and psychological strength are also important (Elfhag & 
R6ssner 2005). 
Contributors to weight regain are likely to include compensatory metabolic responses to 
weight loss such as reductions in resting energy expenditure associated with a lower body 
weight (Wadden et al. 1990) and leptin (Rosenbaum et al. 1997), and increases in ghrelin, 
an appetite-stimulating peptide (Cummings et al. 2002). These are physiological responses 
aiming to protect humans against the adverse effects of starvation; however, there is an 
asymmetrical control of body weight regulation, strongly defending weight loss but not 
weight gain (Blundell & Gillett 2001) and the 'obesogenic' environment of the Western 
world also contributes to weight (re)-gain. Moreover, maintenance of body weight 
requires as much effort as losing weight but provides fewer rewards thus often leading to 
behavioural fatigue (Wadden et al. 2004). 
1.7.6 Glycaernic Index and Obesity 
LGI diets are suggested to have a role in obesity prevention and treatment through their 
effects of stabilising blood glucose concentrations, improving access to stored metabolic 
fuels, decreasing hunger and thus promoting weight loss or preventing weight gain 
(Ludwig 2003). 
An exaggerated anabolic response following consumption of a HG1 diet as hypothesised by 
Ludwig (2002) (Chapter 1, Section 1.2.4) is supported in animal studies and may lead to 
weight gain. Long-term feeding of rats either LGI or HG1 isoenergetic diets led to an 
increase in epididymal fat pads (Pawlak et al. 2001) as well as increased activity of fatty 
acid synthase and lipogenesis in adipose tissue in the HGI fed animals despite having no 
differences in body weight (Kabir et al. 1998). However, the energy bioavailability of the 
diets was not measure. Dietary GI manipulation may also affect energy balance through 
effects on leptin. This hormone produced by the ob gene (Zhang et al. 1994) in the adipose 
tissue signals the magnitude of energy stores to the brain thus regulating food intake (Caro 
et al. 1996). In rats fed LGI or HGI diets for 12 weeks, plasma leptin concentrations and 
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the ob gene fel in the HGI-fed rats without any differences between groups in adipose 
tissue weight. The high leptin concentrations were inversely related to FFA concentrations 
(Kabir et al. 2000). LGI, hypoenergetic diets also caused a smaller decline in energy 
expenditure and leptin concentrations compared to HGI diets during weight loss, although 
the LGI diets in these studies were also higher in protein content (Agus et al. 2000; Pareira, 
et al. 2004). The link between leptin and insulin concentrations or insulin sensitivity is still 
being investigated since present data is contradictory (Kabir et al 2000). Nevertheless, the 
decrease in leptin is in agreement with the concept that HGI diets are less satiating than 
LGI diets (Holt et al. 1992). 
One of the first human intervention studies addressing the issue of GI manipulation and 
weight reduction in hyperinsulinaemic women found that they lost more weight on a 12- 
week LGI, hypoenergetic diet compared with a conventional balanced diet although the 
energy intakes of the two diets did not differ (Slabber et al. 1994). In terms of fat loss, 
men on a 5-week LGI dietary intervention lost about 700g of total fat mass as assessed by 
Dual-Energy X-Ray Absorptiometry (DEXA) without having any change in body weight 
(Bouche et al. 2002). However, this change in fat mass is close to the DEXA measurement 
error so additional confirmation is required (Lohman 1996). However not all studies 
showed that a LGI diet is more beneficial than a HGI or a low fat diet for weight loss and 
maintenance (Ebbeling et al. 2005; Raatz et al. 2005; Sloth et al. 2004) and there is 
vigorous debate on the application of GI to weight regulation since evidence is still 
controversial (Pawlak et al. 2002; Raben 2002). A recently published study showed that 
obese young adults who had a high insulin secretion following a oral glucose tolerance test 
lost more weight and body fat at 18 months on a low GL than a low fat diet. No difference 
in weight or fat loss was seen for those with normal insulin concentration (Ebbeling et aL 
2007). Although in this trial both the quantity and the quality of CHO were changed, this 
finding suggests that phenotypic differences among individuals may explain some of the 
variability between outcomes of different trials and thus more research, especially long 
term, is required to examine the effects of LGI diets in weight management and the 
mechanisms involved. A discussion of GI and appetite regulation is provided in Section 
1.8.2. 
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Summary of Obesity Section 
Obesity, a condition where body fat is in excess, poses a major burden on health. Weight 
loss can be achieved through lifestyle modifications but weight maintenance is a 
prerequisite for sustaining the metabolic benefits. A variety of strategies are being used by 
those who successfully maintain their weight loss. Evidence suggests that a LGI diet, 
through its slow rate and extent of digestion, might be beneficial in body weight 
management but further long-term intervention studies are required. 
1.8 Appetite 
Humans eat in episodes, i. e. meals and snacks (Gibney & Wolever 1997) and the drive to 
eat is determined by appetite. Satiety is the feeling of satisfaction associated with the 
cessation of food intake (Read 1992), whereas the control of meal size through termination 
of the period of eating is termed satiation (Blundell et al 1994). The drive for food is 
generated by energy expenditure, the major determinant of which is the resting metabolic 
rate (Blundell & Gillett 2001). The short-term signals that help to transmit this energy 
need into behaviour i. e. food ingestion, and to terminate intake are reflected in oxidative 
pathways of fuel use (Friedman & Rawson 1994), abrupt changes in blood glucose 
concentrations (Campfield et al. 1985) and gut-hormone signals to the central nervous 
system (Murphy et al. 2006) while the long-term satiety regulators are leptin and insulin 
(Schwartz et al. 2000). 
1.8.1 Carbohydrate Based Feeding Models 
Several CHO-based models of feeding exist: Mayer's glucostatic theory of eating supports 
that a fall in glucose concentrations would signal hunger and a rise would activate 
hypothalamic centers that suppress food intake (Mayer 1952). This theory was based on 
observations in rodents that hypothalamic glucoreceptors respond to the concentration of 
glucose in blood (Mayer 1952). Russek (1963) postulated the presence of glucose 
receptors in the liver and formulated the hepatostatic theory of energy regulation while 
Flatt (1987) extended these models and evolved the glycogenostatic model of appetite 
based on the CHO stores exerting negative feedback on energy intake. However, the 
relevance of these models on food balance in real life is not yet established (Blundell & 
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Stubbs 1999). Nevertheless, it is evident that acute changes in the blood glucose 
concentration have a major impact on gastrointestinal motor function e. g. hyperglycernia 
slows (MacGregor et al. 1976) and hypoglycaemia accelerates (Schvarcz et al. 1993) the 
rate of gastric emptying. 
1.8.2 Glycaernic Index and Appetite 
LGI foods may promote satiety by preventing marked postprandial hyperglycaemia and 
hypoglycaernia (Brand-Miller et al. 2002) and by stimulating nutrient receptors in the 
gastrointestinal tract for a longer period of time than HGI foods resulting in prolonged 
feedback to the satiety centre in the brain (Lavin et al. 1998). 
Studies in both animals and in time-blinded humans have shown that 'transient' declines in 
blood glucose, (described as a 5% reduction below a stable baseline glucose concentration) 
or 'dynamic' declines (described as rapid declines originating from a peak induced by 
nutrient ingestion) were tightly synchronised with spontaneous meal initiation in both the 
postabsorptive and the postprandial phases (Campfield & Smith 2003). In humans isolated 
from food and time cues, an association was demonstrated between transient declines in 
blood glucose concentration and meal requests while changes in hunger ratings and blood 
glucose patterns were predictive of the next intermeal interval (Melanson et al. 1999a). If 
these results are applied to diet GI manipulation, consumption of a HGI diet would lead to 
food ingestion in the late postprandial phase when reactive hypoglycaernia occurs. 
Overall, this can lead to increased appetite and weight gain. In a study where CHO- 
containing drinks were consumed, the higher the blood glucose peaked, the more hungry 
the subjects were before the subsequent meal (Melanson et al. 1999b). However, a study 
comparing typical European breakfasts found no relation between the glycaemic responses 
and the appetite responses (Flint et al. 2006); although this may be explained by the high 
fat content of some of the meals which would delay gastric emptying and lead to lower 
glucose and insulin responses. 
Moreover, voluntary energy intake of obese teenagers was 53% greater following HGI than 
LGI breakfasts (Ludwig et al. 1999). Also, most single meal studies have found GI to be 
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directly related to postprandial hunger and subsequent voluntary food intake (Ebbeling & 
Ludwig 2001; Ludwig 2000; Roberts 2000). However, a review on the same issue by 
Raben (Raben 2002) disagreed with these fmdings and concluded that short-term human 
intervention data do not provide convincing evidence that LGI meals have a more positive 
effect on satiety and hunger than HGI meals. It may be that HGI CHOs are associated with 
a reduction in appetite and food intake in the short-term (e. g. one hour) and the satiating 
effects of lower GI CHOs are delayed (e. g. 2-3 hours) (Anderson & Woodend 2003). For 
example, consumption of a high amylose (which has a LGI) mixed meal increased feelings 
of fullness for up to 6 hours postprandially compared to a low amylose (which has a HGI) 
meal (van Amelsvoort & Weststrate 1992). 
The satiating benefits of LGI foods may also be related to slower rates of digestion and 
absorption in the gut (Holt et al 1992). Mixed meals with LGI induced greater 
cholesystokinin secretion and greater satiety over a 180-min period (Holt et al 1992). A 
slow rate of digestion may lead to inhibition of gastric emptying which has previously been 
shown to be influenced more by the extent of exposure of the small intestine to nutrients 
than by the concentration of nutrients (Lin et al. 1990). This in turn may stimulate the 
secretion of satiety signals such as glucagon like peptide-I (GLP-1) as shown by 
intraduodenal infusions of glucose which caused appetite suppression and reduction in 
subsequent food intake (Lavin et al 1998), cholecystokinin (Holt et al 1992), and glucose- 
dependent insulinotropic polypeptide (GIP) (Juntunen et al. 2002) 
However, in short term studies of one hour, the higher the glycaemic response, the greater 
the satiety (Anderson et al. 2002). On the contrary, a study comparing LGI and HGI foods 
consumed ad libitum for 8 days did not fmd any differences in appetite ratings or food 
intake (Alfenas et al. 2005). This study however, has been criticised for its blood sampling 
methodology (Ludwig & Roberts 2006). 
Summary of Appetite Section 
Appetite is the drive to eat and it is regulated by both metabolic and hormonal 
mechanisms. LGI foods may influence appetite and subsequently weight status through 
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effects on blood glucose concentrations and/or by stimulating receptors in the 
gastrointestinal tract or appetite regulating hormones. This requires further investigation. 
1.9 Hypothesis 
Manipulation of dietary CHO intake through consumption of LGI compared with a HGI 
diet by human subjects, favourably affects CHD risk factors over and above the 
improvements achieved by a combination of traditional healthy eating and weight loss 
advice on CHD risk. A LGI as opposed to HGI diet also enables better attainment of 
weight maintenance following weight loss. The effects of a LGI diet are hypothesised to 
occur through improvements in fasting and postprandial glucose and insulin 
concentrations, arterial compliance, BP and insulin sensitivity. 
1.10 Alms 
To ascertain whether a long-term LGI as opposed to HGI diet in free-living human 
subjects improves heart disease risk factors over and above the effects achieved by 
healthy eating and weight loss advice. This will be determined by examining the 
effect of this dietary intervention on anthropometrics, fasting lipid profile, 24-hour 
glucose profile, arterial compliance, 24-hour BP, fasting and postprandial glucose 
and insulin responses and insulin sensitivity in subjects at risk of heart disease 
before and after the intervention. 
To determine the effects of a long-term LGI and HGI diets on weight maintenance 
following weight loss by assessing anthropometric changes. Appetite changes and 
fasting and postprandial glucose and insulin concentrations and insulin sensitivity 
before and after the dietary intervention will also be examined. 
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2.0 Methodology Introduction 
This Chapter describes the main methodologies used in the investigations within this 
thesis. In the subsequent Chapters, I indicate which methods were employed whilst 
conducting the investigation and explain any additional methodological details employed 
in the investigations. 
2.1 Ethical Approval and Consent 
Ethical approval was obtained before commencing each investigation from the 
Hammersmith, Queen Charlotte's and Chelsea and Acton Hospitals Research Ethics 
Committee following application. Written informed consent was obtained by each subject 
at the start of the screening visit. All potential subjects were allowed at least 24 hours 
between the time of reading the study's information sheet and consenting in order to 
consider participation. At the screening visit, it was confirmed that they had read the 
information sheet and the study's aims and protocol were explained to them. They were 
encouraged to ask any questions or address any concerns. All volunteers were informed 
that their decision to participate would not affect their current or future care at the 
Hammersmith Hospitals NHS Trust or at their GP surgery and that they were free to 
withdraw at any point throughout the study without providing a reason for this or without 
their care being affected. 
2.2 Subject Recruitment and Screening 
2.2.1 Advertisement 
The studies were advertised at the Hammersmith and Charing Cross Hospitals, the BBC's 
newsletters, in local area newspapers, and by posters at the Hammersmith and Charing 
Cross Hospitals. Potential subjects were asked to complete a pre-screening questionnaire 
to obtain demographic details and information on their body weight and height, medical 
history, use of medication, chance of pregnancy, blood cholesterol, BP and smoking 
(Appendix 1). Only those who met the study's criteria at this stage were subsequently 
medically and dietetically screened. 
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2.2.2 Medical Screening 
A physician took a medical history and carried out a brief examination, an ECG, a blood 
test (to test full blood count, urea and electrolytes, liver and thyroid fiinction tests, lipid 
profile and plasma glucose) and measured BP (Chapter 2, Section 2.5). Exclusion criteria 
were heart disease, diabetes, other clinically significant disease, abnormal thyroid function, 
lipid lowering medication, diuretics and thyroxine, abnormalities in assessed blood 
parameters, abnormal ECG, current participation in other studies or recent blood donation. 
Subjects with BP 'a 160/90 mmHg were referred to their GP for treatment. If 
antihypertensive medication was prescribed, the study commenced when the dose was 
stable for at least one month except for Chapter 4 for which subjects on anti-hypertensive 
medication were excluded. 
2.2.3 Dietetic Screening 
Dietetic screening was carried out to assess eating patterns using a diet history and a 
checklist of common foods. Anthropometric assessments of weight, height, body fat 
(except for Chapter 4), waist, and only for Chapter 4, hip circumference were carried out. 
For the anthropornetric assessment protocol see Chapter 2, Section 2.4. Subjects were 
excluded if they were already following a weight loss programme, inappropriately 
excluded major foods or food groups from their diet; were taking weight loss medication or 
had a history of an eating disorder or depression; and were alcohol abusers or illicit drug 
users. 
2.3 Randomisation 
Randomisation was done to ensure that there was no bias in treatment allocation and that 
subjects in each treatment group were comparable in both known and unknown prognostic 
factors (Swinscow 1997). Subjects were randomised to a LGI or HGI diet using random 
numbers produced by the statistical program ARCUS. A list of subject numbers with a 
random allocation to an intervention was produced and was referred to before randomising 
each subject to the appropriate intervention. 
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2.4 Anthropometrics 
In tile fiollowing discussion, accuracy of a measurement is defined as a measurement that is 
both unbiased and precise and reliability or repeatability rctýrs to the same measurements 
yielding the same results time after time. 
2.4.1 Weight 
Measurement of weight Is a quick, easy and convenient way ofasscssing overall body cell 
mass and energy balance and can be used in coný)unction with height to calculate BMI. 
Weight was measured at each visit in all Investigations in order to record weight changes 
and assess energy balance and to direct dietetic advice. Weight was measured oil digital 
scales (Marsden Ltd., Marsden, Oxfordshire, UK) to the nearest 0.2 kg in light clothing, 
without shoes. The scales were calibrated weekly with a 20 kg weight block. 
2.4.2 Height 
Height was measured once at the screening visit against a wall-inounted stadionleter 
(Marsden Ltd., Marsden, Oxfordshire, UK). The subject was asked to stand upright 
without shoes with his/her head held horizontal with the Frankftirt plane. Tile Frankfurt 
plane is a line from the lower border of the left orbit (the bone under the eye) to tile upper 
margin of the ear canal. The subject was asked to stretch up and stand as tall as possible 
and a check that his/her feet were fully on the floor was carried out before taking the 
measurement. The horizontal bar was lowered until it was resting lightly on the subject's 
head and the measurement was taken to tile nearest 0.5 cm. If the reading fell between two 
marks, the lower reading was recorded. The height measurement was used to calculate tile 
BMI and to measure body composition. 
2.4.3 Body Massindex 
BMI or Quetelet index is widely used for assessing body fatness and classifying 
individuals according to their weipht status as shown in Table 2.1. BMI is calculated as: 
weight (kg) BMI: 
height (m') 
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Table 2.1: International Classification of BMI in Adults (WHO 1998) 
Classification BMI (kghn) 
Normal Range 18.5-24.9 
Overweight >25 
Pre-obese 25-29.9 
Obese class 1 30.0-34.9 
Obese class 11 35.0-39.9 
Obese class III >40.0 
Although BMI is the most widely accepted method for classifying weight status (WHO 
2004), it may lead to erroneous interpretations in muscular individuals and the elderly 
since it does not distinguish between lean and fat tissue. Additionally, BMI does not 
differentiate body fat distribution. To overcome these issues, body composition and waist 
and hip circumferences were also measured. 
2.4.4 Body Composition 
Body composition was measured to determine the amount and percentage of lean and fat 
mass, using an eight-polar bioelectrical impedance (BIA) meter at frequencies of 5,50,250 
and 500 kHz (InBody 3.0, Seoul, Korea). BIA is a simple to use, non-invasive, reliable 
and relatively inexpensive way of assessing body composition (Kushner et al. 1990). In 
BIA, a small alternating current is applied to the body and the resistance or impedance of 
the body to that current is measured. Impedance is the vector sum of resistance and 
reactance. Resistance (R) is the opposition to an electrical current related to the length and 
diameter of a cylinder and is measured by electrical currents flowing through the body 
through body water (Cha et al. 1995). 
The InBody 3.0 consists of eight tactile electrodes: two are in contact with the palm and 
thumb of each hand and two with the anterior and posterior aspects of the sole of each foot. 
It uses segmental multi-frequency BIA analysis by sending minute electric currents that the 
sub ect is unable to feel. The analyser treats the body like a series of connected cylinders j 
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(arms, trunk and legs i. e. 5 cylinders) with a known height and relatively constant 
diameter. If length and diameter are known, R reflects the volume of the cylinders and the 
composition of their fluids that carry an electrical charge. As a result, the resistance index 
i. e. height2/resistance is proportional to the hydrated portion of the body which is the total 
body water and lean body mass. By subtracting the lean body mass from the weight, the 
fat mass (the non-hydrated portion of the body) can be calculated (Cha et al 1995). 
According to manufacturer's data, the accuracy and reproducibility of the InBody 3.0 
analyser are high. Compared with gold standard methods such as DEXA, the correlation 
coefficient for the lean body mass was r=0.983 (N=307, SEE=1.92 kg) and its 
reproducibility was within 0.5% of body fat (Biospace 1999). However, there are a few 
issues with this data that question its reliability and applicability. Firstly the correlation 
coefficient seems very high for human data. Agreement between two techniques should 
have been carried out by Bland-Altman plots rather than correlation (Bland & Altman 
1986). Also, most subjects weighed less than 80 kg, whereas in the studies in this thesis, 
the average body weight is higher than this. In comparison, for another body composition 
analyser based on 8 electrodes (Tanita, Tanita Corp., Tokyo, Japan), the correlation 
coefficient between body fat and DEXA was r=0.87 (Pietrobelli et al. 2004). A study 
comparing InBody with DEXA found that BIA offered accurate estimates of total and 
appendicular body composition and reported the between-day precision of InBody 3.0 to 
be < 2.7% and the within day precision: 5 2.0% in obese and non-obese subjects (Malavolti 
et al. 2003; Medici et al. 2005; Sartorio et al. 2005). Lastly, a comparison of the InBody 
3.0 analyser with Magnetic Resonance Spectroscopy (MRI), a gold standard method of 
measuring body fat, revealed an excellent agreement between the two methods assessed by 
Bland-Altman Plots (Thomas et al. 2000). Based on this data, I considered the InBody 3.0 
analyser a valid machine for body composition assessment. 
Measurements were taken in the fasting state with an empty bladder. The subject stood on 
the machine and held the hand electrodes after wetting his/her soles and hands. The 
subject's age, height and gender were input into the machine. The measurement took 
about 2 minutes and a report of the muscle mass (kg), body fat mass (kg), percent body fat, 
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oedema exam and other indices was obtained. The repeatability coefficient was calculated 
on a sub-sample of subjects to examine the variation between measurements (see Chapter 
2, Section 2.20 for methodology, Chapter 4, Section 4.8.4.1.3 and Chapter 5, Section 
5.8.6.3.2 for results). 
2.4.5 Waist Circumference 
Waist circumference relates both to total body fatness and specifically to intra-abdominal 
fat (Lean et al. 1996). Central obesity, defined as waist measurement ý. - 94 cm for men and 
ý: 88 cm for women (International Diabetes Federation 2005) is a major determinant of a 
dysmetabolic risk profile and is closely associated with CHD risk and mortality (Despres 
2006) (Yusuf et al. 2005) (Chapter 1, Section 1.5.3.1). Abdominal obesity has been 
identified as one of the nine risk factors which account for more than 90% of the 
worldwide MI risk (Yusuf et al. 2004). Waist-to-height ratio (WTHR) has also been 
suggested as an alternative method of assessing health risk as it is easier to measure and 
calculate than BMI and a cut-off of 0.5 indicates risk in both genders and across ethnic 
groups (Ashwell & Hsieh 2005). However, other investigators consider the correction of 
waist circumference for height unnecessary (Han et al. 1997). 
Waist circumference was measured to the nearest 0.5 cm over one layer of clothing using a 
flexible, non-stretch measuring tape, at the midpoint between the lowest rib and the iliac 
crest as recommended by WHO (Lean et al 1996). The subject was asked to look straight 
ahead and breathe normally. The measurement was made at the end of a normal 
expiration. The measurement was taken twice and the average of the two measurements 
was recorded. 
Most of the subjects participating in the investigations in this thesis were either overweight 
or obese. Because of the abdominal fat tissue which causes difficulty in locating the bone 
markers, measurement of an obese person's waist is not easy. In order to minimise 
variation, the same methodology was used for taking repeated measurements throughout 
the research study and all measurements in all studies were carried out by myself The 
repeatability coefficient was calculated on a sub-sample of subjects to examine the 
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variation between measurements (see Chapter 2, Section 2.20 for methodology, Chapter 4, 
Section 4.8.4.1.1 and Chapter 5, Section 5.8.6.3.1 for results). 
2.4.6 Hip Circumference 
Hip circumference is related to disease in an inverse way, such that a relatively large hip 
circumference is associated with lower risk of CHD, probably because hip circumference 
reflects muscle mass (Han et al. 2006). Waist-hip ratio (WHR) was introduced on the 
assumption it would predict fat distribution better than waist circumference alone. In a 
study of 52 countries, WHR was found to have the strongest relationship with MI risk 
across all ages and ethnic groups compared with BMI, waist and hip circumference (Yusuf 
et al 2005). However, this study has been criticised for not using a standardised method in 
assessing waist circumference (Han et al 2006). When fat distribution was assessed by 
MRI, waist circumference rather than WHR was found to correlate better with abdominal 
visceral adipose tissue accumulation and was a better indicator of cardiovascular risk 
(Pouliot et al. 1994). Most studies assess only waist circumference rather than WHR. 
Hip circumference was measured to the nearest 0.5 cm, twice over one layer of clothing 
using a flexible, non-stretch measuring tape at the concentration of the hip bone. The 
average of the two measurements was recorded. Measurement was taken only for Chapter 
4. Hip circumference was required as one of the input data by the Complior software for 
Pulse Wave Velocity assessment. The repeatability coefficient was calculated on a sub- 
sample of subjects to examine the variation between measurements (see Chapter 2, Section 
2.20 for methodology, Chapter 4, Section 4.8.4.1.2 for results). 
2.5 Blood Pressure and Pulse 
Blood pressure and pulse were measured in all studies at screening using the automatic 
sphygmomanometer Omron 7051T. Omron 705IT has been validated against the mercucy 
sphygmomanometer and achieved an 'A/A! performance classification under the British 
Hypertension Society criteria (Coleman et al. 2006). The measurement was taken three 
times on the right brachial artery, in the sitting position after resting for at least 5 minutes. 
The average of the readings was calculated and used in analysis. 
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2.6 Energy Requirements 
The energy requirement of an individual is defined as 'the energy intake which will 
balance energy expenditure when the individual has a body size and composition and 
concentration of physical activity consistent with long-term good health' 
(FAO/WHO/UNU 1985). 
2.6.1 Energy Balance 
Energy balance represents the difference between metabolisable energy intake and total 
energy expenditure (Schutz & Garrow 2000). Positive energy balance, which can occur by 
increases in energy intake and/or reductions in expenditure leads to body weight gain and 
negative energy balance is reflected in body weight loss. When a person gains or loses 
weight the labile tissue is 75% fat mass and 25% lean mass, giving it an energy density of 
7000 kcal/kg. Thus, a 500 kcal/day deficit is expected to lead to a reduction of 0.5 kg of 
body weight per week (i. e. 7x 500 = 3500 kcal). 
2.6.2 Estimation of Energy Requirements 
The subjects' energy requirements were calculated in order to compare reported against 
calculated energy intakes and to guide weight loss advice where appropriate. Energy 
requirements are mainly determined by the basal metabolic rate (BMR) and physical 
activity concentrations (PAL). Schofield equations (Schofield 1985) were used to 
calculate the BMR of each subject. Most of the subjects were overweight and since 
adipose tissue has a lower metabolic rate than lean tissue, the BMR of obese persons may 
be over-estimated by the equations. However, when the BM&AiniatedmBMR. easured was 
plotted against In(BMI), for males there was no significant difference between BM&St and 
BMR... while for females, the difference was highly significant for those with BMI > 
35kg/mý (Black et al. 1996; Black 2000). Since only a small portion of the population in 
the investigation fell under this category and could thus be affected, no change to the 
estimated BMR was made. 
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PAL was assigned to each subject according to COMA recommendations (Department of 
Health 1991) (Table 2.2) following questioning on occupational and non-occupational 
activity and using the Baecke Questionnaire scores (Chapter 2, Section 2.12.1). Energy 
requirement (ER) was calculated by multiplying BMR by PAL. 
Table 2.2: Calculated Physical Activity Concentration of Adults at 3 
concentrations each of Occupational and Non-Occupational Activity 
(Department of Health 199 1) 
Non-Occupational 
Activity 
Occupational Activity 
Light Moderate Moderate/Heavy 
Male Female Male Female Male Female 
Non-active 1.4 1.4 1.6 1.5 1.7 1.5 
Moderately active 1.5 1.5 1.7 1.6 1.8 1.6 
Very active 
1 
1.6 1.6 1.8 1.7 1.9 
11 
1.7 
1 
2.7 Dietary Intake 
2.7.1 Food Diaries 
Seven-day food and drink diaries were used to assess habitual food intake at screening in 
all studies and dietary compliance in Chapter 3. Three-day food diaries were used to 
assess dietary compliance in Chapters 4 and 5 (Appendix 2 shows an example of a I-day 
diary). For the 3-day diaries, subjects were asked to record their intake on 3 consecutive 
days including a weekend day or if they worked during the weekend, two working and one 
consecutive non-working day. This was done to obtain an accurate record of energy intake 
since previous research showed that individuals tend to cat 20% more on weekend days 
than weekdays (de Castro 199 1). 
Subjects were asked to record their intake using household measures such as tablespoons 
and descriptions of portion sizes e. g. large pork chop. They were discouraged from 
weighing their foods to prevent altering their intake. Although weighed food records are 
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the gold standard method of assessing food intake, this method may be inconvenient since 
it requires carrying recording equipment and could lead to subjects altering their dietary 
intake in favour of foods that are easier to weigh (Thomas 2001). Household 7-day and 3- 
day food diaries have been shown to correlate well with 7-day weighed food diaries 
(Bingham et al. 1994). Although using household rather than weighed records may lead to 
loss of a certain amount of quantitative accuracy, subject compliance and participation is 
likely to be higher. 
Subjects were given verbal and written instructions on how to record their dietary intake. 
They were asked to record all food and drinks consumed just after consumption to prevent 
recall bias and to give information on the method of preparation and cooking, use of oil, 
addition of sauces, dressings and spreads and provide recipes where possible. They were 
also asked to provide packages and labels of consumed food and these were added directly 
to the diet analysis programme. If eating out, they were asked to provide as much detail as 
possible of the food and portion size consumed. 
When the diaries were returned, any discrepancies were discussed and the Food Portion 
Sizes Photographic Atlas was used to estimate portion sizes where necessary (Nelson et al. 
1997). The Atlas consists of pictures of foods in different portion sizes. The subject was 
shown the food in question (e. g. rice) in different portion sizes as well as a picture of a 
plate in real life dimensions and was asked to indicate which portion size was closer in 
amount to his/her intake. The diaries were analysed using the dietary analysis computer 
programme Dietplan6 (Forrest Hill Software Ltd, Sussex, UK). All diaries were analysed 
by myself or by students and then checked by myself 
2.7.2 Validation of Food Intake Records 
Although food diaries are one of the most accurate ways of assessing food intake, it is 
widely known that overweight persons underestimate and/or underreport their dietary 
intakes by approximately 20% as compared to estimated total energy expenditure (Hoidrup 
et al. 2002). This has been confirmed by using the doubly-labelled water method, by 
measuring urinary nitrogen excretion and by calculating the energy intake to BMR ratio 
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(Bandini et al. 1990; Braarn et al. 1998; Livingstone et al. 1990; Schoeller et al 1990; 
Zhang et al. 2000). Underreporting or 'under-eating' during the assessment period leads to 
food records of poor validity which has implications for the interpretation of studies of diet 
and health (Black 2000). 
Records of poor validity were identified using the Goldberg cut-off method (Black 
2000; Goldberg et al. 1991). This is the lower 95% confidence limit of reported Energy 
Intake to BMR ratio (El,, p: BMR) (which is also the PAL), below which energy records 
should be rejected as they are not compatible with long-term survival (Goldberg et al 
1991). 
A Goldberg cut-off of 1.05 was used, as proposed by Black, for identifying under-reporters 
at an individual concentration, using 7-day records and assuming a PAL of 1.55 (Black 
2000). 1 calculated the EI,, p: BMR ratio for each subject using their baseline 7-day diaries 
and the Schofield equations respectively (Schofield 1985). It should be noted though that 
the Goldberg cut-off is best applied at a population concentration. At an individual 
concentration, the Goldberg method has a poor sensitivity for defining invalid reports since 
it depends on knowledge of energy requirements and energy expenditure, both of which 
were also indirectly estimated and therefore are subject to errors (Black 2000). However, 
the Goldberg method is a widely accepted and used method of identifying underreporters. 
Validation checks were not applied to food records kept after randomisation since most 
subjects in this thesis were advised on weight loss which by definition requires a reduction 
in energy intake. 
2.8 Dietary Glycaemic Index Manipulation 
The individual's dietary GI was altered according to the diet they were randomised to 
follow i. e. LGI or HGL Dietetic advice was provided on a one to one basis and subjects 
were asked to include at least one CHO-containing food with each of their meals and 
snacks from a list of either HGI or LGI CHOs (Appendix 3). 
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On the HGI diet, subjects were asked to C011SUrne white or wholenical bread, french bread, 
breakfast cereals such as Shredded Wheat, Cornflakes, Weetabix, potatoes (baked, mashed, 
roasted), couscous and risotto rice or short-grain, easy-cook rice as their main sources of 
CHO. For snacks, subjects were asked to consurne melon, pineapple, raisins, dates, ryvita, 
rice cakes and water biscuits. On the LGI diet, subjects were asked to consume granary or 
seeded bread, brown pitta bread, breakfast cereals such as Allbran, rnuesh and porridge; 
sweet potatoes, pasta, noodles, basmati slow-cook rice, beans, lentils and Pulses as their 
primary CHO sources. For snacks, they were asked to consurne apples, citrus fruits, dried 
fruit, unsalted nuts, muesli bars and popcorn. Both groups were asked to avoid foods of 
the opposite GI which were also listed. Their baseline food diary was used as a basis of 
advice and to provide alternative ideas for meals and snacks. 
2.9 Dietary Glycaernic Index Calculation 
GI calculation was based on digestible CHOs (not including dietary fibre) as proposed by 
Wolever (1985b). This approach is in line with the methodology used to test tile GI value 
of foods (Foster-Powell et al 2002). The dietary GI value was calculated for each food 
diary. Following analysis of a food diary, a list of CHO-containing foods and their 4: 1 
corresponding percentage CHO contribution (in comparison to the whole diet reported in 
the food diary) was reported. A GI value (taking glucose as the reference food) was 
assigned to all recorded CHO-containing foods for which GI could be feasibly measured 
(i. e. containing ý! 5g CHO/100g of food) or for which it would be possible to consume a 
portion containing 25g CHO within 15 minutes (e. g. most starch-containing foods). This 
methodology excludes foods such as cheese, fats, spreads, sauces and vegetables 
containing a small amount of starch such as green leafy vegetables. Tubers and legumes 
were assigned a GI value. . The 
formula used to calculate the dietary GI is as follows 
(Wolever & Jenkins 1986): 
Gldiet GI O. j x 
Quantity of carbohydrate in the food (g) 
Total quantity of carbohydrate in the diet (g) 
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Foods were assigned a GI value from tile International Table of Glycacmic Index Values 
(Foster-Powell et al 2002) or from the University of Sydney's website of tested foods 
which is regularly updated with new foods (University of Sydney. 2007) or fi-oill other UK 
tested foods (Henry et al. 2005). If the GI of a food was not known, the GI ofan analogue 
food was assigned, for example, clementines were assigned the GI of oranges. 'File GI of 
mixed meals (e. g. apple pie or bean salad) was calculated using standard recipes by 
multiplying the percentage contribution of each of the CHO containing food component by 
its individual GI value (Frost & Dornhorst 2000) using the following formula (Wolever & 
Jenkins 1986): 
Glycaernic Index of Mixed Meal = (Gll)(PCFI) + (Gl, )(PCF, ) + (CI13)(PCF3) 
Where 
The three CHO foods are 1,2 and 3 
The Glycaemic Index for each CHO-containing food is Gli, Gl-, and G13 
The CHO content is C1, C-, and C3 
The total meal CHO (TMC) is (Cl + C-, + C-3) g 
The proportion of CHO from each food (PCF) is PCF, = C, /TMC (g), PCF--, = C2/TMC (g) 
and PCF3 = C3/TMC (g) 
2.10 Dietary Glycaernic Load Calculation 
The dietary GL of each food diary vvas calculated after calculating, dietary GI using the 
following formula: 
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2.11 Calculation of GI Values Obtained from Published 
and Estimated Sources 
The source of the GI value (i. e. published source or estimated) assigned to each food was 
recorded in order to calculate the proportion of CHO assigned a GI value from published 
sources and that for which GI was estimated. The proportion of CHO in GI calculations 
attributable to each source for each food diary was then recorded and a percentage was 
obtained for all analysed diaries. This is recorded in individual study Chapters (Chapters 
3-5). 
2.12 Physical Activity and Fitness Assessment 
2.12.1 Baecke Questionnaire 
The Baecke Questionnaire was used to assess physical activity (Baecke et al. 1982) 
(Appendix 4). The questionnaire was administered before and after the interventions so 
that changes in physical activity could be assessed. The Baecke Questionnaire is widely 
used to assess habitual energy expenditure as it elicits the pattern of the general lifestyle. It 
is a short, self-administered questionnaire consisting of 16 questions which assess 1) 
physical activity at work, 2) sport during leisure time and 3) physical activity during 
leisure time excluding sport, thus determining habitual physical activity (Baecke et al 
1982). Subjects that did not have a regular job were advised to fill in the 'physical activity 
at work' section based on the activities they carried out during the time period of 9: 00- 
17: 00, which are the usual working hours. Questions in each section were scored on a 5- 
point Likert scale, ranging from "never" to "always". The two most frequently reported 
sports activities were explored in additional questions with questions on the number of 
months per year and hours per week of participation. The three derived indices i. e. work, 
sports, and leisure were scored in arbitrary units ranging from 1 to 5. The sum of the three 
indices gave an indicator of total physical activity. 
The Baecke Questionnaire has been validated against energy expenditure measurements 
using the double-labelled water technique in 19 healthy men aged 40 years and a moderate 
correlation was found (r = 0.62) (Philippaerts et al. 1999). Reliability was demonstrated 
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with correlations ranging from 0.65 to Q. 93 for 11-month and 1-month test-retest 
respectively (Pereira et al. 1997). Although the questionnaire is easy to use and score, it is 
subjective and self-completed, therefore, subjects can easily over- or underestimate their 
activity concentrations. The gold standard method of assessing energy expenditure is the 
doubly labelled water (Schoeller & Hnilicka. 1996); however, it is expensive and not 
routinely used. Other ways of assessing physical activity include physical activity diaries 
which are exceedingly demanding of subject co-operation, pedometers (Westerterp 1999) 
and recently available devices which combine accelerometers with heart rate or 
temperature monitoring such as the Actiheart (Cambridge Neurotechnology Ltd, Papworth, 
UK) (Brage et al. 2005) and SenseWear Pro ArmbandTm (Body Media, Pittsburgh, PA) 
(Jakicic et al. 2004) which are more accurate and objective ways of energy expenditure 
assessment. However, these gadgets are expensive, rely on subjects wearing them over a 
few days and were not available when the research studies of this thesis commenced. The 
Baecke Questionnaire was chosen as it provided an easy and inexpensive overall 
assessment of physical activity. 
2.12.2 Shuttle Walking Test 
The test provides an objective assessment of fitness concentrations and was used before 
and after the intervention in Chapter 5. It was developed from a validated running test 
designed to measure functional capacity in sportsmen and women (Leger & Lambert 
1982); (Leger & Gadoury 1989) which was subsequently modified to measure walking 
capacity in patients with chronic airways obstruction (Singh et al. 1992). Obese patients 
have increased dyspnoea and reduced exercise capacity (Parameswaran et al. 2006) thus 
this test was considered appropriate for assessing their fitness. The test has been 
previously used in obesity clinics (Frost et al. 2002), however, although it has been 
validated in other populations (Leger & Lambert 1982; Singh et al 1992; Taylor et al. 
2001), to my knowledge it has not been validated for use in the obese. Nevertheless this 
problem was partly overcome by using a within-subject, repeated-measures design i. e. 
changes in fitness were assessed within individuals before and after the intervention 
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Subjects were required to cover a 10-metre distance within a specified amount of time, 
denoted by bleeps from a pre-recorded tape, which became progressively shorter. The test 
started off at a slow walking pace and progressed to faster walking, jogging and finally to 
fast running. The subjects were instructed to stop when they were feeling 'too out of 
breath to continue' and a record was made of the concentration reached. Some of the 
subjects were not able to perform this test due to previous injuries. The test was scored by 
counting the number of 10-metre shuttles covered. 
2.13 Appetite Assessment 
Hunger, appetite and satiety are not tangible or even objectively observed phenomena 
(Blundell 1979) and the sensations are likely to differ both quantitatively and qualitatively 
between individuals (Monello & Mayer 1967). This suggests that these sensations are best 
measured by within-subject, repeated-measures designs (Stubbs et al. 2000). 
2.13.1 Visual Analogue Scales 
Visual analogue scales (VAS) as modified by Hill and Blundell (Hill & Blundell 1982) are 
extensively used for subjective assessment of appetite. The VAS is a straight line (100 
mm) with two extreme states anchored at either end. For example the question 'How 
hungry do you feel right now?, is anchored with 'not at all hungry' at the left end and 
dextremely hungry' at the right end. Subjects were asked to mark the scale with a vertical 
line to answer questions on hunger and fullness. Questions on pleasantness and amount of 
food consumption were also asked to validate the answers on hunger and fullness 
respectively. The distance between the left-hand end and the mark was measured in 
millimetres to quantify the measurement. 
A major problem with ratings of sensations is that it is difficult to objectively validate 
them. It is possible, however, to assess the reliability of the appetite rating system (Stubbs 
et al 2000). Under free-living conditions, hunger, rated by VAS has been shown to be a 
valid predictor of human feeding behaviour in terms of approximate meal size and 
frequency, but a poor proxy of quantitative variables such as energy intake (de Castro & 
Emore, 1988; Mattes 1990). This is because hunger and food intake are both a reflection of 
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physiological systems and of environmental influences such as food availability. A major 
advantage of using VAS is that they are easy and quick to use and simple to interpret and 
do not require the subject to use their own descriptive terms (Stubbs et al 2000). VAS 
have been shown to be sensitive to changes in appetite caused by sibutramine, a drug 
inhibiting food intake (Barkeling et al. 2003; Hansen et al. 1999) and to those following 
administration of appetite-regulating gut hormones (Flint et al. 1998; Greenough et al. 
1998). This provides an indirect assessment of their validity. Their reproducibility (test- 
retest reliability) has been shown in whole-day (Stubbs et al 2000) and single-meal studies 
(Flint et al. 2000) although this has been disputed by Raben (1995) who reported poor 
reproducibility due to biological day-to-day variation in appetite sensation. VAS yield the 
most valuable information when combined with other measurements of feeding behaviour 
and energy balance (Stubbs et al 2000) therefore they were used in combination with food 
diaries and body weight assessments. Nevertheless, as discussed by Stubbs (2000), a direct 
and high correlation between feeding behaviour and subjectively expressed appetite or 
hunger should not always be expected. 
2.14 Metabolic Response Assessment 
Blood samples were collected for the assessment of the fasting glucose, insulin, cholesterol 
and triacylglycerol concentrations and postprandial glucose and insulin concentrations to a 
mixed meal at different time points in the studies. 
2.14.1 Preparation for Assessment 
Subjects were asked to fast for 12 hours overnight before each assessment and to refrain 
from drinking alcohol and undertaking strenuous exercise 24 hours before the assessment 
to ensure similar glycogen stores before each measurement (Costill 1988). Smokers were 
asked preferably to refrain from smoking or if they did not, to smoke the same number of 
cigarettes before each study day but not more than two cigarettes. This was recorded. All 
subjects were asked to record their food intake 24 hours before each study day but intake 
was not standardised as the airn was to assess the effect of the chronic intervention. 
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2.14.2 Investigation Days 
On the assessment days, subjects were required to arrive at the Hammersmith Hospital 
with the minimum physical effort. Study days commenced between 8: 00 - 10: 30, the 
starting time being similar on both assessment days. Following anthropometric 
measurements and explanation of the investigation day protocol, an intravenous cannula 
was inserted into the antecubital fossa for serial blood sampling. Subjects were required to 
remain resting during the study days and were not allowed to sleep. They were not 
allowed to consume any food or drink except the test meal and smoking was prohibited. 
At time 0, a standard breakfast was provided, which differed for individual studies, and 
subjects were instructed to consume all of this within 15 minutes. The composition of the 
breakfast and the duration of the postprandial assessment are presented in the individual 
study chapters (Chapters 3-5). HGI breakfasts were provided to allow sufficient increases 
in glucose and insulin responses for comparison between study visits. 
2.14.3 Blood Sampling 
Blood samples were taken from the cannula at set time points as detailed in individual 
study chapters (Chapters 3-5). To keep the cannula patent throughout the assessment 
period, it was flushed with 10ml boluses of 0.9% sodium chloride solution at regular 
intervals. At each time point the first 2 ml of aspirate was discarded since it contained the 
sodium chloride solution. 8 ml blood samples were collected into lithium heparin tubes 
containing 0.2 ml of 4000-kIU aprotinin, a protease inhibitor ('Trasylol', Bayer PLC, 
Newbury, Berks, UK) for the analysis of insulin and straight after this, 3 ml blood samples 
were collected into fluoride oxalate tubes for the analysis of glucose. All samples were 
centrifuged at 3000 rpm for 10 minutes and the plasma was separated, aliquoted into 
plastic 2.5 ml tubes, pre-labelled with the subject's initials, investigation number, time 
point and date and frozen at -20'C until analysis. 
2.14.4 Fasting Blood Samples 
Three fasting blood samples were taken in the first 30 minutes (i. e. time -30, -15 and 0) of 
the assessment period before the provision of the mixed meal. These were used for 
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assessing concentrations of glucose, insulin, lipoproteins, and triacylglycerols (see Chapters 
4 and 5 for details). 
2.15 Blood Sample Analysis 
2.15.1 Measurement of Glucose 
I measured plasma glucose concentration in duplicate using an autoanalyser (Olympus AU 
2700, product number: OSR6121) which employs the hexokinase method (Neese et al. 
1976). The inter and intra-assay coefficient of variation (CV) of samples measured with 
this machine at 6.5 mmol/I is 2.9%. Details of the samples analysed can be found in 
Chapters 4 and 5. 
2.15.2 Measurement of Insulin Concentration and Homeostasis 
Model Assessment Calculation 
Plasma insulin concentrations were measured by Mr Kehinde Agoro at the Hammersmith 
Hospital Clinical Chemistry Department using a fully automated immunometric 
microparticle immunoassay performed on an Abbott Axsym provided by Abbott 
Diagnostics, Abbott Park, IL, USA. The inter- and intra-assay CV was 4.4 - 5.2% across 
the working range of the assay. Details of the samples analysed can be found in Chapters 4 
and 5. 
The Homeostasis Model Assessment (HOMA) was used to calculate P-cell function (%P), 
insulin sensitivity (%S) and insulin resistance (IR, the reciprocal of %S) from fasting 
insulin and the corresponding fasting glucose concentrations (Levy et al. 1998; Turner et 
al. 1979). HOMA is a valid and convenient measure of insulin sensitivity in normal, 
insulin resistant and diabetic subjects (Hermans et al. 1999). HOMA provides a predicted 
value for P-cell function and peripheral and hepatic insulin sensitivity since the relationship 
between glucose and insulin in the basal state reflects the balance between hepatic glucose 
output and insulin secretion maintained by a feedback between the liver and the pancreatic 
P-cells (Turner et al 1979). Because insulin is released in a pulsatile manner, the mean of 
three fasting samples taken in at least 5-min intervals is theoretically better than a single 
value (Matthews et al. 1985), however, due to cost constraints, the mean of two samples 
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was used in this thesis. When HOMA %P and HOMA 'YoS were computed frorn the nican 
of three basal samples and from a single basal sample, near-perfect correlations were found 
(r=0.99, P<0.0001), although the intra-subject CV was higher when HOMA was computed 
from one rather than three samples (Wallace et al. 2004a). HOMA correlates well with the 
liyperiiisulinaenilc-euglycaeinic and the hyperglycaernic clanip which are ofien rctlerred to 
as the 'gold standard' tests (Matthews et al 1985), although these measurements are not 
necessary equivalent. HOMA's reproducibility has been reported to be between 7.8-11.7% 
(Bonora et al. 2000; Emoto et al. 1999). The updated HOMA model (Levy et al 1998), 
with nonlinear solutions, is available as a computer programme: the HOMA calculator 
from the University of Oxford, Diabetes Trials Unit, which has been recalibrated in line 
with current insulin assays. It is calculated using the following formula (Matthews et al 
1985): 
%P = 20 x insulin(ý,, uIjV(glucose( 1,,,, )-3.5) 
IR (tile reciprocal of %S) = (IFISUfin(,,, u,, j) x glucose( ..... ol. ft))122.5 
cell function, IR = Insulin Resistance, S= Insulin Sensitivity 
inU/I pmol/6.945 
insulin and glucose refer to fasting values. 
2.15.3 Measurement of Glucose, Lipids and Triacylglycerols by the 
Hospital's Clinical Chemistry Department 
Analysis of glucose, lipids and triacylglycerols on individual fasting blood samples was 
carried out by the Hammersmith Hospital Clinical Chemistry Department by standard 
methodology (see Chapters 3-5 for details of samples analysed). For all these analyses, the 
Olympus AU 2700 analyser was used. Cholesterol analysis was carried out by the 
Olympus product number OSR6116 using an enzymic method. The inter-assay CV of tile 
autoanalyser at 4.5 mmoUl was 2.6%. HDL cholesterol and triacylglycerols were analysed 
by Olympus product number OSR6133 analyser using an immuno inhibit ion/enzymic 
method and an enzymic method, respectively. The inter-assay CV for HDL cholesterol at 
0.75 mmol/I was 2.6% and for triacylglycerols at 1.1 mmot/l, 2.9%. LDL cholesterol was 
calculated using the Friedewald equation as follows (Friedewald et al. 1972). 
LDL cholesterol = total cholesterol - [(HDL cholesterol + triacylglycerol)/2.2] 
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2.16 Area Under the Curve and Incremental Area Under 
the Curve 
2.16.1 Area Under the Curve 
The area under the curve (AUQ is a useful way of surnmarising the intiormation from a 
series of measurements (Altman 1999b). AUC was used in Chapter 3 to assess tile 24-1-ir 
glucose profile. It was calculated using the trapezium rule i. e. by joining the data by 
straight lines to get a 'curve' and then adding the areas under tile curve between each pair 
of consecutive observations. Therefore, if we have measurements y, and y2 at times t, and 
t-,, then the AUC between those two times is: (t, - t-, )(yl+y2)/2 i. e. tile product of tile time 
difference and the average of the two measurements. The total AUC for n+I 
measurements is: 
1 11 -I 
AUC Y -+I-ti)(yi+yi+l) ý 
(t 
2 i=o 
The units of the AUC are the product of the units used for y, and ti. 
2.16.2 Incremental Area under the Curve 
Incremental Area Under the Curve (lAUC) was calculated as recommended by Wolever 
and Jenkins (1986) by applying the trapezium rule and ignoring any area below the fasting 
value. 
IAUC controls for baseline values whereas AUC includes all area, both below and above 
baseline values. IAUC is useful for assessing postprandial response (see Chapters 4 and 5) 
whereas AUC may be more useful when the baseline value is not being controlled for e. g. 
in a free-living situation such as in the assessment of the 24-hr glucose profile (see Chapter 
3) since it measures the total variation from baseline. 
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2.17 Arterial Compliance Measurements 
2.17.1 Conditions of Measurement 
All measurements of arterial compliance were performed in the supine position and a 
pillow was placed under the head. Measurements were done after BP assessment. 
Subjects were in the fasting state and were required to follow the conditions described in 
Chapter 2, Section 2.14.1 for the 24 hours before assessment and the morning of 
assessment. (See Chapter 4 for information on when these measurements were taken). 
2.17.2 Augmentation Index 
Augmentation Index (Al) provides a surrogate assessment of arterial compliance since it 
provides information on wave reflection. It is defined as the difference between the first 
and second peaks of the central arterial waveform, expressed as a percentage of the pulse 
pressure (Wilkinson et al. 1998) (see also Chapter 1, Section 1.6.4.4). 
The Sphygmocorlý system (Version 6-0b, PWV Medical Ptys-Ltd, Sydney, Australia) was 
used to carry out recordings of the right radial and right carotid artery pressure waveforms. 
All data were collected directly into a portable computer. Before commencing 
measurements, the subject's average SBP and DBP, weight and height were input into the 
software package. 
A high fidelity micromanometer-tipped pressure transducer (Millar, model SPT-301, 
Millar Instruments Inc, Houston, Texas, USA) was used to flatten but not occlude the 
artery in question using gentle pressure. When the two surfaces are flattened, 
circumferential pressures are equalised and an accurate pressure waveform. can be 
recorded: this is termed applanation tonometry (Wilkinson et al 1998). Applanation 
tonometry provides a non-invasive means for recording high-fidelity arterial pressure and 
this methodology can be used to estimate aortic AL Radial and carotid tonometries were 
carried out. Radial tonometry is favoured because it is simple to perform and well 
tolerated while carotid tonometry requires a higher degree of technical expertise to achieve 
optimal results and may cause minor discomfort (Adji et al. 2006). 
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The radial artery was measured by lightly applying the probe on the subject's extended 
wrist while the right carotid artery was measured over the subject's extended neck. The 
waveform. was recorded by the Sphygmocoro system for a 10-second period. The software 
system allowed on-line recording of the peripheral waveform, which was assessed visually 
to ensure that the best possible recording was obtained and that artefacts from movement 
were minimised. The software calculates parameters concerning the variability and the 
signal strength of the recorded waves, thus providing a guide to the quality of the 
recording. Two successive recordings were obtained from each artery and measurements 
were repeated if the waveform(s) did not pass the automatic quality control standards 
specified by the software until two recordings of high quality were obtained. The 
SphygmoCor'D system converted radial or carotid waveforms over the 10 second period 
(equal to 8-10 pulses for a person with typical heart rate) into a single ensemble-average 
wave. Radial AI refers to the aortic AI which was calculated by applying a transfer 
function to the radial pulse wave and the brachial BP. Carotid Al refers to the carotid 
artery and a transfer function was not applied. 
The waveforms were taken twice either by the first (myself) or by the second operator 
(Candace Bovill-Taylor (CBT)) and the mean of the two measurements was reported. The 
intra-observer (within observer) and the inter-observer (between observers) repeatability 
coefficient (RC) was calculated on a sub-sample of measurements to assess the variation 
within and between observers (see Chapter 2, Section 2.20 for methodology, Chapter 4, 
Section 4.8.11.2 for results). 
2.17.3 Systemic Arterial Compliance 
Systemic Arterial Compliance (SAC) was calculated based on the 'area' method proposed 
by Liu et al (1989). This uses a multibranched model of the original t-tube model and 
incorporates the entire systemic arterial tree to simulate the impedance of the arterial 
system. Liu et al (1989) demonstrated that the impedance spectrum of this model 
mimicked more closely that of a real arterial system. The 'area' method of SAC 
calculation is the area under the diastolic curve and is based on the calculafion of the area 
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under an arbitrary portion of the diastolic pressure waveform (A,, ) and a VOILIIIIC change 
determined by measurement of stroke volume. It is expressed by the fiollowing equation: 
SAC = Ad/[R(Ps-Pd)] rnl/mrnHg 
where A,, ý area under the diastolic portion of the blood pressure waveform (frorn end- 
systole to end-diastole), 
R total peripheral resistance, 
P, end-systofic blood pressure and 
Pd end-diastolic blood pressure 
Data for measuring SAC were acquired using the Maclab Data System (Chart 0.5, 
MacLab/8e, ADInstruments) by taking a simultaneous recording of the ascending aortic 
blood flow using a Doppler velocimetry probe (MDI Multi-Doplex, Huntleigh Technology, 
Cardiff, UK) placed on the suprasternal notch, and an estimate of aortic root pressure by 
applanation tonometry of the right carotid artery using a Millar probe (as described for 
Carotid Al, Section 2.17.2) (Rajkumar et a] 2000). The Doppler probe provides an analog 
signal proportional to flow in the ascending aorta (Hattie & Angleson 1985). During 
analysis of 10 representative cycles of flow and pressure waveforms using the 
corresponding software, the pressures obtained by tonometry were calibrated against 
brachial diastolic and mean pressure measurements. The braclual mean arterial pressure 
was assigned the area under the carotid waveform and the brachial diastolic pressure was 
assigned the automatically determined end-diastolic point on the carotid waveform. This 
allowed calculation of carotid systolic pressure and thus estimation of central pulse 
pressure (Rajkurnar et al. 1997). Volume flow was calculated as the product of the average 
systolic flow and the aortic root area. Aortic root area was determined indirectly based on 
body surface area and aortic valve radius as shown below: 
Body surface area calculation (as proposed by Dubois and Dubois (1916): 
where BSA = Body Surface Area in in-, W= Weight in kg, H- Height in cm 
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Aortic valve radius was calculated using tile following fiOrmula (McGrath ct al. 1998): 
Aoilic Valve Radius: 0.25 x BSA + 0.52 
Aortic valve area was then calculated by 7rr 2 where r= aortic radius 
Cameron & Dart (1994) found a close correspondence between SAC' calculated froin direct 
intraortic recordings and carotid tonometry. A further evaluation of the area method 
compared to a non-finear computer model of the systemic arterial tree found that the 
method was accurate within 1011/0 except at high heart rates (90 beats/min) (StCrgIOPUlOS Ct 
a]. 1995). 
The RC was calculated on a sub-sample of SAC recordings to assess the reproducibility of 
the measurements (see Chapter 2, Section 2.20 for methodology, Chapter 4, Section 
4.8.11.1 for results). 
2.17.4 Pulse Wave Velocity 
The Complior®R SP (Version 1.1.9r Artech Medical, France) data system was used to 
acquire the pulse wave velocity (PWV) measurements. Bel'ore carrying out tile 
measurements, the subject's BP, weight, height, waist and hip circumferences were input 
into the software and the body distances between carotid-radial and carot id- femoral arteries 
were measured. 
2.17.4.1 Measurement of the Covered Distance Between Two Sites 
The covered distance between the two sites used for PWV recordings was determined by 
superficial (over the skin) measurement with a non-elastic tape. These non-invasive, 
superficial measurements allow only an estimate for the covered distance as accurate 
measurements can only be obtained by catheterisation or angiography. There are a number 
of possible errors related to the superficial measurement methodology (Asmar 1999b). 
With ageing, arteries become longer, larger and more tortuous thus the superficial length is 
usually an underestimation (Sands 1925). In overweight subjects, measurement of tile 
carotid- femoral distance includes the abdominal surface and thus leads to an 
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overestimation of the distance (Asmar 1999b). However, the significance of these errors is 
limited since distance measurements were taken using the same methodology and by the 
same investigator (myself) for all subjects, and repeated measurements of PWV during the 
study were done using the same distances. 
2.17.4.2 Distance Carotid-Radial 
The distance between the two recording sites was measured from the carotid artery going 
past the suprasternal notch to the tip of the clavicle then over the extended right arm to the 
radial artery. 
2.17.4.3 Distance Carotid-Femoral 
The distance between these two recording sites was measured as a straight distance from 
the carotid to the femoral artery. 
For both the above measurements, it has previously been suggested that the distance 
between the suprasternal notch to the carotid artery should be subtracted since the pulse is 
travelling in the opposite direction (Bazett & Dreyer 1922) but this suggestion has not been 
endorsed by this laboratory since it may increase the margin of error as it involves two 
measurements (Asmar 1999b). 
2.17.4.4 Pulse Wave Velocity Measurement 
PWV was estimated by acquiring two simultaneous Doppler flow tracings and the foot-to- 
foot method. Pulse sensors were simultaneously applied at the carotid and radial arteries 
for carotid-radial PWV (brachial PWV) and the carotid and femoral arteries for carotid- 
femoral PWV (aortic PWV) and a recording was taken using the Compliore SP data 
systen-L The measurements were performed on the right side while the subject was lying 
flat. All measurements were performed by the same two investigators (myself and 
Candace Bovril-Taylor (CBT)). Ten consecutive pressure waveforms were recorded to 
cover a complete respiratory cycle since arterial BP is affected by respiration (Asmar 
1999b). All measurements were seen to meet the manufacturers' quality control standards 
indicated in the software package. When a complete cycle was recorded, the distance 
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between the two arteries being measured was input into the program which then 
automatically estimated the PWV. The estimation was made by the foot-to-foot method 
where the time delay between the foot of the two waves is directly measured. The foot is 
defined as the point of intersection of the end of diastole and beginning of systole (Asmar 
1999b). 
The immediately previous version of the Compliore data system has been validated against 
the manual method of measuring PWV which is the 'gold standard'. A significant 
agreement between the PWV values measured by the two methods was found (r = 0.99) 
with a slightly lower (-0.20 ± 0.45 ni/sec) and practically insignificant value taken by the 
automated method (Asmar et al. 1995). Several attempts were made to obtain research on 
validation of this version of the equipment (both from the company and from search 
engines) but these were not successful. 
RC was calculated on a sub-sample of PYN measurements to examine the reproducibility 
of measurements (see Chapter 2, Section 2.20 for methodology, Chapter 4, Section 
4.8.11.1 for results). 
2.18 Ambulatory Blood Pressure Measurement 
24-hr Ambulatory Blood Pressure Monitoring (ABPM) was carried out using the Diasys 
Integra II ABPM system (Novacor SA, Rueil, France) (see Chapter 4). This machine is a 
validated ambulatory BP monitoring device (Gosse et al. 1997; O'Brien et al. 2001) which 
has been used in a number of trials (Constans et al. 1997; Gosse et al. 1994; Pinto et al. 
2006). Before fitting, the monitor was programmed with the subject's details (initials and 
date of birth) using the Diasysoft software (Novacor SA, Rueil, France). The monitor was 
programmed to measure the BP every 30 minutes between 7: 00-22: 00 and every 60 
minutes from 22: 00-7: 00 thus providing a total of 39 readings in a 24-hour period. The 
subject's position, lying or standing was registered at each recording. The monitor was 
fitted on weekdays on both occasions and the subject was instructed not to consume 
alcohol and not to exercise. A 24-hour food diary was kept while the monitor was wom to 
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ensure the subjects followed the dietary regime and restrictions as instructed. When the 
monitor was returned, the information was downloaded and stored. 
The Diasys Integra 11 system comprises the recorder, a cuff with double air/electric tubing 
for connection to the Diasys monitor and an electrocardiogram (ECG) cable with a position 
sensor. A microphone, enclosed within the cuff and placed over the subject's brachial 
artery allowed the detection of Korotkoff sounds. The single-channel ECG cable and 
position sensor recorded the subject's position and also allowed for ECG gating (Pinto et al 
2006). 
The Diasys Integra 11 has two standard modes of operation, the auscultatory (sound) mode 
and the oscillometric (pulse detecting) default mode. At the beginning of each 24-hr 
monitoring, the Diasys run two test measurements. If the quality of the Korotkoff sounds 
was adequate, the monitor operated in auscultatory mode; when Korotkoff sounds could 
not be detected, it operated in oscillometric mode. The ausculatory mode may be used to 
measure arterial compliance using the Q wave (from the ECG) to Korotkoff diastole sound 
interval (Pinto et al 2006). This was not used in this thesis however. 
2.18.1 Editing of the Ambulatory Pressure Recordings 
Prior to statistical analysis, the ambulatory recordings were edited to exclude faulty 
readings. Measurements where the SBP was >240 mmHg or <50 mmHg, the DBP was 
>140 mmHg or <40 mmHg or the pulse rate was >150 or <40 beats per minute and the 
pulse pressure was less than 10% of SBP were excluded. This editing procedure is being 
used in multicentre trials (Staessen et al. 1992). Also, only recordings where at least 25 
out of a possible 39 readings were valid were included in the results. 
2.19 Medtronic MiniMed Continuous Glucose 
Monitoring System 
The MiniMed Continuous Glucose Monitoring System (CGMS) (Minimed, Medtronic, 
USA) was used to record 24-hour glucose profiles in free-living subjects (see Chapter 3). 
It comprises of a sensor connected to a pager-size monitor which can be attached on the 
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subject's waist or kept in his/her pocket. The sensor is a small sterile electrode inserted in 
the abdomen using an automatic insertion device and operated in Situ for all average of 3 
days. It is simple to insert, safe and non-irritating to the body (Monsod et al. 2002). The 
MiniMed CGMS is based on the electrochemical detection of subcutaneous interstitial 
fluid (Mastrototaro 1999). The sensor contains the enzyme glucose oxidase and measures 
glucose concentrations in subcutaneous fluid every 10 seconds, which are then averaged M 
5-minute intervals, recorded and stored in the monitor. The information fi-orn the monitor 
was then downloaded on the computer system. Thus, the CGMS allowed recording of a 
comprehensive profile of 288 glucose readings over 24 hours during normal daily 
activities. A multi-centre clinical trial found a close correlation between interstitial fluid 
glucose concentrations measured by the sensor and blood glucose concentrat lolls 
(Mastrototaro 1999). The MiniMed CGMS was found to detect blood glucose oscillations, 
hypoglycaerma and post-prandial hyperglycaernia to an acceptable clinical accuracy In 
diabetic patients (Monsod et al 2002; Sachedina & Pickup 2003). Moreover, previous 
studies by this department using the MiniMed CGMS on diabetic and healthy subjects 
showed that the CGMS provides accurate and reliable results (Brynes et al. 2003b; Brynes 
et al. 2005). 
2.20 Repeatability Coefficient 
The repeatability coefficient was calculated to assess reproducibility of assessment within 
the same observer or between two different observers (see Chapters 4 and 5). The 
coefficient is the standard deviation (SD) of the estimated difference between two repeated 
measurements performed by the same observer for intra-observer reproducibility and by 
two observers for inter-observer reproducibility. 
RC was calculated using the formula (Bland & Altman 1986): 
RC = 2ý Y_ Di 2 /n 
where n= sample size and Di = difference between two measurements in a pair 
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2.21 Data Processing and Statistical Analysis 
I carried out all data processing and statistical analysis under the supervision of Prof Gary 
Frost., Dr Mary Hickson, Dr Audrey Brynes, and Prof Chakravarthi Rajkumar for Chapter 
4 only. The computer programs SPSS, Excel and Slidewriter were used for undertaking 
statistical analysis, processing and graphically displaying the data. Results in tables are 
presented as mean +/- standard deviation (SD) when normally distributed and median and 
interquartile range [IQR] when non-normally distributed. To determine normality, data 
were tested with the Shapiro-Wilks; test and by examining normality plots on the SPSS 
software. In all analysis, statistical significance was taken as P-<0.05. Results in graphs 
are presented as mean +/- standard error of the mean (SEM) bars. The specific statistical 
tests used for each study are discussed in the corresponding chapters (Chapters 3-5). 
The SEM of a sample is an estimate of the SD that would be obtained from the means of a 
large number of samples drawn from that population or in other words, it is a measure of 
the uncertainty of a single sample mean as an estimate of the population mean. The 
uncertainty decreases as the sample size increases. SEM is defined as the SD divided by 
the square root of the number of observations in the sample (Altman 1999a; Swinscow 
1997) i. e. SEM = SD/4n. 
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3.1 Introduction 
CHD is the leading cause of death in the Western world (Murray & Lopez 1997) and the 
risk of developing this disease is determined by a complex interplay between synergistic 
metabolic abnormalities (Reaven 1988) usually characterised by visceral adiposity and 
insulin resistance (Chapter 1, Section 1.5.3). Impaired glucose tolerance (IGT), 
characterised by elevated postprandial glycaernia, is increasingly being recognised as an 
independent CHD risk factor in non-diabetic individuals (Coutinho et al. 1999; The 
DECODE Study Group 1999). Some evidence suggests that postprandial glycaemia may 
be a better predictor of risk of death from all causes and CVD than fasting glucose 
concentrations (The DECODE Study Group 2001). This may be related to the primary 
determinant of IGT; which is mainly peripheral insulin resistance, as opposed to the main 
factors determining high fasting glucose concentrations i. e. raised hepatic glucose output 
and defects in early insulin secretion (Unwin et al 2002). Even if hyperglycaernia 
increases CHD risk through associated metabolic abnormalities such as insulin resistance, 
the significance of elevated glucose concentration for future CHD development cannot be 
undervalued (Unwin et al 2002). A meta-analysis of prospective studies showed that even 
after adjustment for traditional risk factors, raised blood glucose concentrations were still 
associated with a 19% increase in CVD risk (Levitan et al 2004). The mechan. isms 
directing glucose-mediated vascular damage are discussed extensively in Chapter 1, 
Section 1.5.3.3, but mainly include oxidative stress and inflammation as well as the 
adverse effects caused by insulin resistance. 
A plethora of evidence exists to show that CHD risks are modifiable through avoiding 
smoking, by consuming a healthy diet, increasing physical activity and maintaining a 
healthy weight (Chapter 1, Section 1.5.5) (Third Joint Task Force of European and other 
Societies on Cardiovascular Disease Prevention in Clinical Practice 2003). Consumption 
of a LGI diet, characterised by lower postprandial glucose concentrations (Jenkins et al. 
1987b) was previously shown to lead to significant reductions in 24-hour and overnight 
glucose concentrations in Type II diabetic patients and in healthy subjects (Brynes et al 
2003b; Brynes et al 2005). A LGI diet has also been shown to improve other CHD risk 
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factors including hyperinsulinemia and dyslipidaemia (Jenkins et al. 2002b). However, the 
role of LGI diets in CHD prevention is still not consistent and warrants further 
investigation (Kelly et al 2004). A previous study by Frost et al (2004) which assessed the 
effect of a LGI diet as opposed to a HGI diet provided in addition to healthy eating and 
weight loss advice in heart disease patients, failed to show any benefits on lipid 
concentrations. This might have been due to concurrent drug therapy. The present pilot 
study aimed to assess whether consuming a LGI diet as opposed to a HGI diet in addition 
to following traditional healthy eating and weight loss advice, improves heart disease risk 
factors including 24-hour glucose concentrations, in healthy subjects with heart disease 
risk factors. Subjects on medication were excluded to avoid masking any metabolic effects 
caused by diet. 
3.2 Hypothesis 
Ingestion of a 12-week LGI compared to HGI diet by middle-aged subjects with risks for 
heart disease will improve the following parameters over and above the improvement 
achieved by healthy eating and weight loss alone: 
24-hour free-living glucose profile 
fasting blood glucose 
fasting lipid profile and 
body weight and composition 
thus reducing the overall CHD risk. 
3.3 Ethical Approval and Consent 
The study was ethically approved by the Hammersmith, Queen Charlotte's and Chelsea 
Hospitals Research Ethics Committee (REC: 2003/6727) and subjects gave written 
informed consent before enrolment. 
3.4 Subject Recruitment 
Subjects were recruited by advertisement as described in Chapter 2, Section 2.2.1. 
Subjects were sent the study's information sheet (Appendix 6) and a pre-screening 
questionnaire (Appendix 1) and if deemed eligible at this stage, they were invited for a 
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screening visit (Chapter 2, Sections 2.2.2 - 2.2.3). The following inclusion and exclusion 
criteria applied: 
Inclusion Criteria: 
Healthy subjects aged 35- 65 years old 
At least one recognised risk factor for CHD e. g. fasting total cholesterol > 5.0 
mmol/l, total cholesterol to HDL cholesterol ratio > 5, LDL cholesterol > 3.0 
mmol/l, BMI 27-35 kg/m 2, waist circumference ý: 88 cm for females and ý: 94 cm 
for males, raised BP up to a maximum of 140/90 mmHg and/or family history of 
CHD. Smokers were recruited only if they also had an additional risk factor. The 
Framingham Risk Assessment (Wood et al. 1998) was used to calculate the 10-year 
prospective CHD risk. Individuals with a risk of < 2% or insufficient risk factors 
were not included in the study. 
Exclusion Criteria: 
9 As discussed in Chapter 2, Sections 2.2.2 and 2.2.3. For ease of reading, the main 
exclusion criteria were heart disease, diabetes, other clinically significant disease, 
eating disorder, depression, abnormal thyroid function, abnormalities in blood 
parameters, abnormal ECG, and/or taking lipid lowering medication, anti- 
hypertensive medication or thyroxine. 
Subjects who were deemed eligible for participation were given instructions on how to fill 
in a 7-day food diary as described in Chapter 2, Section 2.7.1 before enrolment in the 
study. 
3.5 Power Calculation 
A power calculation was not carried out since this was a pilot study. 
3.6 Design and Procedures 
3.6.1 Study Design 
The study had a randomised, non-blind, parallel design where subjects were randomised 
(Chapter 2, Section 2.3) to either HGI or LGI diets for 12 weeks. All subjects were advised 
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individually on healthy eating and increasing physical activity and on weight loss HAM > 
25 kg/m 2 (see Section 3.6.2 for details). The fasting and postprandial metabolic response, 
24-hour glycaemic profile and anthropometrics were assessed at baseline and end ot'study. 
The study design is shown in Figure 3.1. 
Figure 3.1: Diagram of Study Design 
Study durawn ( 12 ý, veeks) 
Run-in End 
C'GNIS 12 %veks (fictstry intermition CGNIS 
(med rmed 
AL 41 t 
Baseline Week 6 Week 12 
Test meal Fasting blood sample Test meal 
Anthropometrics Anillroponictfics Anthropometrics 
Small arrows indicate telephone assessments of dietary compliance. The MiniMed Continuous Glucose 
Monitoring System (CGMS) was fitted for 3 days before the start of the study and 3 days before completion 
of the study. The 24-hour period with the lowest mean absolute error in measurement (reported by the 
MiniMed CGMS) was used in the 24-hour analysis. Test meal refers to 3-hour postprandial assessment. 
3.6.2 Intervention 
At the baseline visit, subjects were randornised to either a LGI or HG1 diet and advised on 
dietary changes as explained in Chapter 2, Section 2.8. Tile baseline 7-day food diary was 
used as a basis for providing one-to-one dietary advice. The LGI group was offered a beta- 
glucan bread (GI value: 63), although this was not compulsory and only a few subjects 
consumed it. All subjects were advised on healthy eating for heart disease prevention 
aiming for 50-55% of energy intake from CHOs, <30% energy from total fat, of which 
<10% saturated fat, replacing saturated fats by monounsaturated fats, consurning oily fish 
twice a week and limiting alcohol and salt intake (Wood et a] 2005). They were also 
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encouraged to increase their activity concentrations over and above their current 
concentrations to the equivalent of at least 30 minutes walking a day. Overweight subjects 
(BMI > 25 kg/mý) were advised on weight loss by achieving a deficit of 500 kcal/day, 
which would be expected to lead to a 0.5 kg reduction per week. This was achieved by 
special emphasis on reduction of high fat and sugar sources, limiting portion sizes and 
avoiding alcohol consumption. No energy prescription was provided since it was judged 
that this would have prevented assessment of the diet in free-living subjects. 
3.6.3 Food Diaries 
Subjects were required to fill in a 7-day food diary of their habitual intake before the 
baseline visit. After randomisation, they were required to fill in 7-day diaries at week 5 
and week II of the intervention (Chapter 2, Section 2.7.1). 
3.6.4 Dietary Compliance 
Dietary compliance was assessed at dietetic consultations on weeks 6 and 12 by discussing 
food intake including the CHO-containing foods consumed and avoided, by checking food 
diaries and by taking anthropometric measurements to assess weight and body composition 
changes. Additionally at weeks 3 and 9, telephone dietary assessments were carried out 
which included a 24-hour dietary recall and a checklist of CHO-containing foods 
consumed. Subjects were encouraged to discuss specific concerns including travelling and 
eating out at the above time-points or any other time during the study. If necessary further 
food and snack ideas were provided as well as encouragement to follow the diet. Physical 
activity concentrations were also assessed at all aforementioned time points and 
encouragement to exercise was provided. 
3.6.5 Anthropometrics 
Body weight, waist circumference and percentage body fat were measured at baseline, 
week 6 and week 12 of the study. For details of assessment protocols see Chapter 2, 
Section 2.4. 
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3.6.6 Baecke Questionnaire 
The Baecke Questionnaire (Chapter 2, Section 2.12.1) was used to assess activity 
concentrations at baseline and week 12. 
3.6.7 Medtronic MiniMed Continuous Glucose Monitoring System 
The MiniMed CGMS (Minimed, Medtronic, USA) was used to record 24-hour glucose 
profiles in the free-living subjects before the intervention and during the last 3 days of the 
study as described in Chapter 2, Section 2.19. While the monitor was worn, subjects kept a 
food intake diary and abstained from alcohol consumption since alcohol has a blood 
glucose lowering effect. They were advised to carry on with their usual activity patterns 
but avoid strenuous exercise to prevent displacement of the sensor. To assess the 
correlation of the CGMS readings with blood glucose, subjects were instructed to take four 
finger-prick tests spread out over the day for every 24 hours the sensor was in-situ, using 
portable glucose meters. The 24-hour data with the lowest mean absolute error (as 
reported by the monitor) between the sensor readings and the blood glucose values were 
used in the analysis. The number of eating episodes during the reported 24-hour period 
was measured. An eating episode was defined as any food or drink providing ý: 50 kcal or 
ý: 1 Og CHO and separated by ý: 30 minutes from another food or drink consumed. 
3.6.8 Fasting Blood Tests 
Fasting blood samples were taken at baseline, week 6 and week 12 of the study. At 
baseline and week 12 of study, a total of 3 fasting blood samples were taken before 
provision of the test meal for the metabolic assessment as discussed in Chapter 2, Section 
2.14.3. Subjects were required to follow the conditions described in Chapter 2, Section 
2.14.1 before assessment. From these samples, one was sent to the Hospital's Clinical 
Chemistry Department for analysis of glucose, lipoproteins and TG (Chapter 2, Section 
2.15.3). The other samples were centrifuged and the plasma separated and frozen to -20'C 
until analysis. At week 6, only one fasting blood sample was taken. 
88 
Chapter 3: The Effect of a 12-week Dietary Glycaernic Index Manipulation on Heart Disease Risk Factors 
and 24-hour Glycaernic Profile in Healthy Middle-Aged Subjects at Risk of Heart Disease: A Pilot Study 
3.6.9 Postprandial Metabolic Assessment 
A 3-hour postprandial metabolic assessment was carried out at baseline and week 12 of the 
study. The preparation for assessment and the procedure is explained in Chapter 2, Section 
2.14.1. Blood samples were taken at times -30, -15,0, +15, +30,45,60,90,120,150 and 
180 minutes. The test meal was served at time 0 (to) minutes. 
3.6.9.1 Test Meal 
The test breakfast was served immediately after taking the last fasting blood sample at to 
minutes. It consisted of 60g wholemeal bread, 20g margarine, 40g Weetabix, 250ml semi- 
skimmed milk, 6g sugar and decaffeinated tea or coffee and provided 551 kcal, 73.7g 
CHO, 22.6g fat and 17.8g protein (expressed as percentage of energy: 50.2% CHO, 36.9% 
fat, 12.9% protein). Subjects were instructed to consume all this meal within 15 minutes. 
3.6.10 Blood Sample Analysis 
Fasting blood samples were analysed by the Clinical Chemistry Department as described in 
Chapter 2, Section 2.15.3. Postprandial blood samples were not analysed since no changes 
were seen in the fasting blood samples (see Section 3.7.5). 
3.6.11 Dietary Analysis 
All food diaries were analysed using Dietplan 6 (Forestfield Software). Likely under- 
reporters were identified from baseline 7-day diaries as described in Chapter 2, Section 
2.7.2. 
3.6.12 Calculations of Glycaernic Index (GI), Glycaemic Load and GI 
Sources 
Calculations of GI, GL and GI value sources were carried out as described in Chapter 2, 
Sections 2.9-2.11. 
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3.6.13 Outcome measures 
The primary outcome was the 24-hour glucose profile. Other outcomes were fasting 
glucose and lipid profiles and anthropometric measurements. 
3.6.14 Statistical Analysis 
Data were analysed using SPSS for Windows (Version 12.0, SPSS, Chicago, Illinois, 
USA). The data distribution was assessed using the Shapiro-Wilks test and by examining 
the normality plots. Data are presented as mean ± sd when normally distributed or median 
[Interquartile range QQR)] when non-normally distributed. For all tests, aP value of 
: 50.05,2-sided was considered statistically significant. 
Between-group comparison at baseline, at week 12 and of the changes from baseline was 
done by unpaired Student's t tests for normally distributed data and log-transformed non- 
normally distributed data, by Mann-Whitney U tests for non-normally distributed data and 
data that could not be log-transformed and by chi-square (j2 ) tests for categorical data. A 
within-group analysis of baseline and week 12 values was also carried out to examine 
changes within groups using paired t tests for normally distributed data and Wilcoxon tests 
for non-normally distributed data. The latter analysis was carried out to facilitate direction 
of future work. 
Analysis of the 24-hour and overnight (defined as 21: 00-5: 00) glucose profiles recorded by 
the CGMS was carried out by calculating the AUC using the trapezoid rule (Chapter 2, 
Section 2.16-1). The CGMS results were analysed by carrying out between-group and 
within-group comparisons at baseline, week 12 and changes from baseline using statistical 
tests as above. 
3.7 Results 
3.7.1 Study Population 
Thirty-four subjects were screened, 15 failed to meet the inclusion/exclusion criteria and 
one subject was eligible but failed to start the study. Eighteen subjects were randomly 
allocated to a LGI or HGI diet for 12 weeks. Four subjects dropped out at week 6; 1 due to 
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unrelated health problems, 1 due to work commitments, 1 on the HGI diet because of 
disliking the diet and 1 without giving a reason. Therefore, 14 subjects completed the 
study but I subject in the HGI group was excluded from analysis due to his high alcohol 
intake (24.5% of energy intake) and TG concentrations (4.57 mmol/1) (> mean + 2SDs), 
leaving 13 subjects in total, 7 in the LGI group and 6 in the HGI group. 
3.7.2 Subjects' Demographics 
The demographic details of subjects who completed the study are shown in Table 3.1. 
Although the two groups were not statistically significantly different, the HGI is 
characterised as younger and more overweight than the LGI group. Lack of statistical 
significance was probably due to the small sample size and high variation between 
individual subjects. 
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Table 3.1: Baseline Demographic Details of Subjects by Group 
(Values are numbers (%), mean ± sd or median [IQR]) 
HGI group (n=6) LGI group (n=7) P-valuc* 
Age (y) 44.7±6.4 51.0±7.0 0.1 
Gender 
Male 2(33.3) 4(57.1) 
0.8 
Female 4(66.7) 3(42.9) 
Ethnicify 
Caucasian 4(66.7) 7(100) 
0.4 
Asian 2(33.3) 0 
Weight (kg) 89.7 ± 12.8 81.5 ±4.7 0.2 
BMI (kg/m) 31.5 ±4.4 28.7 ±2.1 0.2 
Body fat (%) 36.7 ± 11.4 31.2± 8.8 0.3 
Waist (cm) 105.1 [102.5-112.5] 99.0 [97.3-100.3] 0.4 
Smoking status 
Smokers 1(16.7) 1(14.3) 
Non-Smokers 2(33.3) 2(28.6) 0.8 
Ex-Smokers 3(50.0) 4(57.4) 
SBP (mmHg) 139 ±15 135 ± 16 0.8 
DBP (mmHg) 88 [81-95] 83 [78-83] 0.4 
Fasting Hood tests 
Total cholesterol (mmol/1) 5.53 ± 0.71 5.49 ± 1.08 0.9 
LDL cholesterol (mmol/1) 3.48 ±0.40 3.61 ±0.88 0.7 
HDL cholesterol (mmol/1) 1.33 ± 0.28 1.38 ± 0.32 0.8 
Total Chol: HDL 4.23 ± 0.62 4.09 ± 0.80 0.7 
Triacylglycerols (mmol/1) 1.58 ± 0.66 1.09 ± 0.46 0.2 
Glucose (mmol/1) 5.10 [4.90-5.30] 5.20 [5.05-5.50] 0.9 
HGI = 11igh Glycaemic Index, LGI = Low Glycaemic Index, BMI Body Mass Index, LDL = Low Density 
Lipoprotein, HDL = High Density Lipoprotein, Total Chol: HDL Total Cholesterol to HDL Cholesterol 
ratio. *P value of between-group comparison by independent t-tests for normally distributed data and log- 
transformed non-normally distributed data, non-parametric tests for non-normally distributed data and for 
data where one group was normally distributed and the other was not normal and could not be log- 
transformed. Chi-squared tests were used for categorical data. 
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3.7.3 Dietary Intake and Composition 
3.7.3.1 Validation of Dietary Intake Records 
The validity of the 7-day food diaries at baseline was assessed using the Goldberg cut-off 
method (Black 2000; Goldberg et al 1991) as discussed in Chapter 2, Section 2.7.2. All of 
the baseline diaries were returned. Three subjects were defmed as under-reporters using a 
EIreP: BMR cut-off of 1.05 (1 in the HGI group and 2 in the LGI group). The high 
prevalence of under-reporting was probably due to most subjects being either overweight 
or obese (Hoidrup et al 2002). 
3.7.3.2 Dietary Composition 
3.7.3.2.1 Comparison between groups 
The dietary intake and composition of the LGI and HG1 groups assessed at baseline, week 
12 and the changes from baseline are shown in Table 3.2. All the diaries at baseline and 
week 12 were returned. There were no significant differences between the groups at 
baseline. At week 12, the HGI group had a significantly higher percentage energy intake 
from starch (P--0.001) and a significantly higher diet GI than the LGI group (P--0.035). A 
between-group comparison of the changes from baseline showed that the HGI group had a 
significantly bigger reduction in energy intake (P'--0.016), which was reflected in the 
Energy Intake to Energy Requirements ratio (EI: EQ (P--0.007). 
3.7.3.2.2 Comparison Within Groups 
3.7.3.2.2.1 High Glycaemic Index Group 
By week 12, there was a significant reduction in energy intake compared with baseline 
(P--0.007) which was also reflected in the EI: Ereq which was lower than baseline 
(P--0.016). The HGI group also had a significant reduction in fibre intake per 1000 kcal 
(P=0.048). 
3.7.3.2.2.2 Low Glycaemic Index Group 
By week 12, energy intake (P--0.007) and EI: Feq ratio (P--0.006) were significantly lower 
compared to baseline. There was also a significant reduction in percentage intake from 
polyunsaturated fat over the 12-week period (P--0.02 1). 
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3.7.4 Sources of Glycaernic Index Calculations 
Table 3.3 shows the contribution of different sources i. e. published or estimated to GI 
calculations during the study expressed as percentage CHO intake. For all GI calculations, 
69.4% of CHO was assigned a GI value from published sources while 26.7% of CHO was 
assigned an estimated GI value. 3.0% of CHO intake was not assigned a GI value. This 
includes foods such as cream, cheese, sauces and vegetables with a low CHO content. The 
percentage of CHO assigned a GI value from published or estimated sources was similar in 
both HGI and LGI groups during the study period. 
Table 3.3: Contribution of Different Sources to Glycaemic Index Calculations 
Expressed as Percentage Carbohydrate Intake at Baseline, Week 6 and 
Week 12 (Values are %) 
Carbohydrate Intake 
Source of GI Value Week 6 Week 12 
Baseline HGI group LGI group HGI group LGI group 
International Tables 42.9 48.6 44.6 37.1 41.5 
mean of several values 
(Foster-Powell et al 2002) 
International Tables 18.9 21.5 22.9 34.7 28.2 
single value (Foster- 
Powell et al 2002) 
University of Sydney 6.3 3.3 10.5 6.6 10.5 
website (University of 
Sydney. 2007) 
Other published 1.3 1.4 0.3 1.9 1.1 
sources (Henry et al 2005) 
Total Published 69.4 74.8 78.3 80.3 81.3 
Sources 
Personal 0.9 3.2 0.5 0.6 0.4 
Communication* 
Estimated 26.7 19.5 19.2 15.9 14.9 
Not coded 3.0 2.5 2.0 3.2 3.4 
HGI = Iligh Glycaemic Index, LGI = Low Glycaemic Index. * Personal communication with Professor 
Jennie Brand-Miller (University of Sydney) regarding the GI assigned to alcoholic drinks such as beer and 
wine which is estimated by their laboratory as 66. 
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3.7.5 Anthropometrics, Activity Concentrations and Fasting Blood 
Tests 
3.7.5.1 Comparison Between Groups 
The results of the anthropometric measurements, activity concentrations and fasting blood 
tests at baseline and week 12 and the changes from baseline are shown in Table 3.4. The 
groups did not differ at baseline or week 12 or in the changes from baseline. Since no 
differences were seen in fasting blood parameters, the postprandial blood samples were not 
analysed. 
3.7.5.2 Comparison Within Groups 
3.7.5.2.1 High Glycaemic Index Group 
There were no significant differences over the study period. 
3.7.5.2.2 Low Glycaemic Index Group 
By week 12, there were significant reductions in weight (P---0.005), BMI (P--0.003) and 
waist circumference (P--0.006) compared with baseline. 
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3.7.6 MiniMed Continuous Glucose Monitoring System 
Complete sets of data from the MiniMed CGMS at baseline and week 12 were collected 
from 12 subjects. The sensor failed in 2 subjects. The subject who consumed an excess of 
alcohol was excluded from analysis as was done before, therefore data for II subjects are 
presented. 
The MiniMed CGMS data at baseline, week 12 and changes from baseline are shown in 
Table 3.5. The 24-hour glucose profiles at baseline and week 12 are shown in Figures 3.2 
and 3.3 respectively. The fasting glucose value refers to the glucose reading at 5: 00 am 
since none of the subjects consumed any food or drink before this time. The mean CGMS 
glucose refers to the average of the 288 readings recorded (one reading every 5 minutes) 
over the 24-hour period, and the overnight mean glucose refers to the average of 96 
readings taken between 21: 00-5: 00. At baseline, there were no differences between the 
groups. By week 12, the LGI group had a significantly lower 24-hour AUC (P-4.053), 
overnight AUC (, P---0.02) and overnight mean glucose concentration (P--0.02) compared 
with the HGI group. There were no differences between the groups in the changes from 
baseline. 
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Figure 3.2: 24-hour Glucose Profiles of the High Glycaemic Index (GI) and the Low 
GI Groups at Baseline Assessed by the MiniMed Continuous Glucose 
Monitoring System (Values are mean ± SEM) 
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Figure 3.3: 24-hour Glucose Profiles of the High Glycaemic Index (GI) and the 
Low GI Groups at Week 12 Assessed by the MiniMed Continuous 
Glucose Monitoring System (Values are mean ± SEM) 
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3.7.6.1 Reliability of the MiniMed Continuous Glucose Monitoring 
System 
The reliability of the CGMS was checked by comparing 89 paired data points (7-11 points 
from 11 subjects) between the CGMS readings and the capillary blood finger tests obtained 
using the portable glucose meter. A good correlation was found between the two (df = 87 
r-- 0.741, P<0.01). A Bland and Altman plot (Bland & Altman 1986) of the MiniMed 
CGMS readings and the capillary blood readings was used to assess agreement between the 
two methods (Figure 3.4). The mean difference (95% confidence interval (Q) between 
sensor and meter readings was -0.13 (0.31-0.05) mmol/l and most of the measurements lay 
around this value. The upper and lower limits of agreement were 1.59 (CI: 1.40-1.77) 
mmol/l and -1.85 (CI: -2.03-(-)1.66) mmol/l respectively, suggesting that the monitor 
could over- or under-estimate blood glucose concentration up to these values. 
Figure 3.4: Bland and Altman Plot Showing Agreement Analysis Between the 
MiniMed Continuous Glucose Monitoring System and the Blood 
Glucose Meter Readings 
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A linear regression line plot of the mean difference between the CGMS readings and the 
blood glucose meter readings against the mean CGMS and blood glucose measurements is 
shown in Figure 3.5. The downward slope suggests that at higher glucose values, the 
agreement between the sensor and the blood glucose meter reading was lower. However, 
the lower agreement between sensor and blood glucose meter at higher glucose 
concentrations may be explained by the fact that the study population was non-diabetic and 
therefore there were only very few measurements above 8 mmol/l. 
Figure 3.5: Linear Regression Comparing the Mean Difference Between the 
Continuous Glucose Monitoring System (CGMS) Sensor and the Blood 
Glucose Meter Readings Taken from 89 Data Points of the MinIMed 
CGMS 
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3.8 Discussion 
This pilot study aimed to assess whether changing diet GI provides benefits over and above 
those achieved by healthy eating, weight loss and exercise advice usually given for the 
management of heart disease risks, in healthy subjects at risk of CHD. 
At baseline, the diet of both groups could be characterised as LGI. Over the study period, 
the diet continued to be low in GI in the LGI group and increased in GI in the HGI group, 
thus by week 12, groups had a different diet GI. The lack of change in dietary GI of the 
LGI group could be attributed to a number of possibilities. Firstly, as the baseline diet GI 
was low, it was more difficult to achieve a further reduction. Secondly, some of the 
subjects' compliance with the dietary advice was only moderate. Thirdly, previous studies 
that achieved a bigger reduction in GI (Brynes et al 2003a; Frost et al. 1996) provided 
more free foods to subjects. In this study, a beta-glucan bread of a moderate GI (GI: 63) 
was provided to the LGI group but this was only taken by some subjects. This 
methodology was chosen to assess the feasibility of lowering the diet GI for a 12-week 
period in a free-living population. Nevertheless, even though diet GI was not significantly 
reduced over the study period, a LGI diet was consumed by the LGI group as per intention. 
Consumption of a LGI diet reduced the 24-hour and overnight glucose profile confirming 
previous findings (Brynes et al 2003b; Brynes et al 2005). This might suggest an 
improvement in hepatic insulin sensitivity resulting in a decrease in hepatic glucose output 
following meals (Thorburn et al. 1993). Even though blood samples were collected, 
assessment of insulin concentrations and insulin sensitivity was not carried out in the 
present study due to cost constraints. However, in a previous study, whole body glucose 
utilisation assessed by euglycaemic-hyperinsulinaemic clamp was shown to improve on a 
LGI diet (Rizkalla et al 2004) and LGI diets were also shown to improve glucose tolerance 
and insulin sensitivity in a number of studies (Frost et al 1996; Frost et al 1998; Wolever & 
Mehling 2002). The reduction in 24-hour glucose concentrations in the present study is 
clinically relevant since raised postprandial glycaemia would increase CVD risk (The 
DECODE Study Group 2001). Glucose may lead to atherosclerosis through oxidative 
stress (Giugliano et al 1996) and non-enzymatic glycation of LDL cholesterol and clotting 
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factors (Vlassara. et al 1994). Damage may result from AGE products deposited in the 
vessel wall and matrix activating inflammation (Brownlee 1994). 
It is of note that both dietary groups reduced their CHO intake by week 12 and thus there 
was no difference in diet GL, a product of GI and CHO intake, between the groups. 
Although both groups consumed a diet of similar GL, only the LGI group had an 
improvement in glucose profile supporting the observation by Wolever (2003) that the 
metabolic advantage of a slowly digested diet is greater than its glycaemic impact. 
Reducing GL via reduction in CHO intake increases postprandial FFA possibly via 
reduced insulin secretion and sensitivity, whereas consuming a LGI diet leads to a 
prolonged suppression of FFA (Wolever et al. 1995; Wolever & Mehling 2003b). High 
plasma FFA concentration is associated with insulin resistance and dyslipidaernia and 
increased risk of CVD (Carlsson et al 2000) (Chapter 1, Section 1.5.3.2). 
There was no significant change in the lipid profile during the study. This may be 
explained by the baseline concentrations being only moderately raised and the small 
sample size. This result is similar to a previous study where the same intervention was 
used in heart disease patients (Frost et al. 2004). However the lack of change was 
previously thought to be due to concurrent drug therapy (Frost et al 2004). The lack of 
differences between groups may also be due to the weight loss in the LGI group masking 
any effects of changing diet GI. This has also been shown in a comparison of LGI and low 
fat weight loss diets where the LGI did not have any added benefit on glucose or TG 
concentrations or insulin sensitivity (Raatz et al 2005), as well as in other studies 
comparing the effect of LGI and HGI weight-loss diets on CVD risk factors (Millan-Price 
et al. 2006; Pittas et al. 2006). 
In the present study, only the LGI group had a significant reduction in weight although 
both groups reduced their energy intake. Physical activity did not increase in either group 
as intended. It has been suggested that LGI foods promote satiety by preventing marked 
postprandial glucose oscillations (Brand-Miller et al 2002) and enhance weight loss by 
improving access to stored metabolic fuels (Ludwig 2002). Additionally, some LGI foods 
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such as beans may be less energy dense and may not completely digested due to starch 
encapsulation (Chapter 1, Section 1.2.2) thus yielding less energy. However, a number of 
studies found no differences in weight when dietary GI or GL was manipulated and thus 
further research is needed in this area (Ebbeling et al 2005; Raatz et al 2005; Sloth ct al. 
2004). 
3.8.1 Strengths and Limitations 
Since this was a pilot study, the sample size was small therefore results should be assessed 
with caution. A major strength of the study is the use of the 24-hour CGMS which allowed 
assessment of glucose concentrations in free-living subjects and provided a comprehensive 
24-hour glucose profile, which would not have been available by blood tests. Moreover, 
the subjects were able to carry on with their daily activities while the sensor recorded their 
glucose concentration without causing any pain. The Bland and Altman plot (Figure 3.4) 
revealed that the limits of agreement between the sensor and capillary blood readings were 
wide, with a difference of up to 1.85 mmol/I between the glucose reading from 
subcutaneous fluid and the capillary blood glucose concentration. An exact agreement 
between the two methods could not be achieved, neither was it expected, since glucose was 
being measured in two different body fluids and the blood glucose readings were recorded 
by free-living subjects. Nevertheless, adoption of a within-subject, repeated-measures 
design using the same methodology and body fluid to examine glucose concentrations pre 
and post the intervention, reduced the influence of inaccurate recordings to the minimum. 
A previous study of diabetic subjects using the MiniMed CGMS at home, found the mean 
absolute difference between sensor and capillary tests to be 18.0 ± 19.8% (Gross et al. 
2000). 
Despite attempts to reduce diet GI in the LGI group, this was not achieved. Nevertheless, 
since diet GI increased in the HGI group over the study period, there was a significant 
difference between groups in diet GI by the end of the study. Despite the increase in GI, 
the HGI group did not experience any adverse effects possibly because of consumption of 
a healthy diet. In fact, some HGI foods such as wholemeal bread, Weetabix, raisins and 
others are often recommended as part of a healthy eating diet. Nevertheless, since only the 
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LGI group lost weight, it is difficult to separate the effects of weight loss from those of 
reducing diet GI. 
Dietary compliance is another issue in free-living subjects. In this study, diet was assessed 
by 7-day diaries which is one of the most accurate ways of assessment (Bingham et al 
1994). Even so, there was no objective way of assessing compliance. This is discussed 
further in Chapter 6. 
For calculating diet GI, the majority of GI values were obtained from published rather than 
estimated sources thus increasing the accuracy of calculations. Since the same GI, either 
published or estimated was assigned to foods throughout the study, any errors in 
measurement would be systematic. 
3.9 Conclusion 
In this pilot study, the CGMS provided some preliminary evidence that a LGI diet, in 
addition to traditional healthy eating and weight loss advice for CHD prevention, may be 
more effective in reducing heart disease risk. A longer term and larger scale study on heart 
disease prevention was thus designed (Chapter 4) to further assess how manipulating 
dietary GI in conjunction with healthy eating and weight loss affects heart disease risks. 
Moreover, the fact that a lower diet GI led to more weight loss than a HGI diet will be 
further explored by looking at the effect of GI on weight maintenance following weight 
loss (Chapter 5). 
3.10 Study Publication 
Philippou E., McGowan B., Brynes A. E., Dornhorst A., Leeds AR and Frost G. S. 2008 
The effect of a 12-week low glycaemic index diet on heart disease risk factors and 24 hour 
glycaemic response in healthy middle-aged volunteers at risk of heart disease: a pilot 
study. European Journal of Clinical Nutrition vol. 62, no. 1, pp. 145-149. (Appendix 9) 
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4.1 Introduction 
As discussed in Chapter 1, Section 1.5.3, the development of CHD is determined by many 
metabolic abnormalities. Data from the pilot study in Chapter 3, showed that a LGI diet 
may be more beneficial for CHD prevention. Following on from this study, a longer-term 
study was designed to test whether the same dietary manipulation can also improve other 
CHD risks. Worsening of arterial compliance, i. e. of the capacity of the arterial system to 
change in volume at a specific concentration of pressure (O'Rourke 1990), is becoming 
recognised as another CHD risk factor (Chapter 1, Section 1.6.3), and hypertension is well 
known to increase CHD risk (Chapter 1, Section 1.5.3.6). The two conditions are 
interrelated (Safar & London 1994) and the mechanism behind both conditions is most 
probably insulin resistance. Haemodynamic insulin actions (Chapter 1, Section 1.4) 
include stimulation of the production of NO from endothelium, the main vasodilator which 
also has anti-inflammatory actions (Kim et al 2006). In the insulin resistant state, the 
reduced activity of NO caused by high concentrations of FFAs (Chapter 1, Sections 1.5.3.2 
and 1.6.3), leads to endothelial dysfunction through glucotoxicity, lipotoxicity and 
inflammation (Kim et al 2006). The compensatory hyperglycaemia also contributes to 
endothelial dysfunction mainly through oxidative stress and collagen modification caused 
by AGE products (Kim et al 2006). 
Epidemiological studies have shown that arterial compliance worsens with ageing (Bulpitt 
et al 1999) and parameters of the metabolic syndrome such as hypertension (Safar & 
London 1994), glucose intolerance, insulin -resistance 
(Henry et al 2003; Schram et al 
2004) and obesity (Toto-Moukouo et al 1986). Weight loss has been shown to improve 
arterial compliance; an improvement resulting either as a direct effect of weight loss or 
indirectly through improvements on BP, insulin sensitivity, blood lipids, and glucose 
concentrations induced by weight loss (Toto-Moukouo et al 1986; Wildman et al 2003; 
Zebekakis et al. 2005). In addition to the effect of metabolic syndrome parameters on 
arterial compliance, these parameters (i. e. insulin resistance, hyperglycaemia, 
dyslipidaemia, hypertriglyceridaemia and hypertension) are also well known to increase 
CHD risk through other mechanisms as previously discussed (Chapter 1, Section 1.5.3). 
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To date, the effect of a LGI diet on arterial compliance has not been examined while 
previous studies did not report any additional benefit of LGI diets on BP (Ebbeling et al 
2005; Maki et al. 2007; Sloth et al 2004). A Cochrane review on the effect of a LGI diet 
on CHD prevention found that it only caused a small reduction in total cholesterol and 
called for finiher long-term randomised controlled trials with sufficient power to reach a 
conclusive answer on this issue (Kelly et al 2004). 
The present study was designed to examine whether in addition to healthy eating and 
weight loss, consumption of a LGI diet compared to a HGI diet for six months, would 
improve arterial compliance and 24-hour BP in middle-aged men at risk of heart disease. 
To examine change in overall CHD risk and also assess potential mechanisms behind the 
dietary intervention, changes in fasting and postprandial glucose, insulin sensitivity, fasting 
lipid concentrations and anthropometric measurements were also measured. 
4.2 Hypothesis 
Ingestion of a LGI compared to HGI diet for 6 months by middle-aged men at risk of CHD 
will improve the following CHD risk factors over and above the improvement achieved by 
healthy eating and weight loss alone: 
arterial compliance 
24-hour blood pressure 
fasting and postprandial glucose concentrations 
fasting and postprandial insulin concentrations and insulin sensitivity 
fasting lipid profiles and 
body weight and composition 
thus reducing the overall risk for heart disease. 
The proposed mechanisms behind these effects are improvement in insulin sensitivity 
which was previously shown to occur following consumption of a LGI diet (Frost et al 
1996; Frost et al 1998; Laaksonen et al 2005; Ostman et al 2006; Wolever & Mehling 
2002) and prolonged suppression of FFA concentrations (Wolever et al 1995). 
109 
Chapter 4: The Effect of a 6-Month Dietary Glycaemic Index Manipulation on Arterial Compliance, Blood 
Pressure, Lipid Profile, Fasting and Postprandial Glucose and Insulin Responses in Middle-Aged Men at Risk 
of Heart Disease 
4.3 Ethical Approval and Consent 
The study was ethically approved by the Hammersmith, Queen Charlotte's and Chelsea 
Hospitals Research Ethics Committee (REC: 04/QO406/1 11) and subjects gave written 
informed consent before enrolment. 
4.4 Subject Recruitment 
Subjects were recruited by advertisement as discussed in Chapter 2, Section 2.2.1 and 
additionally by advertisements in London newspapers. Moreover, I visited GP surgeries 
where, in collaboration with the practice nurse, a search was carried out for potential 
subjects meeting the inclusion and exclusion criteria in the surgery's database. Lists of 
names and addresses of potentially eligible subjects were obtained and they were invited to 
participate by letter emphasising that their decision to participate or not would not affect 
their care at the Hammersmith Hospital NHS Trust or their GP surgery. Lastly, subjects 
who participated in previous studies at the Nutrition and Dietetic Department were also 
invited to participate if they met the inclusion/exclusion criteria. Potential subjects were 
sent the study's information sheet (Appendix 7) and a pre-screening questionnaire 
(Appendix 1). In total, 8 advertisements were posted in London newspapers, 2 
advertisements in local newspapers and 3 GP surgeries were visited. In total, 1629 
subjects were sent information on the study (Flow Diagram 4.1). Those who were deemed 
eligible following completion of the pre-screening questionnaire were screened as 
described in Chapter 2, Sections 2.2.2 - 2.2.3. The following inclusion and exclusion 
criteria applied: 
inclusion Criteria: 
* Healthy men aged 35- 65 years old. Men were chosen since CHD mortality is 
known to be higher in men than women due to the protective effects of oestrogen in 
women and other environmental factors (Lawlor et al. 2001). 
9 At least one recognised risk factor for CHD e. g. fasting total cholesterol > 5.0 
mmol/l, total cholesterol to HDL cholesterol ratio > 5, LDL cholesterol > 3.0 
mmol/L BMI 27-35 kg/m2, waist circumference ý: 94 cm, raised BP up to a 
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maximum of 140/90 mmHg and/or family history of CHD. Smokers were recruited 
only if they also had an additional risk factor. 
Exclusion Criteria: 
9 As discussed in Chapter 2, Sections 2.2.2 and 2.2.3. The main exclusion criteria 
were heart disease, diabetes, other clinically significant disease, eating disorder, 
depression, abnormal thyroid function, abnormalities in blood parameters, 
abnormal ECG, and/or taking lipid lowering medication, anti-hypertensive 
medication or thyroxine. 
Subjects who were deemed eligible to participate were given instructions on how to fill in a 
7-day food diary before enrolment as explained in Chapter 2, Section 2.7.1. 
4.5 Power Calculation 
The power calculation was based on Carotid-Femoral Pulse Wave Velocity (PWV). 
Assuming a difference between groups of 1.5 m/sec (11.2 m/sec and 12.7 m/sec) and a SD 
of 2, at 5% concentration and 80% power (2-sided), 28 subjects would be needed in each 
group. Assuming a 20% dropout rate, approximately 40 subjects would need to be 
recruited in each group. 
4.6 Design and Procedures '- 
4.6.1 Study Design 
The study had a randomised, non-blind, parallel design. Blood lipid analysis and insulin 
assays were carried out by technicians blinded to the study's design and subject 
randomisation. Subjects were randomised (Chapter 2, Section 2.3) to either HGI or LGI 
diets for 6 months. All subjects were advised on healthy eating and weight loss if BMI > 
25 kg/mý (Chapter 4, Section 4.6.2). Subjects were seen monthly for assessments of dietary 
compliance and anthropometric measurements. Arterial compliance, 24-hour BP, fasting 
and postprandial glucose and insulin responses were assessed at baseline and at the end of 
the 6-month period. At month 3, arterial compliance was assessed and a fasting blood test 
was taken. The study design is shown in Figure 4.1. 
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Figure 4.1: Diagram of Study Design 
Study duration (6 months) 
## 
Month 0 Month 3 Month 6 
Arterial compliance Arterial compliance Arterial compliance 
Test meal Fasting blood sample Test nical 
Anthropometrics Anthropoinctrics Anthropoinctrics 
ABPM = Ambulatory Blood Pressure Monitoring. Small arrows indicate study visits at monthly intervals 
during which dietary compliance was checked and anthropornetric measurements were taken. Test meal 
refers to 6-hour postprandial assessment. 
4.6.2 Intervention 
The dietary intervention was the same as that of Chapter 3. At the baseline visit, subjects 
were randomlsed to either a LGI or HGI diet and advised on dietary changes as explained 
in Chapter 2, Section 2.8. The baseline 7-day food diary was used as a basis for providing 
one-to-one dietary advice. All subjects were advised on healthy eating for heart disease 
prevention aiming for 50-55% of energy intake from CHOs, <30% energy from total fat, of 
which <10% saturated fat, replacing saturated fats by monounsaturated fats, consurning 
oily fish twice a week and limiting alcohol and salt intake (Wood et al 2005). They were 
also encouraged to increase their activity concentrations over and above current 
concentrations to the equivalent of at least 30 minutes walking a day. Overweight subjects 
were advised on weight loss by achieving a deficit of 500 kcal/day, which would be 
expected to lead to a 0.5 kg reduction per week. This was achieved by special emphasis on 
reduction of high fat and sugar sources, limiting portion sizes and alcohol. No energy 
prescription was provided. 
112 
Chapter 4: "Me Effect of a 6-Month Dietary Glycaernic Index Manipulation on Arterial Compliance, Blood 
Pressure, Lipid Profile, Fasting and Postprandial Glucose and Insulin Responses in Middle-Aged Men at Risk 
of Heart Disease 
4.6.3 Monthly Visits 
Subjects were seen on a one-to-one basis each month for a dietetic assessment and 
anthropometric measurements. All subjects were seen by myself. 
4.6.4 Food diaries 
Subjects were required to fill in a 7-day food diary of their habitual intake before the 
baseline visit. 3-day food diaries were kept at each month of the study (Chapter 2, Section 
2.7.1). 
4.6.5 Dietary Compliance 
Dietary compliance was assessed at monthly visits using the food diaries and a diet history 
as well as by checking the CHO-containing foods consumed and avoided. Compliance 
was also assessed by checking changes in body weight. Specific issues or concerns 
including travelling and eating out were discussed and further food and snack ideas were 
provided where necessary as well as encouragement to follow the diet. Physical activity 
was also assessed and encouragement to exercise was provided. 
4.6.6 Anthropometrics 
Body weight, waist and hip circumferences were measured at baseline and at each monthly 
visit. In addition percentage body fat was assessed at baseline, month 3 and month 6 study 
visits. For details of assessment protocols see Chapter 2, Section 2.4. 
4.6.7 Blood Pressure and Pulse 
Blood pressure and pulse were assessed using the validated automatic sphygmomanometer 
Omron 705IT at baseline, month 3 and month 6 visits before carrying out the arterial 
compliance assessment. The protocol of measurement differed from that of the screening 
visit (Chapter 2, Section 2.5). BP and pulse were measured on the right arm two times in 
the supine position after the subject had been lying flat for at least 5 minutes. 
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4.6.8 Arterial Compliance Assessment 
Arterial compliance was assessed by taking the arterial compliance measurements 
discussed in Chapter 2, Section 2.17 at baseline, month 3 and month 6 visits under the 
conditions described in Chapter 2, Section 2.17.1. Intra and inter-observer repeatability 
coefficients (RC) for a sub-sample of the arterial compliance measurements, were 
calculated as described in Chapter 2, Section 2.20. 
4.6.9 Ambulatory Blood Pressure Measurement 
The 24-hr ambulatory BP was assessed at baseline and month 6 of the study by fitting the 
ABPM system as described in Chapter 2, Section 2.18 when the subject attended for the 
postprandial assessment study day. 
4.6.10 Baecke Questionnaire 
The Baecke Questionnaire was completed by subjects at baseline and month 6 to assess 
physical activity (Chapter 2, Section 2.12.1). 
4.6.11 Fasting Blood Tests 
A fasting blood sample was taken at month 3 of the study. At baseline and month 6 study 
visits, a total of three fasting blood samples were taken before provision of the test meal for 
the metabolic assessment as discussed in Chapter 2, Section 2.14.4. Subjects were 
required to follow the conditions described in Chapter 2, Section 2.14.1 before assessment. 
4.6.12 Postprandial Metabolic Assessment 
A 6-hour postprandial metabolic assessment was carried out at baseline (before 
randomisation. ) and at month 6 of the study for analysis of glucose, insulin and 
lipoproteins. The preparation for assessment and the procedure is explained in Chapter 2, 
Section 2.14. Blood samples were taken at times -30, -15,0, +30,60,120,180,240,300 
and 360 minutes. The test meal was served at time 0 (to) minutes. 
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4.6.12.1 Test Meal 
The test breakfast was served immediately after taking the fasting blood sample at to 
minutes. It consisted of 60g white bread, lOg margarine, 60g cornflakes, 100ml double 
cream (mixed with 150ml water to have a milky consistency), lOg sugar and decaffeinated 
tea or coffee and provided 946 kcal, 93.6g CHO, 61 g fat, 11.1 g protein (expressed as 
percentage of energy: 47% CHO, 33% fat, 15% protein). Subjects were instructed to 
consume all the meal within 15 minutes. The breakfast was high in fat to allow assessment 
of postprandial lipid concentrations. However, due to time constraints, this analysis has 
not been performed yet. 
4.6.13 Blood Sample Analysis 
On each blood collection, one fasting blood sample was sent to the Clinical Chemistry 
Department for analysis of glucose, lipoproteins and TG (Chapter 2, Section 2.15.3). The 
rest of the fasting samples and the postprandial samples were centrifuged and the plasma 
separated and frozen to -20'C until analysis (Chapter 2, Section 2.14.3). From these 
samples, I analysed the fasting and postprandial plasma glucose (Chapter 2, Section 2.15.1) 
and the Clinical Chemistry Department analysed the fasting and postprandial insulin 
(Chapter 2, Section 2.15.2). The glucose and insulin 6-hour lAUC were calculated as 
described in Chapter 2, Section 2.16-2) and HOMA was used to assess insulin sensitivity 
and P cell function (Chapter 2, Section 2.15.2). 
4.6.14 Dietary Analysis 
All food diaries were analysed using Dietplan 6 (Forestfield Software). Likely 
underreporters were identified from baseline 7-day diaries as described in Chapter 2, 
Section 2.7.2. 
4.6.15 Calculation of Glycaernic Index (GI), Glycaernic Load and GI 
Sources 
Calculations of GI, GL and GI value sources were carried out as described in Chapter 2, 
Sections 2.9-2.11. 
115 
Chapter 4: The Effect of a 6-Month Dietary Glycaemic Index Manipulation on Arterial Compliance, Blood 
Pressure, Lipid Profile, Fasting and Postprandial Glucose and Insulin Responses in Middle-Aged Men at Risk 
of Heart Disease 
4.6.16 Outcome Measures 
The primary outcomes were the changes in arterial compliance especially Carotid-Femoral 
PWV and systemic arterial compliance (SAC). Other outcome measures were changes in 
Carotid-Radial PVN, Augmentation Index (AI), 24-hour BP, fasting and postprandial 
glucose and insulin concentrations, insulin sensitivity, fasting lipid profile and 
anthropometrics during the study. 
4.7 Statistical Analysis 
Since this study is still not complete, an interim statistical analysis was carried out which 
may differ in some aspects from subsequent analysis of the completed study. Analysis was 
carried out using SPSS for Windows (Version 14.0, SPSS, Chicago, Illinois, USA). Data 
was checked for normality before all statistical analysis using the Shapiro Wilks test and by 
examining the normality plots. Data is presented as mean ± sd when normally distributed 
or median [Interquartile range (IQR)] when non-normally distributed. For all tests, a P- 
value of :ý0.05,2-sided was considered statistically significant. 
The groups were compared at randomisation using unpaired Student's t tests for normally 
distributed data, Mann-Whitney U tests for non-normally distributed data and X' tests for 
categorical data. Between-group comparison of dietary intake and composition data at 
baseline and the changes from baseline was done by unpaired Student's t tests or Mann- 
Whitney U tests as appropriate. A within-group analysis of baseline and month 6 data was 
also carried out to assess changes within individual groups using paired-samples t tests for 
normally distributed data and Wilcoxon tests for non-normally distributed data. 
Dietary GI and GL, anthropometric and fasting blood results were analysed by applying 
mixed models to test the effect of diet group, time and the diet group x time interaction. 
Non-normally distributed data were log-transformed before applying linear mixed models. 
If the diet group x time interaction was not significant, the model was reduced (i. e. 
interaction was not considered). The F ratio and P-value of significance for time, diet 
group and diet group x time interaction are presented for each of these comparisons. The F 
ratio represents the variance between the groups, divided by the variance within the groups. 
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A large F ratio indicates that there is more variability between the groups (caused by the 
independent variable) than there is within each treatment group (referred to as the error 
term). For fasting blood test results, a between-group comparison of month 6 data was 
also carried out after adjusting for baseline values by analysis of covariance (ANCOVA). 
Furthermore, a within-group analysis of baseline and month 6 fasting blood test variables 
was carried out to examine whether individual groups changed. 
Fasting and postprandial glucose and insulin results at baseline and month 6 were plotted 
as mean ± SEM. HOMA was calculated as described in Chapter 2, Section 2.15.2. The 
IAUC for the 6-hour postprandial glucose and insulin were calculated as described in 
Chapter 2, Section 2.16.2. Repeated measures ANOVA was used to compare glucose and 
insulin responses with time (-30, -15,0, +30,60,120,180,240,300,360 minutes for 
glucose and -15,0, +30,60,120,180,360 minutes for insulin), group and visit (baseline 
and month 6) as independent factors. Between-group comparisons of data at baseline, 
month 6 and changes from baseline in IAUC glucose and insulin, HOMA and Baecke 
questionnaire results were carried out using unpaired Student's t tests for normally 
distributed data and Mann-Whitney U tests for non-normally distributed data. Again a 
within-group analysis of these variables was also carried out as described above. 
The quality of the recorded arterial compliance measurements was checked by myself and 
Prof Rajkumar and poor quality measurements were dismissed (<10 measurements). Since 
only a small sample size was available, assessment of arterial compliance was done by 
categorising the changes at month 3 and month 6 into higher, lower or no change from 
baseline. An intention to treat analysis was employed where month 3 data were carried 
forward to month 6 to replace missing values in an attempt to increase the power of the 
study. Chi-squared tests were employed on the categorical data to compare the two groups 
at months 3 and 6. The )C 2 value, degrees of freedom and P-value are presented for all such 
tests. 
The ABPM data are presented as values at baseline, month 6 and changes from baseline. 
Changes from baseline were compared using unpaired Student's t tests for normally 
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distributed data and log-transformed non-normally distributed data and Mann-Whitney U 
tests for non-normally distributed data or data that could not be log-transformed. 
The RC was calculated on a sub-sample of measurements to assess reproducibility of 
waist, hip, body fat measurements and arterial compliance measurements (Chapter 2, 
Section 2.20). The mean =1: SD of differences between two consecutive measurements of 
the two observers was calculated and paired t tests were carried out to assess differences. 
4.8 Results 
4.8.1 Subject Recruitment 
Flow Chart 4.1 shows a breakdown of the number of people contacted, screened, recruited 
and participated in the study. Approximately 6% people sent information on the study 
were subsequently screened and of those screened 62% were recruited. 22% of subjects 
who started the study did not complete it. The drop-out reasons are given in Flow Chart 
4.1. 
4.8.2 Subjects' Demographics 
Table 4.1 shows the demographic details of the HGI and LGI groups. Although there were 
no statistical differences between the groups in any of the variables shown, concentrations 
of total cholesterol, LDL cholesterol and TG were slightly higher in the LGI than the HGI 
group. 
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Flow Chart 4.1: Number of Subjects Contacted, Screened, Recruited, 
Participated and Completed the Study 
Contacted through 
GP surgeries 
(n = 1224) 
Answered 
advertisements 
(n = 388) 
Contacted through 
in house database 
(n = 17) 
Total n= 1629 
sent info on study 
Screened I 
(n = 91) 
1 
Recruited I 
(n = 56) 
1 
Started study 
(n = 49) 
1 
Completed study 
(n = 38) 
1 
Not responded/not eligible/ 
not interested (n = 1538) 
1 
Not eligible 
(n = 35) 
1 
Did not start study 
(n = 7) 
1 
Dropped out (n = 6) 
Lost to follow up (n = 3) 
Started statins (n = 1) 
Cancer diagnosis (n = 1) 
Lost to follow-up refers to not being contactable after several 
attempts. The reasons for drop out were: time issues (n = 2), 
difficulty following the diet (n =I HGI group), moved country 
(n =I LGI group) and could not follow diet due to work 
commitments (n =1 HGI group). 
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Table 4.1: Demographics of Subjects by Group 
(Values are mean ± sd or median [IQR] or numbers (*/o) where indicated) 
HGI group (n= 16) LGI group (n=22) P value 
Age 46.9 ± 8.6 49.0 ± 8.5 0.5 
Ethnicity 0.3 
Caucasian 10(62.5) 17(77.3) 
Black 2(12.5) 2(9.1) 
Asian 3(18.8) 2(9.1) 
Other 1(6.3) 1(4.5) 
Current smokers 3(18.8) 2(9.1) 
SBP (mnfflg) 132 ± 15 130 ± 13 0.6 
DBP (mmHg) 81 ±10 81 ±11 1.0 
Pulse (bpm) 64 ±10 64 8 1.0 
Weight (kg) 97.5 16.4 91.3 14.8 0.2 
BMI (kgIm 2 30.5 3.5 29.1 3.6 0.2 
Waist (cm) 109.2 ±11.1 104.3 ±10.9 0.2 
Fasting Blood tests 
Total Cholesterol 5.19±0.91 5.61 ± 0.79 0.1 
(mmol/1) 
LDL Cholesterol 3.34 ± 0.80 3.62 ±0.63 0.2 
(mmol/1) 
HDL Cholesterol 1.10 [0.96-1.37] 1.10 [1.01-1.26] 0.3 
(mmol/1) 
Total chol: HDL 4.61 ±1.17 4.88 ±1.18 0.5 
Triacylglycerols 1.29 [1.06-1.78] 1.63 [1.23-2.83] 0.3 
(MMOIA) 
Glucose (mmol/1) 5.14 ± 0.36 5.20 ±0.47 0.7 
HGI = High Glycaemic Index, LGI = Low Glycaemic Index, SBP = Systolic Blood Pressure, DBP = 
Diastolic Blood Pressure, BMI Body Mass Index, LDL = Low Density Lipoprotein, HDL = ffigh Density 
Lipoprotein, Total Chol: HDL Total Cholesterol to HDL Cholesterol ratio. P value comparing groups. 
Unpaired Student's t tests were used to compare normally distributed data, Mann-Whitney tests used to 
compare non-normally distributed data and chi square tests used for categorical data. No significant 
differences found. 
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4.8.3 Dietary Intake and Composition 
Out of a total of 266 diaries, 90% were retumed (i. e. 240 diaries); 88% (98/112) in the HGI 
group and 90% (142/154) in the LGI group. 
4.8.3.1 Validation of Dietary Intake Records 
The validity of the 7-day food diaries at baseline was assessed as discussed in Chapter 2, 
Section 2.7.2. All of the baseline diaries were returned. Four subjects were defmed as 
underreporters using an Energy Intake: Basal Metabolic Rate ratio (EI: BMR) cut-off of 
1.05 (3 in the HGI group and 1 in the LGI group) (Black 2000; Goldberg et al 1991). 
4.8.3.2 Comparison Between Groups 
The subjects' dietary intake and composition at baseline, month 6 and the changes from 
baseline are shown in Table 4.2. Since changes from baseline were assessed, only subjects 
for which both the baseline and the month 6 diaries were returned were included in the 
statistical analysis. Table 4.3 and Table 4.4 show the diet GI and GL respectively of the 
two groups during the study. At baseline, the HGI group had a lower alcohol intake than 
the LGI group (11---0.021). There were no other differences between the groups. At month 
6, the HGI group had a higher CHO intake (P=0.005) and a higher starch intake (P<0.00 1). 
At month 6, the groups differed in diet GI (P <0.001), diet GL (P<0.001) and CHO intake 
(P<0.001). The groups differed in the changes from baseline in starch intake (P--0.004), 
diet GI (P<0.001) and diet GL (P=0.014). Mixed models assessment showed that the 
groups differed in diet GI and GL during the study (P<0.001) (Tables 4.3 and 4.4). 
4.8.3.3 Comparison Within Groups 
4.8.3.3.1 High Glycaernic Index Group 
By month 6, there was a significant increase in starch intake (P--0.002) and diet GI 
(P--0.00 15) compared with' baseline. 
4.8.3.3.2 Low Glycaemic Index Group 
By month 6, there was a significant reduction in energy intake (P--0.001), diet GI 
(P---0.005), diet GL (P=0.002) and CHO intake (11---0.004) compared with baseline. 
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4.8.3.4 Sources of Glycaernic Index Calculations 
Table 4.5 shows the percentage contribution of different sources i. e. published or estimated 
to GI calculations during the study. The GI values assigned from the International Tables 
(Foster-Powell et al 2002) and the University of Sydney GI website (University of Sydney. 
2007) were sub-divided into those obtained from a mean of 2 or more GI values and those 
GI values obtained from only one tested food (single value). For all GI calculations, 3.1% 
of CHO intake was not taken into consideration in GI calculations due to the insignificant 
CHO content of foods such as cheese, sauces and vegetables of low CHO content. 16.5% 
of the CHO was assigned a GI value from estimated sources and approximately 80.4% of 
CHO was assigned a GI value from published sources. The percentage of CHO assigned a 
GI value from published or estimated sources was similar between groups and during the 
study period. 
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Table 4.5: Percentage Carbohydrate Contribution of Different Sources to Glycacmic Index (Gl) 
Calculations for all GI Calculations and by High GI and the Low GI Groups at 
Baseline and Month 6 (Values are %) 
Carbohydrate Intake 
Source of GI Values 
All GI 
calculations 
Baseline 
IlGI LGI 
group group 
IIGI 
group 
Month 6 
LGI 
group 
International Tables mean of 51.7 55.1 49.9 47.7 52.7 
several values (Foster-Powell et al 
2002) 
international Tables single 20.0 15.2 20.1 24.3 21.3 
value (Foster-Powell et al 2002) 
University of Sydney Website 2.4 1.4 1.7 3.5 1.0 
mean of several values 
(University of Sydney. 2007) 
University of Sydney Website 4.0 3.6 2.3 2.9 3.1 
single value (University of 
Sydney. 2007) 
Other Published Sources 2.3 1.8 2.5 2.1 3.4 
(Henry et al 2005) 
Total of Published Sources 80.4 77.1 76.5 80.5 81.5 
Personal Communication* 1.5 0.7 1.7 1.3 1.7 
Estimated on Similar Foods 10.5 15.0 11.7 12.3 8.9 
Estimated on Recipe 3.3 3.4 5.0 2.6 2.3 
Mixed Meal 1.2 1.1 1.1 0.4 2.0 
Total of Estimated Sources 16.5 20.2 19.5 16.6 14.9 
Not coded 3.1 2.8 3.9 3.0 3.6 
HGI = High Glycaemic Index, LGI = Low Glycaemic Index. 
* Personal communication with Professor Jennie Brand-Miller (University of Sydney) regarding the GI 
assigned to alcoholic drinks such as beer and wine which is estimated by their laboratory as 66. 
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4.8.4 Anthropometrics 
Table 4.6 shows the anthropornetrics of the HGI and LGI groups at baseline, months 3 and 
6 and the changes from baseline. At baseline, there were no differences between the 
groups. Because diet group x time interaction was not significant for any of the variables, 
the model was reduced to test only the effect of time and diet group. All anthropornetric 
measurements significantly reduced over time (P<0.001 for weight, BMI, waist and hip 
and P=0.004 for body fat), however there were no differences between groups. The weight 
reduction expressed as percentage over 6 months was 2.9 ± 3.4% in the HGI group and 2.3 
± 3.9% in the LGI group. 
4.8.4.1 Repeatability of Anthropornetric Variables 
4.8.4.1.1 Repeatability Coefficient of Waist Measurements 
The waist circumference RC was calculated on 176 measurements taken twice at the 
beginning and end of the consultation on fasted subjects. The mean ± SD of measurements 
was 103.6 ± 11 .1 cm and the mean ± SD of differences was 0.26 ± 1.09 cm (SEM of 
differences: 0.08 cm). The RC was 2.24 and there were no significant differences between 
the first and second measurement (P'--O. 1). 
4.8.4.1.2 Repeatability Coefficient of Hip Measurements 
The hip circumference RC was calculated on 176 measurements taken twice at the 
beginning and end of the consultation on fasted subjects. The mean ± SD of measurements 
was 105.7 ± 8.9 cm and the mean + SD of differences was 0.14 ± 1.09 cin (SEM of 
differences: 0.08). The RC for this measurement was 2.19 and there were no significant 
differences between the first and second measurement (P--O. 1) 
4.8.4.1.3 Repeatability Coefficient of Body Fat Measurements 
The % body fat RC was calculated on 11 measurements taken twice. To standardise 
conditions, subjects were asked not to consume alcohol or do strenuous exercise for 24 
hours before the measurement. The measurements were taken in the fasted state after 
subjects emptied their bladder. The mean ± SD of measurements was 25.1 ± 2.7 %, the 
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mean ± SD of differences being: 0.10 ± 0.19 % (SEM of differences: 0.06%) and the RC 
was 0.42. There was no difference between the first and the second measurement (P--O. 1). 
4.8.5 Fasting Lipid and Glucose Profiles 
Table 4.7 shows the fasting lipid and glucose profiles of the HGI and LGI groups at 
baseline, months 3 and 6 and changes from baseline. In addition to the mixed model 
analysis shown in the table, further statistical analysis was carried out as explained in 
Section 4.7. At baseline, there were no differences between the groups. 
The mean percentage change from baseline in total cholesterol was -0.1 :E9.9 % in the HGI 
group and -8.1 ± 11.5% in the LGI group. According to mixed model analysis, total 
cholesterol changed over time (P'-0.016), however, the change did not differ between 
groups (P--0.8). A comparison between the groups at month 6 after adjusting for baseline 
values (by ANCOVA) revealed a significantly lower total cholesterol in the LGI group 
(111-4.023). The different findings of the statistical tests may be due to the slightly higher 
baseline concentration of total cholesterol in the LGI group. A within-group analysis 
comparing baseline and month 6 values showed that total cholesterol was significantly 
lower in the LGI group (P--0.003) but did not change over the 6-month period in the HGI 
group 
LDL cholesterol, HDL cholesterol and the ratio of total cholesterol to HDL cholesterol 
showed no significant changes over time or between groups. Applying ANCOVA to 
month 6 values after adjustment for baseline also did not reveal any significant differences 
between groups (P--0.4 for LDL cholesterol, P--0.6 for HDL cholesterol and 11---0.3 for 
total to HDL cholesterol ratio). However, a within-group comparison of baseline and 
month 6 values showed that LDL cholesterol was significantly lower in the LGI group by 
month 6 (P--0.049) but did not change in the HGI group (P--0.6). The mean percentage 
change in LDL cholesterol from baseline was -6.1 27.6 % in the HGI group and -6.0 ± 
13.3 % in the LGI group, in HDL cholesterol: 1.1 15.9 % and - 1.7 ± 22.6 % in the HGI 
group and LGI group respectively and in total cholesterol to HDL cholesterol ratio: HGI 
group: -1.4 ± 13.5 % and LGI group: -5.8 ± 20.2 %. 
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TG concentrations fell over time (P--0.004), but groups did not differ (P--0.9). Applying 
ANCOVA to month 6 values after adjustment for baseline also showed that groups did not 
differ (P--0.1). A within-group analysis of baseline and month 6 TG concentrations 
showed that there was a significant reduction in the LGI group (P--O. O 16) but no change in 
the HGI group (P--0.5). The median percentage change in the HGI group over 6 months 
was: - 1.3 [IQR: - 19.0-8.3] % and in the LGI group -25.0 (IQR: -43.7-3.4] %. 
Glucose concentrations changed over time (11---0.01) but there was no difference between 
groups (PL--0.7). Comparison of month 6 values after adjusting for baseline by ANCOVA 
also showed no differences between groups (P--0.3). A within-group analysis confirmed 
that fasting glucose did not change significantly over the study period in either of the 
groups (HGI group: P-4.3; LGI group: P--0.087). The mean percentage change in fasting 
glucose in the HGI group over 6 months was -1.7 ± 6.4 % and in the LGI group: -3.1 ± 4.2 
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4.8.6 Postprandial Glucose Profile 
The 6-hour postprandial glucose IAUC of the two groups at baseline and month 6 is shown 
in Figures 4.2a and 4.2b. Valid results were available from 15 out of 16 subjects in the 
HGI group and 18 out of 22 subjects in the LGI group, because of either haemolysis or 
cannula failure during the postprandial assessment. There were no differences between 
groups at baseline or at month 6 or in the changes from baseline as assessed by Mann- 
Whitney U test. Repeated measures ANOVA of IAUC-30-36o revealed a significant effect 
of time (i. e. the 6.5-hour period) (P<0.001), but no differences between groups (11---l. 0) or 
visits (i. e. baseline or month 6) (P-45) and no interaction effect. At baseline, glucose 
peaked at 60 minutes postprandially at 6.39 ± 1.71 mmol/I in the HGI group and 6.71 ± 
2.53 mmol/I in the LGI group (P--0.7). At month 6, glucose peaked at 120 minutes 
postprandially in the HGI group at 6.39 ± 2.07 mmol/I and at 60 minutes in the LGI group 
at 6.74 ± 1.60 mmol/I (P--0.7). 
4.8.7 Fasting Insulin, Insulin Sensitivity and Postprandial Insulin 
Concentrations 
Fasting insulin concentrations, P-cell function (HOMA %P), insulin sensitivity (HOMA 
%S), insulin resistance (HOMA %IR) and 6-hour postprandial insulin response are shown 
in Table 4.8 and Figures 4.3a and 4.3b. Valid results were available from 14 out of 16 
subjects in the HGI group and 19 out of 22 subjects in the LGI group, for similar reasons to 
those mentioned above (Section 4.8.6). There were no differences between the groups at 
randomisation. By month 6, fasting insulin and HOMA %IR were lower in the LGI group 
(P--0.012 and P-4.02 respectively) and HOMA %S showed a trend to be higher in the LGI 
compared to the HGI group (P--0.06). A within-group analysis comparing baseline and 
month 6 data showed that the LGI group only had significant reductions in fasting insulin 
(P--0.007) and HOMA %IR (, P----0.013) and an increase in HOMA %S (P-4.003). Beta cell 
function reduced (P-4.004) possibly because of the increase in insulin sensitivity since 
when sensitivity increases, the P cells can function at a lower rate than before (Wallace et 
al. 2004b). Calculation of IAUC 0-360 insulin was based on plasma samples taken at -15,0, 
30,60,120,180 and 360 minutes only. Samples collected at other time points were not 
analysed due to cost constraints. Repeated measures ANOVA of IAUC-15-360 showed a 
131 
Chapter 4: The Effect of a 6-Month Dietary Glycacmic Index Maniptilation on Arterial Compliance, Blood 
Pressure, Lipid Profile, Fasting and Postprandial Glucose and Insulin Responses in Middle-Aged Men at Risk 
of Heart Disease 
significant effect of time (P<0.001) (i. e. the 6-hour period) but no significant effect of 
group (Pý-0.3) or visit (Pý0.1) and no interaction effects. At baseline, insulin peaked at 
120 minutes postprandially at 499.7 4: 262.3 pniol/I in the I IG I group and at 453.8 1 295.5 
pinol/I in the LGI group (13---0.7). At month 6,111SLIfin peaked at 120 Minutes 
postprandially at 398.9 ± 152.5 prnoU1 in the HG1 group and at 60 minutes postprandially 
at 414.0 ± 278.0 pniol/I in the LGI group (P=0.9). 
Table 4.8: Fasting Insulin and "omeostasis Model Assessment Results of the lligh 
Glycaemic Index (HGI) and the Low GI (LGI) Groups at Baseline, 
Month 6 and Changes from Baseline 
(\%11L1eS are mean + SID or inedian [IQR]) 
HGI group LGI group P value* 
(ný 14) (11--19) 
Fasting insulin (pniol/1) 
Baseline 56.7 ± 29.8 44.3 19.2 0.2 
Month 6 48.9 ± 21.8 3 2.6 13.1 'ý 0.012 
A from baseline -7.8 -ý 28.3 -11.7+ 16.8 0.6 
HONIA % 
Baseline 102.0 [76.6-176.7] 94.3 166.1-126.01 0.3 
Month 6 87.1 [68.8-144.5] 73.5 [51.1-96.4]ý'ý (). I 
A from baseline -19.5 [-52.9-10.91 -19.2 [-55.9-(-)2.81 0.5 
HOVIA %S 
Baseline 110.4 [90.1-148.71 137.8 [102.6-181.8] 0.2 
Month 6 126.5 [103.6-145.2] 170.3 [131.0-240.5]"$ 0.06 
A ftom baseline 26.9 [-18.3-44.91 32.5 [-6.5-84.1] 0.3 
HOVIA IR 
Baseline 1.02 ± 0.53 0.807ý: 0.33 0.2 
Month 6 0.88 ± 0.39 0.61 +0.24 
b$ 0.02 
A frorn baseline -0.14 ± 0.50 -0.19 ± 0.31 0.7 
HG1 - High Glycaemic Index, LGI = Low Glycaemic Index, Aý Change, HOMA - Homeostasis Model Assessment, 
0/, ý P-P cell function, %S- insuhn sensitivity, IR = insulin resistance. *P value of between-group comparison by 
Mann-Whitney U tests for non-normally distributed data or data that one group was non-normally distributed and could 
not be log-transformed. Paired mests used to compare normally distributed data and Wilcoxon tests used to compare 
non-normally distributed data for within-group analysis, b$ P50.01 between baseline and month 6 "ithin-group. 
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Figure 4.2a: Fasting and 6-hour Postprandial Glucose Response of the High 
Glycaemic Index (HGI) and the Low GI (LGI) Groups to a Standard 
Meal at Baseline and at Month 6 (Values are mean ± SEM) 
41, IRA (bs) a H(31 (1116) A LGI (b. "') A LOI 0116) 
-j 
-0 m 
8 
30 16 0,6o- 60 78 90 1D5 120 i3b 160 166 190 i9b 210 295 240 266 270 PSb 300 116 -0 3ý 360 
I Time (minutois) 
TOSI meal 
HGI = High Glycaemic Index, LGI = Low Glycaemic Index, bs; = baseline, m6 = month 6. Repeated 
measures ANOVA revealed a significant effect of time (P<0.001), no differences between groups (P--l. 0) or 
visits (P--0.5) and no interaction effects. 
Figure 4.2b: 6-hour IAUC Glucose of the High Glycaemic Index (HGI) and the Low 
GI (LGI) Groups at Baseline and at Month 6 (Values are mean ± SEM) 
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HGI = High Glycaemic Index, LGI = Low Glycaemic Index. Between-group comparison of IAUCO-360 
glucose by Mann-Whitney U test revealed no differences at baseline (Pý-O. 1) or at month 6 (P=0.6). 
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Figure 4.3a: Fasting and 6-hour Postprandial Insulin Response of the High 
Glycaemic Index G1 (HGI) and the Low GI (LGI) Groups to a 
Standard Meal at Baseline and at Month 6 (Values are mean ± SEM) 
41, HOI (bs) 0 HG I (m6) A LG I (bs) 
600 
500 
400 
300 
200 
100 
A LG l (m6) 
HGI = High Glycaemic Index, LGI = Low Glycaemic Index, bs = baseline, m6 = month 6. Repeated 
measures ANOVA revealed a significant effect of time (P<0.001), no differences between groups (P--0.3) or 
visits (P--O. 1) and no interaction effects. 
Figure 4.3b: 6-hour IAUC Insulin of the High Glycaetnic Index (HGI) and the Low 
GI (LGI) Groups at Baseline and at Month 6 (Values are mean ± SEM) 
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HGI = High Glycaemic Index, LGI = Low Glycaemic Index. Between-group comparison of IAUCO-360 
insulin by Mann-Whitney U test revealed no differences at baseline (P--O. 1) or at month 6 (P--0.6). 
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4.8.8 Physical Activity 
The activity concentration was assessed by the Baecke Questionnaire and results are shown 
in Table 4.9. The groups did not differ at baseline or month 6 and both had only a small 
and insignificant change from baseline. 
Table 4.9: Activity Concentrations Assessed by Baecke Questionnaire of the High 
Glycaemic Index (GI) and the Low GI Groups at Baseline, Month 6 
and Changes from Baseline (Values are mean ± scl) 
Baecke Questionnaire HGI group LGI group P value* 
(n= 16) (n=22) 
Baseline 7.1 ± 1.0 8.0 ± 0.3 0.2 
Month 6 7.6 ± 1.7 7.5 ± 0.7 0.9 
A from baseline 0.03 ± 1.2 -0.4 ± 0.6 0.5 
HGI = High Glycaernic Index, LGI = Low Glycaemic Index, A= Change. *P value of between-group comparison by 
impaired Student's t tests. Paired t tests used for within-group comparisons and no significant changes were found. 
4.8.9 Blood Pressure and Pulse 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate 
measurements at baseline, months 3 and 6 and changes from baseline are shown in Tables 
4.10and4.11. The groups did not differ at baseline. 
4.8.9.1 Blood Pressure and Pulse at Month 3 
In both groups, SBP, DBP and pulse rate were lower in most subjects by month 3. There 
were no differences between groups in the changes from baseline assessed by X2 test. SBP 
fell by 4.0 ± 6.0 % in the HGI group and by 3.0 ± 6.9 % in the LGI group in the first 3 
months. DBP fell by 2.2 ± 6.6 % in the HGI group and 0.8 ± 8.7 % in the LGI group while 
pulse rate fell by 6.0 ± 11.0 % and by 3.8 ± 14.1 % in the HGI and LGI groups 
respectively. Between-group comparison of the numerical and percentage changes from 
baseline (by unpaired t tests) also revealed no differences (SBP: P--0.9 for numerical 
change, 11--0.7 for percentage change; DBP: P--0.7 for numerical change, P--0.6 for 
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percentage change, and pulse rate: P---0.8 for numerical change, PL--0.6 for percentage 
change). 
4.8.9.2 Blood Pressure and Pulse at Month 6 
As in month 3, SBP, DBP and pulse rate were lower in most subjects at month 6 compared 
with baseline with no differences between groups. SBP fell by 7.5 ± 6.8 % in the HGI 
group and 3.2 ± 7.6 % in the LGI group in six months. DBP fell by 5.4 ± 8.6 % in the HGI 
group and 1.9 ± 11.7 % in the LGI group while pulse rate fell by 8.2 ± 8.7 % and by 2.8 ± 
9.7 % in the HGI and LGI groups respectively. Comparison of the numerical and 
percentage changes from baseline also showed no significant differences between groups 
(SBP: P--0.7 for numerical change, 11---0.08 for percentage change; DBP: P'-0.4 for 
numerical change, P--0.3 for percentage change and pulse rate: P---O. 1 for numerical 
change, P---0.09 for percentage change). 
4.8.10 Arterial Compliance 
Arterial Compliance surrogate measures at baseline, months 3 and 6 and changes from 
baseline are shown in Tables 4.10 and 4.11. Because of the small sample size, statistical 
analysis and commenting on the results was kept to the minimum. (See Section 4.9.7 for 
discussion of reasons for small sample size). 
4.8.10.1 Systemic Arterial Compliance 
A reduction in SAC indicates worsening in arterial compliance. The groups did not differ 
at baseline. At month 3, a higher percentage of subjects in the HGI group had an 
improvement in SAC but groups did not differ statistically (P--0.3). By month 6, most 
subjects in both groups experienced an improvement in SAC, again without a difference 
between groups (P=0.9). 
4.8.10.2 Carotid-Radial Pulse Wave Velocity 
A reduction in Carotid-Radial PWV indicates improvement in arterial compliance. The 
groups did not differ at baseline. At month 3, most subjects in the HGI group and 50% of 
subjects in the LGI group had an improvement in this parameter, but there was no 
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statistical difference between groups (PL--0.4). At month 6, about half the subjects in both 
groups experienced an improvement from baseline and groups did not differ (P--0.4). 
4.8.10.3 Carotid-Femoral Pulse Wave Velocity 
A reduction in Carotid-Femoral PWV indicates improvement in arterial compliance. The 
groups did not differ at baseline. At month 3, the percentage of subjects who had an 
improvement in this measurement did not differ between groups (P--0.3). By month 6, 
most subjects in both groups had a lower Carotid-Femoral PWV but groups did not differ 
(P--O. 1). Another comparison between groups was done after combining the subjects who 
improved with those who did not experience any change (i. e. 88.9% of subjects in the LGI 
group). However, again there was no statistical difference between groups (Xý=2.79, 
P14.2). 
4.8.10.4 Carotid Augmentation Index 
A reduction in Carotid AI indicates improvement in arterial compliance. The groups did 
not differ at baseline. A slightly lower percentage of subjects in the LGI than the HGI 
group had an improvement in this measurement but no significant difference between 
groups was observed at month 3 (P--0.2) or at month 6 (PL--0.4). 
4.8.10.5 Radial Augmentation Index 
A reduction in Radial AI indicates improvement in arterial compliance. The groups did not 
differ at baseline. Only about 25-30% of subjects had an improvement in this 
measurement with no differences between groups either at month 3 (P--0.5) or at month 6 
(P--0.3). 
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4.8.11 Repeatability of Arterial Compliance Measurements 
4.8.11.1 Systemic Arterial Compliance and Pulse Wave Velocity 
Repeatability Assessment 
Assessment of SAC and PWV requires two observers working together. Repeatability of 
these readings was carried out by taking two consecutive measurements on a subsample of 
subjects. Results were plotted as Bland and Altman Plots shown in Figures 4.4a-c and RCs 
were calculated as shown in Table 4.12. There were no significant differences between the 
first and second measurements (P'-O. 8 for SAC, P'-0.2 for Carotid-Radial PWV and P'-O. 1 
for Carotid-Femoral PWV). 
4.8.11.2 Augmentation Index Repeatability Assessment 
Assessment of carotid and radial Al requires only one observer to take the measurement. 
This was performed either by myself (EP) or Candace Bovill Taylor (CBT). Repeatability 
was assessed by carrying out two consecutive measurements on a subsample of subjects. 
To examine variation of consecutive measurements performed by the same observer, intra- 
observer (i. e. within the same observer) repeatability was calculated for observer I 
(myself. EP) and observer 2 (CBT). To assess variation between observers (EP and CBT), 
inter-observer repeatability was calculated. Results were plotted as Bland and Altman 
Plots shown in Figures 4.5a-b and 4.6a-b for intra-observer repeatability and Figures 4.7a- 
b for inter-observer repeatability. Calculated RCs are shown in Table 4.13. There was no 
difference between the first and second carotid Al or radial Al in either of the observers 
(Carotid Al: PL--0.4 for EP, P'-O. 1 for CBT; Radial AL 1"--0.4 for EP, P--0.4 for CBT). 
Also, measurements taken by the two observers were not different (P, --0.7 for Carotid Al 
and P--0.6 for Radial AI). 
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Figures 4.4a-c: Bland and Altman Plots of Repeatability of Systemic Arterial 
Compliance (SAC), Carotid-Femoral Pulse Wave Velocity (PWV) 
and Carotid-Radial PWV Measurements 
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Table 4.12: Repeatability of Systemic Arterial Compliance and Pulse Wave Velocity 
Assessed by Performing two Consecutive Measurements on a 
Subsample of Subjects 
n Mean ± SD Mean ± SD RC 
of measurements of differences 
SAC (ml/mmHg) 10 0.7 ± 0.3 0.01±0.12 0.2 
(SEM: 0.04) 
Carotid-Femoral PWV (m/sec) 94 10.1 ±1.2 0.05 ± 0.30 0.6 
(SEM: 0.03) 
Carotid-Radial PWV (m/sec) 101 13.4±1.5 0.05 ± 0.30 0.6 
(SEM: 0.03) 
RC = Repeatability Coefficient, SAC = Systemic Arterial Compliance, PWV = Pulse Wave Velocity, 
m/sec = metres per second 
Figures 4.5a-b: Bland and Altman Plots of Intra-Observer Repeatability of Carotid 
and Radial Augmentation Index (AI) of Observer 1 (EP) 
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Figures 4.6a-b: Bland and Altman Plots of Intra-Observer Repeatability of Carotid 
and Radial Augmentation Index (AI) for Observer 2 (CBT) 
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Figures 4.7a-b: Bland and Altman Plots Comparing Inter-Observer Repeatability of 
Carotid and Radial Augmentation Index (AI) 
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Table 4.13: Intra and Inter-Observer Repeatability of Carotid and Radial 
Augmentation Index Assessed by Performing two Consecutive 
Measurements on a Subsample of Subjects 
n Mean ± SD Mean±SD RC 
of measurements of differences 
Intra-observer repeatability 
Carotid Al (%) EP 36 28.0 ± 8.2 0.36 ± 2.66 5.3 
(SEM: 0.44) 
Carotid AI (%) CBT 40 25.6 ± 10.5 0.60 ± 2.25 4.6 
(SEM: 0.36) 
Radial Al (%) EP 80 18.3 ±11.0 0.15 ± 1.73 3.5 
(SEM: 0.19) 
Radial Al (1/o) CBT 16 17.3 ±9.1 0.40 ± 1.60 3.2 
(SEM: 0.41) 
Inter-observer repeatability 
Carotid Al (%) EP-CBT 17 28.5 ± 9.0 0.24 ± 2.30 4.5 
(SEM: 0.56) 
Radial Al (%) EP-CBT 16 15.5 ±9.7 0.19± 1.47 2.9 
(SEM: 0.37) 
RC = Repeatability Coefficient, Al = Augmentation Index, EP = Elena Philippou, CBT = Candace Bovill-Taylor, SEM 
Standard Error of the Mean 
4.8.12 Ambulatory Blood Pressure 
Ambulatory blood pressure results at baseline, month 6 and changes from baseline are 
shown in Table 4.14. Valid results were obtained from 11 subjects in the HGI group and 
20 subjects in the LGI group. In the rest of the subjects, results were not valid either at 
baseline or at month 6 or both due to failure of the ABPM monitors. The LGI group had 
bigger reductions in 24-hour SBP, 24-hr DBP and daytime SBP and DBP than the HGI 
group (see Table 4.14 for P values). The percentage change in 24-hr SBP was 3.2 ± 15.1 
% in the HGI group and -9.1 ± 12.0 % in the LGI group, and in 24-hr DBP -0.3 ± 6.3 % in 
the HGI group and -6.5 ± 5.9 % in the LGI group (P=NS). 
144 
GA 
"0 
c3 
2J 
Z. 
Z 
Q) 
Z 
r) -T CD r14 
C 
00 7q r- Do 
. r- 
+I +I +I +I 
r 2 
+I +I +I +I 
- 
= ý= 
01. 
C14 
+1 
n 
- 
+1 
r- r- 
+1 
C7, ýc 
rq 
+1 
r- = 
rA 
00 
'A Lý 
oc 
+1 
- r- 
W" 
- 
+1 
wl CD 
00 
+1 
= r- 
r- 
+1 
- 'r, 
oc, 
Wý 
+1 
oc 
+1 
r) 
+1 
- C) ýý 
DC 
+1 
m 
+1 
oc 
+1 
wl 
+1 
" 
oc 
+1 +1 +1 
rn rA 
+1 +1 +1 +1 
ot 
+I 
I 
+I 
r- 
+I 
r- 
+1 rq 
r1l 
oc 
+1 
Cý4 r- 
+1 
2 
+1 
Ic 
+1 
Irl 
ci 0 c 
.E 00 00 00 00 - M C7, qo 4A Lo - ý7, 
+1 
r'l 
+1 
a, 
kA Lý +1 C') 
+1 
- 
+1 
r'l 
+1 
r- 
oc 
! 
ti) = 
E 
E 
C. 
v) 
to = 
E 
E 
C- 
E 
E 
') 
C. 
E 
Cý z 
E 
P 
m 
Z 
cz 
Z 
vi 
C- 
V3 I 
u 
ct 
cl 
E 
7ý 
.; = 1 
.Z, 
3 -0 
50 
CD 
D -0 
LO 
Chapter 4: The Effect of a 6-Month Dietary Glycaernic Index Manipulation on Arterial Compliance, Blood 
Pressure, Lipid Profile, Fasting and Postprandial Glucose and Insulin Responses in Middle-Aged Men at Risk 
of Heart Disease 
4.9 Discussion 
This randomised intervention trial examined the effects of dietary GI manipulation on heart 
disease risk factors, over and above those of traditional healthy eating and weight loss 
advice. Assessment of arterial compliance, 24-hour BP, lipid profiles, fasting and 
postprandial glucose and insulin, insulin sensitivity and anthropometry was carried out 
before and after the 6-month intervention in middle-aged men. 
The intended dietary GI manipulation was achieved since the groups consumed diets that 
differed in both GI and GL. However, the percentage reduction in GI over the study period 
(6.7 ± 10.2%) and the changes within individual subjects were small and may not have 
been sufficient to result in metabolic benefit. This was partly because the baseline diet of 
the LGI group was low in GI (54.3 ± 4.1 GI units). Other studies achieved a diet GI 
reduction varying from 12% (Frost et al 2004) which did not have any metabolic benefits, 
to 20% which did result in metabolic improvements (Frost et al 1996; Frost et al 1998). 
The effect on metabolic parameters may also depend on the types of LGI foods consumed 
since not all LGI foods are equally beneficial to health (Chapter 1, Section 1.2.2. ) and the 
mechanisms by which different LGI foods exert their effects vary (Chapter 1, Section 
1.2.4). 
4.9.1 Anthropometrics 
All subjects were advised on weight loss, and as expected both groups experienced a 
significant reduction in weight, BMI, waist and hip circumferences and percentage body 
fat over the 6-month study period. There were no differences between the groups in any of 
these measurements. Repeatability assessment of waist and hip circumferences and 
percentage body fat showed that the measurement error was within acceptable limits. 
Although the LGI group might have been expected to lose more weight due to the satiating 
effects of LGI foods (Pawlak et al 2002) and their proposed benefits on postprandial 
metabolism (Ludwig 2002), this did not occur. 
Nevertheless, intentional weight loss, even if it is modest and even after adjustment for 
confounding factors reduces CHD risk development (Eilat-Adar et al. 2005). Moreover, 
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modest weight reduction reduces the clustering of major CVD risk factors. Individuals in 
the Framingham cohort who lost at least 2.25 kg, had a 40-50% reduction in their total risk 
factor score, which is based on clustering of risk factors (Wilson et al. 1999). 
4.9.2 Fasting Cholesterol Profile and Triacylglycerol 
Concentrations 
Total cholesterol and TG concentrations fell in both groups probably due to weight loss 
(Dattilo & Kris-Etherton 1992). At month 6, the LGI group had significantly lower total 
cholesterol after adjustment for baseline compared to the HGI group. Moreover, a within- 
group analysis revealed a significant reduction in LDL cholesterol and TG concentrations 
only in the LGI group. 
These findings agree with a Cochrane Review of the effect of a LGI diet on CHD risk 
factors, reporting that such a diet leads to a small reduction in total cholesterol (Kelly et al 
2004). Similarly, a meta-analysis examining the effects of GI on lipid metabolism, found 
that total cholesterol falls by 0.33 mmol/I when GI is lowered by 22 units (Opperman et al 
2004). In the present study, the LGI group achieved a reduction of 3.9 1 5.6 GI units 
which resulted in 0.45 ± 0.62 mmol/I reduction in cholesterol, i. e. higher than expected 
from the meta-analysis data (Opperman et al 2004). Expressed as percentage change from 
baseline, the reduction was 8.1 :L 11 .5% which is also greater than what would be expected 
from weight loss alone, estimated to be 2.2% (i. e. 1% reduction per Ikg loss) (Dattilo & 
Kris-Etherton 1992). It is possible that the reduction was greater than expected because of 
the greater initial concentration compared to that of the HGI group, known to result in a 
greater change (Dattilo & Kris-Etherton 1992) or because of the combination of healthy 
eating, weight loss and a LGI diet. 
Previous studies showed that a LGI diet leads to significant reductions in TG, total 
cholesterol and LDL cholesterol in hyperlipidaemic patients (Jenkins et al 1987c) and 
reduces LDL cholesterol (Sloth et al 2004) and TG concentrations in healthy subjects 
(Brynes et al, 2003a; Ebbeling et al. 2005). LGI diets may lead to faster clearance of 
intestinally derived TG remnants which are associated with atherosclerosis (Harbis et al 
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2001). On the other hand, HGI diets lead to a deleterious early and exaggerated 
postprandial accumulation of both intestinally and hepatically-derived chylomicrons in 
obese, insulin resistant subjects (Harbis et al 2004). The latter may be caused by acute 
hyperinsulinaemia which inhibits lipoprotein lipase action. 
4.9.3 Fasting and Postprandial Glucose Profile 
Fasting glucose concentrations fell significantly during the study period but the reduction 
did not differ between groups. The reduction in fasting glucose may be attributed to 
weight loss (Anderson & Konz 2001). No changes were found in the postprandial glucose 
concentrations over the study period or between the groups. This may be due to 
confounding factors such as stress influencing the 6-hour period over which postprandial 
glucose was assessed. 
Previous intervention studies showed improvements in glycaemic control, glucose 
tolerance and insulin sensitivity following consumption of a LGI diet in subjects with heart 
disease (Frost et al 1996; Frost et al 1998), in subjects with impaired glucose tolerance 
(Wolever & Mehling 2002) and in Type II diabetic patients (Jenkins et al. 1988; Wolever 
et al. 1992) while only a few studies have been published that found no difference between 
LGI and HGI diets (Calle-Pascual et al. 1988; Raatz et al 2005). In the latter two studies, 
both the LGI and HGI groups lost weight which may have masked the effects of lowering 
diet GI. Weight loss is also a potential confounding factor in the present study. 
4.9.4 Insulin Sensitivity and Postprandial Insulin Profile 
After six months of dietary intervention, fasting insulin concentrations and insulin 
resistance were significantly lower in the LGI compared with the HGI group while insulin 
sensitivity showed a tendency to be better in the LGI group. Additionally, only the LGI 
group showed a within-group improvement in these variables. The reduction in 0 cell 
function over the 6-month period in the LGI group was probably caused by the increase in 
insulin sensitivity which enabled the 0 cells to function at a lower rate. This can be 
confirmed by the fact that both insulin resistance and sensitivity improved in this group. 
No differences were found over the study period or between groups in the postprandial 
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insulin concentrations possibly because of confounders such as stress as mentioned above 
which may have influenced the 6-hour assessment period. 
A previous study found that LGI foods improved both in vivo insulin sensitivity (measured 
by the rate of fall in plasma glucose after an intravenous insulin injection) and in vitro 
insulin responsiveness of adipocytes (Frost et al 1998) in women with heart disease. In 
subjects with the metabolic syndrome, a 12-week LGI diet increased first-phase insulin 
release suggesting an improvement in P cell function (Laaksonen et al 2005) while subjects 
with IGT had an improvement in insulin secretion (Wolever & Mehling 2002) and a 
reduction in insulin demand even without a change in postprandial glucose (Ostman et al 
2006). The improved insulin sensitivity also caused a prolonged suppression of plasma 
FFAs (Wolever et al 1995; Wolever & Mehling 2002), high concentrations of which have 
deleterious effects as discussed in Chapter 1, Section 1.5.3.2. It is of note that in the 
aforementioned studies, body weight did not change over the study period, whereas in 
studies where weight loss occurred, insulin sensitivity improved equally on LGI (or LGL) 
and HGI (or HGL) diets suggesting that absolute weight loss rather than dietary CHO 
composition may be the primary determinant of improvements in glucose-insulin dynamics 
(Ebbeling et al 2005; Pittas et al 2006; Raatz et al 2005; Sloth et al 2004). 
Weight loss, which occurred in both groups in the present study, may have improved the 
subjects' insulin sensitivity, and could explain why groups did not differ when results were 
expressed as changes from baseline. Expressing the results as changes from baseline 
controls for any differences between the groups in the baseline data. In the present study, 
groups differed only at month 6 as mentioned above. This discrepancy makes the 
interpretation of the results more complicated and before concluding on whether lowering 
diet GI provides an additional benefit on insulin sensitivity over that of healthy eating and 
weight loss in this population group, further data collection is warranted. 
4.9.5 Physical Activity 
According to the results of the Baecke Questionnaire, subjects did not increase their 
physical activity during the study as intended and there was no difference between groups 
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in activity concentrations. This may be a true result or it may be attributed to an inability 
of the Baecke Questionnaire to capture small changes in physical activity during leisure 
time. Moreover, since this was a 6-month study, the results may have been confounded by 
seasonal changes in activity. 
4.9.6 Blood Pressure and Pulse Rate 
Blood pressure was recorded in two ways in this study- as the average of two BP readings 
taken at the hospital in the supine position and as ambulatory blood pressure over a 24- 
hour period. Pulse rate was also recorded at the same time as BP both at the hospital and 
during the 24-hour period. In both the HGI and LGI groups, most subjects had a reduction 
in both SBP and DBP and in pulse rate measured at the hospital both at 3 months and at 6 
months compared to baseline. Part of the reduction in BP and pulse was probably due to 
subjects being more familiar with the investigators, the environment and the procedure 
after the first assessment. Nevertheless, observed SBP and DBP changes (ranging between 
5-10 mmHg) were of clinical significance. The reduction was similar in both groups and 
may be attributed to body weight loss. 
Several randomised controlled trials have demonstrated the positive effect of modest 
weight loss in both hypertensive patients (Langford et al. 1985; Stamler et al. 1987; 
Whelton et al. 1998), and in preventing hypertension in high-risk patients (Trials of 
Hypertension Prevention group 1992). Phase I of the Trials of Hypertension Prevention 
(Trials of Hypertension Prevention group 1992) evaluated the effect of weight reduction on 
BP in patients with high normal BP and showed'that modest weight loss halved the 
incidence of hypertension in the 18-month follow up period compared to the control group. 
The pathophysio logical mechanisms of the BP lowering effect of weight loss are not 
completely understood but are most likely a result of an improvement in insulin sensitivity 
and a decrease in sympathetic nervous system activity. Ikeda et al (1996) examined the 
change in insulin sensitivity after weight loss in 24 obese hypertensive subjects by the 
euglycaemic hyperinsulinemic glucose clamp method. Regression analysis showed that 
changes of plasma adrenaline, insulin sensitivity index, plasma renin activity and age were 
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significant predictive factors for the change of mean BP after weight loss. Moreover, in 
the setting of insulin resistance, the normal vasodilatory effect of insulin can be lost (Tooke 
& Hannemann 2000) (Chapter 1, Section 1.4). 
Questions were previously raised as to whether the effects of weight loss on BP are 
independent of dietary sodium intake and physical activity (Mertens & Van Gaal 2000). In 
a study where sodium intake and physical activity were similar, only the group that lost 
weight had significant reductions in BP (Singh et al. 1995). In the present study, dietary 
sodium intake was not reported since subjects were not asked to keep records of added salt. 
Nevertheless, it is quite unlikely that the groups differed in sodium consumption since 
dietary composition, except for diet GI and GL was similar. Moreover groups received the 
same dietary and exercise advice and did not differ in physical activity concentrations. 
Weight loss also led to reductions in pulse rate probably through reducing heart workload 
and sympathetic nervous system activity (Poirier et al 2006b; Sharma & Golay 2002). 
Although the groups did not differ in BP changes measured at the hospital; the LGI group 
had bigger reductions than the HGI group in 24-hour SBP and DBP measured by the 
ABPM as a result of bigger reductions in daytime (6: 00 am-midnight) BP. However, 
results should be assessed with caution, since the study is incomplete and only a few 
measurements were valid in the HGI group. The discrepancy between the changes in BP 
measured at the hospital and those measured by the ABPM may be due to the difference in 
the number of subjects for which valid measurements were available, i. e. there were less 
valid readings in the HGI than the LGI group purely due to chance. 
Nevertheless, the reduction in BP in the LGI group is of clinical significance. Part of the 
reduction was probably due to subject familiarisation with the monitor but it may also be 
explained by physiological mechanisms. Although previous studies did not report any 
additional benefit of LGI diets on BP (Ebbeling et al 2005; Maki et al 2007; Sloth et al 
2004), in these studies a LGI diet was combined with weight loss. It is possible that long- 
term consumption of a LGI diet may reduce BP through its beneficial effects on insulin 
sensitivity and FFA release. Whether this applies in the present study cannot be known 
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until more subjects are recruited for the assessment of 24-hour BP and insulin sensitivity 
and by measuring plasma FFA concentrations in the postprandial state. 
4.9.7 Arterial Compliance 
Results from arterial compliance measurements should be looked at with caution since the 
study is incomplete and the sample size is small. 
4.9.7.1 Systemic Arterial Compliance 
SAC reflects the overall buffering capacity of the arterial system, but mainly the proximal 
aorta. Valid SAC measurements were obtained from only a subsample of subjects due to 
the difficulty of carrying out this measurement. Attempts to measure SAC were carried out 
on all subjects. The procedure requires simultaneous recording of ten valid cycles of 
carotid AI and ascending aortic blood flow, measurements which depend on both the 
observers' technical experience and on the subject's anatomy. Measurements were 
difficult in obese subjects who accumulated a lot of fat near the carotid pulse and in those 
that recording blood flow required an especially uncomfortable extension of the neck. A 
number of attempts were carried out before abandoning the procedure, always paying 
consideration to subject tolerability and acceptance. 
4.9.7.2 Carotid-Radial Pulse Wave Velocity (PWV) and Carotid- 
Femoral PWV 
For both of these measurements, the sample size was bigger than SAC since they were 
technically easier to perform However, sample size is still small. 
Most subjects experienced either an improvement or no change in Carotid-Radial PWV 
(brachial compliance) during the study and most subjects also experienced an improvement 
in Carotid-Femoral PWV (aortic compliance). Groups did not differ in either 
measurement. The median change in Carotid-Femoral PWV in the HGI group was -0.3 
[IQR: -0.6-0.5] mi/sec and in the LGI group -0.4 [IQR: -1.4-0.0] m/sec. Based on 
estimations from cross-sectional studies, a 50-100 cm/sec increase in aortic PWV occurs 
with ageing 10 years (Wildman et al 2003), so an improvement of 30-40 cm/sec induced 
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by dietary intervention is of an important clinical effect. In comparison, angiotensin- 
converting enzyme (ACE) inhibitors cause a 1.1 ± 1.4 m/sec reduction after 6 months 
(Asmar et al. 2001). On the other hand, an increase of I m/sec in aortic PWV has been 
shown to equate to 39% increase in risk of cardiovascular events (Blacher et al. 1999). 
4.9.7.3 Carotid and Radial Augmentation Index 
A smaller percentage of subjects had an improvement in Carotid and Radial Al over the 
study period compared to SAC and PWV measurements. However, because of the small 
sample size, it is inappropriate to comment in detail on these results. Part of the 
explanation for the small sample size for Carotid Al lies in the difficulty in locating and 
stabilising the carotid artery for a sufficient time to obtain an acceptable measurement. 
This was especially evident in subjects with excessive amounts of fat around the carotid 
pulse or those whose pulse could only be felt very deeply down the neck. Another 
practical issue was the proximity of the pulse to the larynx and baroreceptors (AdJi et al 
2006). Subject positioning was manoeuvred to find the position where the carotid pulse 
could be felt strongest. This was done by placing a rolled pillow under the subject's neck 
to extend it or by relaxing or slightly turning the neck. 
Radial Al was measured in more subjects than Carotid AI since the latter measurement was 
easier to perform. Radial pulse is palpable and the subject's wrist could be easily 
stabilised. Radial tonometry was also previously reported to be better tolerated than carotid 
tonometry (AdJi et al 2006), and although tolerability was not directly assessed in this 
study, clinical experience and the smaller sample size for carotid than radial AI provide 
indirect evidence for this. 
4.9.7.4 Possible Mechanisms Inducing Arterial Compliance Changes 
Arterial compliance assessment provides an overall assessment of the arterial wa ut it 
does not provide information about the exact underlying mechanisms or factors that create 
arterial abnormalities. Changes in arterial compliance may be related to changes in 
structural parameters such as arterial wall thickness or internal diameter, or to functional 
parameters such as changes in BP (Asmar et al 2001). Another difficulty is that it is 
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unclear which of the arterial compliance mechanisms elicit reversible versus irreversible 
damage. It may be that restoration of the NO system, which underlies endothelium- 
dependent vasodilation could re-establish endothelial function returning arterial 
compliance to 'baseline' values. However, certain changes in elastin-collagen composition 
may happen over a period of years (Safar et al. 1987) and the change may be irreversible; 
thus it is unlikely to be the physiological mechanism underlying reductions in arterial 
compliance induced by short-term lifestyle modifications (Tanaka & Safar 2005). On the 
contrary, it is possible to break AGE products over a period of a few weeks, nevertheless, it 
is still not clear whether all vascular beds are equally favoured (Kass et al. 2001b). The 
extent of the effect may also depend on the artery e. g. vasodilator drugs may have active 
effects on muscular arteries such as the femoral artery but only passive effects on elastic 
arteries such as the aorta and carotid artery (Nichols & Singh 2002). Arteries may also 
differ in response to dietary modifications. Thus, further intervention studies are needed to 
determine the dietary and lifestyle reversibility of mechanisms underlying obesity- 
associated vascular damage. 
Obesity may have a direct influence on arterial distensibility or it may exert its effects 
through insulin resistance, hypertension, dyslipidaemia or inflammation. The 
i mprovement in SAC and PWV measurements observed in the present study may be due to 
weight reduction per se or an epiphenomenon of BP reduction and/or improvement in lipid 
profile. It is also possible that the changes were due to other (possibly even unknown) 
mechanisms related to healthy eating. Previous studies showed that medication such as 
angiotensin-converting enzyme inhibitors and statins improve arterial compliance (Asmar 
et al 2001; Ferrier et al. 2002) but it is not clear how much of this effect is due to 
reductions in BP, or reduction in lipid concentrations and inflammation and how much is 
independent of it. Body weight loss is associated with improvement in Carotid-Femoral 
PWV either directly or as a result of BP reduction (Toto-Moukouo et al 1986; Wildman et 
al. 2005) while exercise training has been shown to increase SAC compliance (Cameron & 
Dart 1994) suggesting a reversible component of the effects of obesity on the vasculature 
(Wildman et al 2005). In the present study, however, subjects did not report an increase in 
activity concentrations. 
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The effect of weight loss on arterial compliance is not completely understood but it may 
involve improvements in insulin resistance; the detrimental effects of which on the 
vascular endothelium, are discussed in detail in Chapter 1, Section 1.6.3. The LGI diet was 
hypothesised to confer even bigger improvements on arterial compliance than those 
achieved by healthy eating and weight loss alone, through improving insulin sensitivity. 
Indeed, fasting insulin and insulin resistance improved in the LGI compared to the HGI 
group after 6 months of dietary intervention; however, the hypothesis cannot be confirmed 
yet since the study is incomplete and the sample size is small. 
Obesity is not only characterised by insulin resistance but also by low grade inflammation, 
shown by higher concentrations of CRP (Hak et al. 1999). Concentrations of CRP mark 
vascular inflammation and may directly contribute to the pathogenesis of endothelial 
dysfunction by decreasing eNOS expression (Venugopal et al. 2002) and up-regulating 
angiotensin-receptor type 1 expression in the endothelium. (Wang et al. 2003). A HGI diet 
was found to be associated with elevated high-sensitivity CRP in healthy women (Liu et al. 
2002) suggesting that the inflammatory process may be worsened by diets containing these 
types of CHOs. This finding is consistent with intervention studies where subjects on low 
GL diets had significant reductions in CRP concentrations compared to low fat (Pereira et 
al. 2004b) or high GL weight reducing diets (Pittas et al 2006). 
In addition to weight loss, healthy eating may improve arterial compliance through other 
mechanisms. For example, the antioxidant vitamins, ascorbic acid and a-tocopherol were 
reported to improve radial Al (Mullan et al. 2002) and SAC, respectively (Mottram et al. 
1999), probably by acting as free radical scavengers in the endothelium (Tanaka & Safar 
2005). Moreover, fish oil as well as folic acid supplementation were independently found 
to improve arterial compliance (Nestel et al. 2002; Williams et al. 2005) while dietary 
isoflavones in soya improve SAC and PWV in older women (Teede et al. 2003). 
Moreover, a 3-month dietary sodium restriction improved aortic PWV and carotid Al; 
effects which were independent of changes in BP and body weight (Seals et al. 2001). 
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4.9.7.5 Repeatability of Arterial Compliance Measurements 
Repeatability assessment of the arterial compliance measurements was carried out to 
examine the variation between measurements and between observers both of which were 
found to be at an acceptable concentration. 
The RC for the SAC measurement was 0.2 which compares well with the RC of 0.31 found 
in a study comparing visit I and visit 2 data taken within 2.5 weeks in 50 healthy 
volunteers (Liang et al. 1998). The repeatability of Carotid-Radial and Carotid-Femoral 
PWV was good (RC=0.6 for both measurements). Previously, RC for Carotid-Femoral 
PVN was found to be 1.37 (Liang et al 1998). The Carotid-Femoral PVN mean 
difference was 0.05 m/sec, which is slightly better than 0.08 m/sec found in a previous 
study using the same equipment (Scuteri et al. 2007). 
Carotid and radial Al measurements were carried out by one observer therefore intra- and 
inter-observer repeatability were assessed. RC for intra- and inter-observer carotid AI 
were similar at 4.5-5.3 and lower than 7.1 found in a study comparing measurements taken 
at two different visits (Liang et al 1998). The RC of Radial AI indicated a good 
repeatability in this measurement. The - mean -differences between measurements and 
between observers are very similar to a previous study which reported the intra-observer 
difference in Al as mean ± SEM: 0.49 ± 0.93 and the inter-observer difference as 0.23 ± 
0.66 (Wilkinson et al 1998). The RC for carotid AI was slightly higher than the Radial AI, 
which may be related to the technical difficulties in carrying out the former measurement. 
Similarly, Adii et al (2006) also found the inter-observer difference to be higher for carotid 
Al than radial AL 
4.9.7.6 Strengths and Limitations 
The main strength of this study is its originality since it is the first study to examine the 
effect of diet GI manipulation on arterial compliance and ambulatory BP. It also involved 
simultaneous assessment of many CHD risk factors over a long intervention period. 
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As shown by monthly 3-day diaries, compliance to the dietary changes was good and diet 
GI significantly differed between groups throughout the study period. Since no foods were 
provided to achieve a change in GI, it was shown that consumption of a LGI diet is 
attainable and can be maintained over a 6-month period in free-living subjects. However, 
by not providing foods, assessment of dietary compliance is only based on subject 
interviews and dietary records. Furthermore, provision of stable foods may have caused a 
bigger change in dietary GI from baseline. 
The accuracy of diet GI calculations was assessed by calculating the percentage of CHO 
that was assigned a published or an estimated GI value. The majority of CHO (80.4%) was 
assigned a GI value from a published source, with only 16.5% of CHO being assigned an 
estimated GI value. Since the same estimations were used throughout the study, any errors 
in estimations would be systematic thus still allowing comparison between groups. 
Recruitment issues meant that the study could not be completed therefore conclusions on 
the arterial compliance and 24-hour BP results cannot be made. Although hundreds of 
potential subjects were contacted, response and participation rate were low presumably due 
to work and fan-ffly commitments making it difficult to accommodate a 6-month study 
requiring monthly visits, two of which were whole-day visits to the hospital. Moreover, 
some people may have found the idea of a hospital-based study and especially 
measurement of arteries daunting (although measurements do not cause any pain) while 
others may have not been prepared to follow a 6-month dietary intervention. Nevertheless, 
the attrition rate was satisfactory. All of these factors may have led to selection bias in the 
population i. e. participants might have been more interested in nutrition and/or weight loss, 
more health conscious, more ready and committed to change, or of a higher socio- 
economic status since except for travel expenses, no payment was provided for 
participation. 
Lastly, only men were recruited in this study since they are known to have a higher CHD 
risk, therefore it is not known whether women would be affected in a similar way by this 
dietary manipulation. 
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4.10 Conclusion 
Preliminary results from a 6-month consumption of a LGI diet taken in addition to healthy 
eating and weight reduction, showed that this diet caused a bigger reduction in total 
cholesterol, fasting insulin, insulin resistance and 24-hour BP in middle-aged men at risk 
of CHD than a HGI diet. However, since the study is not yet complete, all results and 
especially 24-hour BP results should be assessed with caution, and it is inappropriate to 
comment on arterial compliance measurements. 
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5.1 Introduction 
As discussed in Chapter 1, Section 1.7, obesity has detrimental effects on all organs 
increasing the risk for CHD, diabetes and cancer whereas weight loss can significantly 
reduce these risks. Weight loss maintenance is imperative for sustaining the metabolic 
benefits of weight loss. 
LGI diets were previously shown to enhance weight and fat loss as discussed in Chapter 1, 
Sections 1.7.6 and 1.8.2. A LGI diet may facilitate weight maintenance by improving 
access to stored metabolic fuels between meals and by preventing marked postprandial 
glucose excursions thus decreasing hunger (Ludwig 2003). It may also cause smaller 
declines in resting energy expenditure than a HGI diet (Agus, et al 2000). However not all 
studies showed that a LGI diet is more beneficial than a HGI or a low fat diet for weight 
loss and maintenance (Ebbeling et al 2005; Raatz et al 2005; Sloth et al 2004). A recent 
study comparing a low GL to a low fat, portion controlled diet showed that although the 
low GL diet led to more weight loss, it had no clear superiority for weight maintenance 
(Maki et al 2007). However, this study and other recently published studies (Das et al. 
2007; Ebbeling et al 2007) employed a low GL diet to assess weight loss, which is, by 
definition, low in CHO. Moreover, they focused on weight loss rather than maintenance. 
The present investigation aimed to assess the effect of manipulation of the type of CHO but 
not the amount of CHO consumed on body weight maintenance. 
5.2 Hypothesis 
9 In the setting of healthy eating, consumption of a LGI diet compared to a HGI diet, 
over a four month period by overweight and obese subjects will be more beneficial 
for weight loss maintenance and body composition after a 5% reduction in body 
weight. 
The same dietary intervention will lead to an improvement in fasting and 
postprandial. blood glucose and insulin concentrations, insulin sensitivity and lipid 
concentrations as well as a reduction in appetite. 
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5.3 Ethical Approval and Consent 
The study was ethically approved by the Hammersmith, Queen Charlotte's and Chelsea 
Hospitals Research Ethics Committee (REC: 2003/6728) and subjects gave written 
informed consent before enrolment. 
5.4 Subject Recruitment 
Subjects were recruited by advertisement as discussed in Chapter 2, Section 2.2-1. 
Subjects were sent the study's information sheet (Appendix 8) and a pre-screening 
questionnaire (Appendix 1) and if they were deemed eligible at this stage, they were 
invited for screening (Chapter 2, Sections 2.2.2 - 2.2.3). The following inclusion and 
exclusion criteria applied. 
Inclusion Criteria: 
Healthy subjects aged 18- 65 years old 
BMI: 27-45 kghný 
Exclusion Criteria: 
* As discussed in Chapter 2, Sections 2.2.2 and 2.2.3. Briefly, the main exclusion 
criteria were heart disease, diabetes, other clinically significant disease, eating 
disorder, depression, abnormal thyroid function, abnormalities in blood parameters, 
abnormal ECG, and/or taking lipid lowering medication, anti-hypertensive 
medication or thyroxine. 
Subjects who were deemed eligible for participation were given instructions as explained 
in Chapter 2, Section 2.7.1 on how to fill in a 7-day food diary before enrohnent in the 
study. 
5.5 Power Calculation 
A power calculation was not carried out since this was a pilot study. 
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5.6 Design and Procedures 
5.6.1 Study Design 
The study consisted of two parts: the weight loss phase, during which subjects were 
required to lose 5% of body weight; and the 4-month weight maintenance phase. The 
weight loss phase was only a pre-requisite for investigating the dietary GI manipulation 
during the weight maintenance phase. The weight loss phase was not randormsed; all 
subjects were treated in a similar way. They were then randomised (Chapter 2, Section 
2.3) to either a LGI or a HGI diet for a 4-month weight maintenance period. The weight 
maintenance phase had a randomised, non-blind parallel design. It should be noted that 
'baseline' refers to the start of the study i. e. the start of the weight loss phase and 
'randomisation' refers to the start of the weight maintenance phase. Subjects were seen by 
myself monthly for assessments of dietary compliance and anthropometrics during both tile 
weight loss and the weight maintenance phases. At the baseline visit, a fasting blood 
sample was taken. The fasting and postprandial glucose and insulin responses were 
assessed at randomisation and at month 4 of the weight maintenance phase. A fasting 
blood sample was also taken at month 2 of the weight maintenance phase. The fitness 
concentrat ions were assessed at baseline, randomisation, month 2 and month 4 of the 
weight maintenance phase. The study design is shown in Figure 5.1. 
Figure 5.1: Diagram of Study Design 
Study duration 
Baseline 
Fasting blood 
Anthropornetrics 
Fitness test 
IýUndornisafion 
Test Meal 
Anthropometrics 
Fitness test 
NI 2 Maint 
Fast ing blood 
Anthropometrics 
Fitness test 
M4 Mai nt 
Test Meal 
Anthropometrics 
Fitness test 
M- Month. Small arrows indicate study visits at monthly intervals during which anthropornetric 
measurements were taken. Test meal refers to 3-hour postprandial assessment. 
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5.6.2 Intervention 
5.6.2.1 Formulation of Dietary Advice During the Weight Loss Phase 
The purpose of this study was to assess the effectiveness of a LGI diet on weight 
maintenance following 5% body weight loss. Thus, the weight loss phase of the study 
served only as a prerequisite for moving on to the weight maintenance phase. 
Subjects were seen on a one-to-one basis and given weight loss advice based on the 7-day 
diary completed at screening. All subjects were seen by myself The aim of the weight 
loss phase was to achieve a 500-1000 kcal deficit per day through diet and exercise leading 
to a weight loss of approximately 0.5-1.0 kg a week. Meal replacement drinks (Slinifaste, 
Unilever UK Foods Ltd, Crawley, West Sussex, UK) were supplied (free of charge) to 
replace two meals per day. Several studies previously showed that these were effective for 
weight loss in both diabetic and non-diabetic subjects (Fleclitner-Mors et al. 2000; 
Heymsfield et al. 2003; Yip et al. 2001). A meta-analysis (Heynisfield et al 2003) of 
weight loss studies using meal replacement products found that this dietary intervention 
resulted in a 7-8 % body weight loss in 3 months. For the third meal, subjects were 
advised to reduce their portion sizes, especially high-fat foods, and to increase their 
vegetable consumption. Subjects were allowed up to three low fat snacks per day 
containing up to 100 kcal each (preferably fruit). Those subjects who disliked the meal 
replacement drinks were advised on weight loss using a conventional low kcal, low fat 
diet. All subjects were also advised to increase their exercise over and above current 
concentrations to a minimum of half an hour equivalent of walking every day. 
Subjects were required to achieve a 5% body weight loss within two months. 
Unsuccessful weight loss led to dismissal from the study. However, an extension to the 2- 
month period was given to those who consistently lost weight but at a slow rate. Thus the 
weight loss period varied for each subject. 
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5.6.2.2 Formulation of Dietary Advice During the Weight Maintenance 
Phase 
Following 5% weight loss, subjects were randomised to a LGI or a HGI diet for a 4-month 
weight maintenance period. In addition to changing the dietary GI as discussed in Chapter 
2, Section 2.8, all subjects were advised to avoid high fat and sugary foods and to follow 
their intrinsic cues for food intake i. e. their appetite as much as possible. The aim of this 
advice was to change dietary GI in the setting of a healthy eating diet and to eat to appetite. 
Subjects were encouraged to continue exercising to at least half an hour equivalent of 
walking every day. 
5.6.3 Monthly Visits 
I saw subjects on a one-to-one basis each month for a dietetic assessment and 
anthropometric measurements of weight and waist circumference. 
5.6.4 Food Diaries 
Subjects were required to fill in a 7-day food diary of their habitual intake before the 
baseline visit. 3-day food diaries were kept between month 1-2 of the weight loss phase 
and between month 1-2 and month 3-4 of the weight maintenance phase of the study 
(Chapter 2, Section 2.7.1). 
5.6.5 Dietary Compliance 
5.6.5.1 Weight Loss Phase 
Dietary compliance was assessed at monthly visits. The individual weight loss target of 
5% was explained at baseline to all subjects. Subjects were required to achieve a weight 
loss equivalent to 0.5 kg a week and non-compliant subjects were dismissed from the study 
during the weight loss phase. At month 1-2 of the weight loss phase, subjects were 
required to keep a 3-day diary as explained in Chapter 2, Section 2.7.1 which was used 
together with a diet history to assess compliance. Compliance was also assessed by 
comparing the expected weight loss based on energy deficit to the observed. Specific 
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issues or concerns including travelling and eating out were discussed and encouragement to 
follow the diet and exercise was provided. 
5.6.5.2 Weight Maintenance Phase 
Dietary compliance was assessed at monthly visits using the food diaries, by taking a diet 
history, by checking the main CHO-containing foods consumed and avoided and by body 
weight checks. In contrast to the weight loss phase, the importance of dietary compliance 
was especially emphasised and again specific issues or concerns were discussed. Where 
necessary, further food and snack ideas were provided, together with encouragement to 
follow the diet and eat to appetite. Physical activity concentrations were also assessed and 
subjects were encouraged to meet their individual aims previously set. 
5.6.6 Anthropometrics 
Body weight and waist circumference were measured at baseline and at each monthly visit. 
In addition, body composition was assessed at baseline, randomisation, month 2 and month 
4 of the weight maintenance phase. For details of assessment protocols see Chapter 2, 
Section 2.4. RCs were calculated for waist and body fat measurements as described in 
Chapter 2, Section 2.20. 
5.6.7 Physical Fitness Assessment 
5.6.7.1 Baecke Questionnaire 
The Baecke Questionnaire was provided at baseline, randomisation and month 4 of the 
maintenance phase to assess physical activity (Chapter 2, Section 2.12.1). 
5.6.7.2 Shuttle Walking Test 
The shuttle walking test was used to assess fitness concentrations at baseline, 
randomisation, month 2 and month 4 of the weight maintenance phase (Chapter 2, Section 
2.12.2). 
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5.6.8 Appetite Assessment 
Appetite was assessed using VAS (Chapter 2, Section 2.13.1). Free-living subjects were 
required to rate their hunger and fullness for 3 consecutive days including one weekend or 
non-working day, upon waking, before and after each meal and before sleeping at month I- 
2 and month 3-4 of the weight maintenance phase (Appendix 5 shows a I-day VAS 
example). Questions on general feelings of hunger and fullness for each whole day were 
also asked. The VAS were filled in on the same days as the food diaries. 
5.6.9 Fasting Blood Tests 
Single fasting blood samples were taken at baseline and month 2 of the maintenance phase 
of the study. At randomisation and month 4 of the weight maintenance phase, three fasting 
blood tests were taken (at -30, -15 and 0 minutes) before provision of the test meal for the 
postprandial assessment as discussed in Chapter 2, Section 2.14.4. Subjects were required 
to follow the conditions described in Chapter 2, Section 2.14.1 before blood collection. 
5.6.10 Postprandial Metabolic Assessment 
A 3-hour postprandial metabolic assessment was carried out at randomisation and at month 
4 of weight maintenance phase. The preparation for assessment and the procedure is 
explained in Chapter 2, Section 2.14.1. Blood samples were taken at times -30, -15,0, 
+15, +30,45,60,90,120,150 and 180 minutes. The test meal was served at time 0 (to) 
minutes. 
5.6.10.1 Test Meal 
The test breakfast was served immediately after taking the fasting blood sample at to 
minutes. It consisted of 60g wholemeal bread, lOg margarine, 20g cheddar cheese, 40g 
Weetabix, 200ml semi-skimmed milk, 6g sugar and decaffeinated tea or coffee and 
provided 538 kcal, 71.3g CHO, 20. Ig fat and 21. lg protein (expressed as percentage of 
energy: 50.2% CHO, 34% fat, 15.9% protein). Subjects were instructed to consume all the 
meal within 15 minutes. 
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5.6.11 Blood sample Analysis 
On each blood collection, one fasting blood sample was sent to the Clinical Chemistry 
Department for analysis of glucose, lipoproteins and TG (Chapter 2, Section 2.15.3). The 
rest of the fasting samples and the postprandial samples were centrifuged and the plasma 
was separated and frozen to -20'C until analysis (Chapter 2, Section 2.14.3). From these 
samples, I analysed the fasting and postprandial plasma glucose (Chapter 2, Section 2.15.1) 
and the Clinical Chemistry Department analysed the fasting and postprandial insulin 
(Chapter 2, Section 2.15.2). The glucose and insulin 3-hour postprandial IAUC was 
calculated as described in Chapter 2, Section 2.16.2 and HOMA was used to assess insulin 
sensitivity, insulin resistance and P cell function (Chapter 2, Section 2.15.2). 
5.6.12 Dietary Analysis 
All food diaries were analysed using Dietplan 6 (Forestfield Software). Likely under- 
reporters were identified from baseline 7-day diaries as described in Chapter 2, Section 
2.7.2). 
5.6.13 Glycaernic Index (GI), Glycaernic Load and GI sources 
Calculations of GI, GL and GI value sources were caff ied out as described in Chapter 2, 
Section 2.9-2.11. 
5.6.14 Outcome Measures 
The primary outcome was the change in weight during the weight maintenance phase. 
Other outcomes were changes in waist circumference and body fat concentrations, changes 
in appetite, changes in fasting and postprandial glucose profiles, insulin sensitivity and 
fasting lipid concentrations during the weight maintenance phase. 
5.7 Statistical Analysis 
Data was analysed using SPSS for Windows (Version 14.0, SPSS, Chicago, Illinois, USA). 
Data was checked for normality using the Shapiro Wilks test and by examining the 
normality plots. Data is presented as mean ± sd when normally distributed or median 
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[Interquartile range (IQR)] when non-normally distributed. Data in graphs is presented as 
mean ± SEM. For all tests, a P-value of 50.05,2-sided was considered statistically 
significant. 
To check if there were any demographic differences between all recruited subjects, 
subjects who completed the weight loss phase and subjects who completed the whole 
study, comparisons were carried out by unpaired Student's t tests for normally distributed 
data, Mann-Whitney U tests for non-nonnally distributed data and chi-square tests for 
categorical data. For the rest of the statistical analysis, only data from subjects who 
completed the whole study were analysed. An intention-to-treat analysis of outcome 
variables using data for subjects with ; -> 1 post-randomisation body weight measurement 
was not carried out since subjects who dropped out following randomisation did not return 
for a further visit. 
For the weight loss phase, paired Student's t tests were used to compare data at baseline 
and after weight loss for normally distributed data and Wilcoxon tests for non-normally 
distributed data. If data in only one of the time points (i. e. baseline and following weight 
loss) was normally distributed, a log-transformation was carried out before applying a 
paired Student's t test. For data that did not normalise even after log-transformation, a 
non-parametric Wilcoxon test was applied. 
For the weight maintenance phase, groups were compared at randomisation by Student's 
unpaired t test for normally distributed data or Mann-Whitney U tests for non-normally 
distributed data. Anthropometric: variables and fasting blood test results over the 4-month 
maintenance period were analysed by applying linear mixed models to test the effect of 
diet group, time and the diet group x time interaction. Non-normally distributed data were 
log-transformed before applying mixed models. If the diet group x time interaction was 
not significant, the model was reduced (i. e. interaction was not considered). The F ratio 
and P-value of significance for time, diet group and diet group x time interaction are 
presented for each of these comparisons. The F ratio represents the variance between the 
groups, divided by the variance within the groups. A large F ratio indicates that there is 
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more variability between the groups (caused by the independent variable) than there is 
within each treatment group (referred to as the error term). A within-group analysis of 
anthropometric variables was also carried out using paired Student's t tests to examine 
whether individual groups changed. 
The mean ± SEM fasting and postprandial glucose and insulin at randomisation and month 
4 were plotted. Repeated measures ANOVA was used to compare postprandial glucose 
and insulin responses with time (time points -30, -15,0, +15, +30,45,60,90,120,150, 
180 minutes for glucose and -15,0, +30,60,120,180 minutes for insulin), diet group and 
visit (randomisation and month 4) as independent factors. Interaction effects were also 
assessed. IAUC of postprandial glucose and insulin were calculated as described in 
Chapter 2, Section 2.16.2. HOMA was used to calculate insulin sensitivity, insulin 
resistance and P cell function from fasting glucose and insulin values as explained in 
Chapter 2, Section 2.15.2. A between-group comparison of the 3-hour IAUCs glucose and 
insulin, HOMA results and activity and fitness concentrations data at randomisation, 
month 4 and changes from randomisation was done using unpaired Student's t tests for 
normally distributed data and log-transformed non-normal data and Mann-Whitney U tests 
for non-normally distributed data or data which could not be log-transformed. 
The VAS were analysed by taking the average of the ratings for hunger and fullness from 
the 3 recorded days at each timepoint (e. g. before breakfast, after breakfast) and employing 
repeated-measures ANOVA, with time (eight time points throughout the day) and group as 
independent factors. The mean ± SEM of hunger and fullness of the two groups at each 
time point were plotted for months 1 and 3 of the weight maintenance phase. Between- 
group comparison of the whole day concentrations of hunger and fullness was carried out 
using unpaired Student's t tests. 
The RC (Chapter 2, Section 2.20) was calculated for a sub-sample of waist circumference 
and body fat measurements to assess reproducibility of the measurements. The mean ± SD 
of differences between the first and second measurements was calculated and differences 
between the measurements were assessed by paired Mests. 
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5.8 Results 
5.8.1 Subject Recruitment 
The number of people recruited and retained during the study are shown in Flow Chart 5.1. 
Approximately half (149/302) the people informed of the study were subsequently screened 
and about a third (111/302) of those were recruited. Out of these, 22 people failed to start 
the study. No differences in demographics where found between those who failed to start 
the study compared to those who started (compared by unpaired Student's t tests and chi- 
squared tests; results not shown). Of the 89 subjects who started the study, 56% (50/89) 
were randomised to the weight maintenance phase and 47% (42/89) completed the study. 
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Flow Chart 5.1: Number of Subjects Contacted, Screened, Recruited, Participated 
and Completed the Study 
Sent info on study 
(n = 302) 
1 
Screened for study 
(n = 149) 
1 
Recruited I 
(n= 111) 
1 
Started study 
(i. e. wt loss phase) 
(n = 89) 
Randomised to wt 
maintenance phase 
(n = 50) 
Completed study 
(n = 42) 
1 
Not responded/not 
interested (n = 153) 
Not eligible (n = 38) 
Failed to start (n = 22) 
Failed to lose weight (n = 17) 
Dropped out (n = 17) 
Lost to follow up (n = 4) 
Started contraindicating medication (n = 1) 
Dropped out (n = 5) 
Lost to follow up (n = 3) 
Lost to follow up refers to not being contactable after several attempts. The reasons for drop out during the 
weight loss phase were: personal problems (5 subjects), no weight loss (4 subjects), time issues (3 subjects), 
Slimfast@ side-effects (headaches, loose stools, nausea) (2 subjects), bereavement (I subject), depression (I 
subject), moved country (I subject). The reasons for drop out during the weight maintenance were: did not 
want to follow diet (one subject randomised to LGI and two to HGI diet), personal problems (I subject), time 
issues (I subject). 
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5.8.2 Demographics of all Recruited Subjects, those who 
Completed Weight Loss Phase only and those who 
Completed the Whole Study 
Table 5.1 shows the demographic details of all recruited subjects, those who completed the 
weight loss phase and those who completed all of the study. A comparison of the subjects 
who completed the study (n = 42) to those who did not complete the study (n = 47) showed 
that the former were older (44.8 ± 10.7 vs 37.4 ± 8.5 years old, P<0.001). Moreover, a 
comparison between the subjects who completed the weight loss phase (n = 50) to those 
who did not complete the weight loss phase (n = 39) also found the former to be older 
(43.1 ± 10.9 vs 3 8.0 ± 8.8 years old, P-4.0 19). 
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5.8.3 Demographics of the High Glycaemic Index (HGI) and the Low 
GI (LGI) Groups 
Table 5.2 shows the demographic details of the HGI and LGI groups at randomisation. (i. e. 
following the weight loss phase). There were no significant differences between the two 
groups. 
Table 5.2: Demographic Data of the High Glycaemic Index (HGI) and the Low GI 
(LGI) Groups at Randomisation (Values are numbers (%) or mean ± sd) 
HGI group (n=19) LGI group (n=23) P-Value 
Age 45.1 ±9.4 44.6± 11.9 0.5 
Gender 
Male 2(10.5) 1(4.3) 0.4 
Female 17(89.5) 22(95.7) 
Ethnicity 
Caucasian 8(42.1) 9(39.1) 
Black 8(42.1) 7(30.4) 0.5 
Asian 1(5.3) 3(13.0) 
Other 2(10.5) 4(17.4) 
Weight (kg) 83.6 ± 13.4 87.2 ± 15.3 0.4 
BMI (kg/rný) 31.3 ±4.8 32.5 ±4.8 0.4 
Waist (cm) 98.4 ±11.7 100.5 9.6 0.5 
Body fat 37.1 ± 7.9 38.8 5.7 0.4 
Smokers 2(10.5) 2(8.7) 0.3 
Fasting blood tests 
Total cholesterol (mmol/1) 4.87 ± 0.67 4.67 ± 0.93 0.4 
LDL cholesterol (mmol/1) 3.21 ±0.58 3.01 ± 0.81 0.4 
HDL cholesterol (mmol/1) 1.19 ± 0.16 1.26 ±0.21 0.2 
Total chol: HDL 4.14 ± 0.60 3.78 ±0.74 0.1 
Triacylglycerols (mmol/1) 1.04 ± 0.34 0.93 ±0.31 0.3 
Glucose (mmol/1) 4.92 ±0.47 4.82 ± 0.47 0.5 
HGI = High Glycaemic Index, LGI = Low Glycaemic Index, BMI = Body Mass Index, LDL = Low Density 
Lipoprotein, UDL = I-Egh Density Lipoprotein, Total Chol: HDL = Total Cholesterol to HDL Cholesterol 
ratio. P value of between-group comparison. Unpaired Student's t tests used to compare normally distributed 
data, Mann-Whitney tests used to compare non-normally distributed data and chi-square tests used for 
categorical data. No significant differences found. 
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5.8.4 Dietary Intake and Composition 
5.8.4.1 Validation of Dietary Intake Records at Baseline 
Out of a total of 168 diaries, 93% were returned (156/168 diaries), of which 93% (71/76 
diaries) of the HGI group and 92% of the LGI group (85/92 diaries). All of the baseline 
diaries were returned. 
The validity of the 7-day food diaries at baseline was assessed using the Goldberg cut-off 
of 1.05 (Chapter 2, Section 2.7.2) (Black 2000; Goldberg et al 1991) and 12 subjects (4 in 
HGI group and 8 in LGI group) were defted as under-reporters. The high prevalence of 
under-reporting was probably due to most subjects being overweight or obese and 
therefore more likely to underreport (Hoidrup et al 2002). 
5.8.5 Weight Loss Phase 
5.8.5.1 Dietary Intake and Composition 
The subjects' dietary intake and composition at baseline, during the weight loss phase and 
the change from baseline are shown in Table 5.3. In comparison to baseline, there were 
significant reductions in energy intake (P<0.001), percentage energy from total fat 
(P--0.002), monounsaturated (P<0.001), polyunsaturated (P<0.001), saturated fat 
(P<0.001) and starch intake (P--0.002). Fibre intake expressed as g/1000 kcal increased 
(P--0.019). There were significant increases in percentage energy from protein (P--0.014), 
CHO (P<0.001) and sugar (P<0.001) intakes. Alcohol intake was minimal at baseline and 
did not change. There were also significant reductions in diet G1 (P<0.001) and diet GL 
(P<0.001). The reduction in diet GL was a reflection of the reduction in both diet GL and 
CHO intake. 
5.8.5.2 Anthropometrics 
The weight loss phase lasted a median of 2.9 [IQR: 2.0-3.5] months and led to a median 
weight loss of 6.1 [IQR: 5.2-7.1 ]% body weight. During this phase, there were significant 
reductions in body weight, BMI, waist circumference and body fat (P<0.001). 
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5.8.5.3 Activity and Fitness 
During the weight loss phase, activity assessed by both the Baecke Questionnaire and by 
assigning a PAL factor, increased (P--0.013; P--0.002 respectively). Fitness concentration 
assessed by the Shuttle Walking Test also significantly increased (P--0.003). 
5.8.5.4 Fasting Blood Tests 
During the weight loss phase, there were significant reductions in total cholesterol 
(P<0.001), LDL cholesterol (P<0.001) and HDL cholesterol (P<0.001). Because both total 
and HDL cholesterol reduced, there was no significant difference in total cholesterol to 
HDL cholesterol ratio (P--0.8). TG and glucose concentrations also fell significantly 
during the weight loss phase (P<0.00 1; P--0.002 respectively). 
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5.8.6 Weight Maintenance Phase 
5.8.6.1 Dietary Intake and Composition 
The dietary composition of the HGI and LGI groups at months 2 and 4 of the weight 
maintenance phase is shown in Table 5.5. The groups differed in diet GI (P<0.001 at 
month 2 and P<0.001 at month 4) and in diet GL (P--0.044 at month 2 and P--0.002 at 
month 4). Since CHO intake did not differ, the difference in diet GL was a reflection of the 
difference in diet GI only. The groups were also significantly different in percentage 
energy intake from starch (P<0.001 at month 2 and 11--0.005 at month 4). The fibre intake 
was similar in the two groups at month 2; but by month 4 the LGI group consumed more 
fibre per 1000 kcal than the HG1 group (11--0.020). 
5.8.6.2 Anthropometrics 
5.8.6.2.1 Comparisons Between Groups 
Table 5.6 shows the anthropornetrics of the HGI and LGI groups at the randomisation visit, 
month 2 and month 4 of the weight maintenance phase and the changes from 
randomisation. Figure 5.2 shows the weight changes throughout the study. 
At randoniisation, there were no differences in anthropometrics between the groups. 
Because diet group x time interaction for weight, BMI and waist were not significant, the 
model was reduced to test only time and diet group. There was a significant difference in 
body weight and BMI over time (P--0.05 for both variables), however, there was no 
difference in these variables between groups (11--0.5). During the 4-month period, the LGI 
group lost a fin-ther 0.7 ± 2.9 kg weight whereas the HGI group gained 0.3 ± 1.9 kg but this 
difference was not of statistical significance (P=0.3 assessed by independent t test). The 
percentage of subjects who gained weight during the 4-month weight maintenance phase 
was also compared and was similar in the two groups (52% of subjects in the HGI group; 
39% in the LGI group, P=0.4 assessed by)? test). Waist circumference did not change 
over time (P--0.4) and was not different between groups (P--0.8). During the 4 months of 
weight maintenance, body fat did not change (P--0.5) and there was no difference between 
groups (P--0.6). 
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5.8.6.2.2 Comparisons Within Groups 
5.8.6.2.2.1 High Glycaemic Index Group 
There were no significant differences in anthropometrics during the weight maintenance 
phase in the HGI group (Table 5.6) 
5.8.6.2.2.2 Low Glycaemic Index Group 
At month 2 of the weight maintenance phase, there was a significant reduction in 
percentage body fat compared with randomisation in the LGI group (randomisation vs 
month 2 maintenance: 38.8 ± 5.7 % vs 38.0 ± 6.3 %, P--0.053). There were no other 
differences in anthropometrics during the weight maintenance phase (Table 5.6). 
Figure 5.2: Weight Loss and Maintenance During the Study 
(Values are mean ± SEM) 
6 All subjectB (n-42) A HGI group (n-19) i LGI group (n-23) 
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5.8.6.3 Repeatability Coefficients of Anthropometric Variables 
5.8.6.3.1 Repeatability Coefficient of Waist Measurement 
The waist circumference RC was based on 31 measurements repeated twice at the 
beginning and end of a consultation on fasted subjects. The mean ± SD of measurements 
was 101.2 ± 11.8 cm and the mean ± SD of differences was 0.22 ± 1.12 (SEM of 
differences: 0.20 cm). The RC of measurements was 2.24. Paired Mest used to assess 
differences between measurements showed no differences between the first and the second 
measurement (P---0.3). 
5.8.6.3.2 Repeatability Coefficient of Body Fat Measurement 
The % body fat RC was based on 10 measurements repeated twice. To standardise 
conditions, subjects were asked not to consume alcohol or do strenuous exercise for 24 
hours before the measurement, fasted for 12 hours and had an empty bladder. The mean ± 
SD of measurements was 34.7 ± 3.2 % and the mean + SD of differences was 0.12 ± 0.28 
% (SEM of differences: 0.09%). The RC of measurements was 0.58 and there were no 
significant differences between the first and the second measurement (P--0.2). 
5.8.6.4 Activity and Fitness Concentrations 
Table 5.7 shows the activity and fitness concentrations of the two groups at randomisation 
and month 4 maintenance. There were no differences between the groups in any of the 
parameters at any point. 
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Table 5.7: Activity and Fitness Concentrations of the High Glycacmic Index (IlGt) and the Low 
GI (LGI) Groups at Randomisation and at Month 4 of the Weight Maintenance Phase 
and Changes from Randomisation (Values are mean ± sd or median [IQR]) 
HGl group (n=19) LG I group (n--23 *) P value 
Physical Activity 
Concentration 
Randomisation 1.45 [1.40 - 1.50] 1.50 [1.45 - 1.53] 0.1 
Month 4 1.45 [1 AO - 1.50] 1.45 [1.40 - 1.55] 0.3 
A from randomisation 0.00 [-0.05-0.00] 0.00 [-0.05-0.00] 0.8 
Baecke Questionnaire 
Randomisation 7.37 ± 1.20 7.95 ± 1.34 0.2 
Month 4 7.13 ± 1.35 7.57 ± 1.62 0.4 
A from randomisation -0.26 1.12 -0.41 1.20 0.7 
Shuttle Walldng Test 
(shuttles) 
Randomisation 63 19 59 16 0.5 
Month 4 65 21 63 13 0.3 
A from randomisation 0±74± It 0.2 
HGI = High Glycaernic Index, LGI = Low Glycaernic Index, A= Change. P value comparing groups. Unpaired 
Student's t tests used to compare normally distributed data and Mann-Whitney U tests used to compare non- 
normally distributed data. *LGI group n--17 subjects completed the Shuttle Walking Test due to previous 
injuries. 
5.8.6.5 Appetite Assessment 
5.8.6.5.1 Month I Maintenance 
Figures 5.3a and 5.3b show the mean daytime concentrations of hunger and fullness 
respectively of the two groups at month 1 of the maintenance phase. Complete VAS were 
provided by 14 subjects in the HGI group and 20 subjects in the LGI group. There was a 
significant effect of time (P<0.001) as expected due to appetite variation during the day, 
but no difference between the groups (11--0.4) for hunger or for fullness (13---0.7). The 
whole day concentrations of hunger and fullness of the two groups were also compared. 
Neither the concentration of hunger (HGI group: 31.6 ± 20.1 mm; LGI group: 35.1 ± 17.4 
mm, Pl---0.6), nor the concentration of fullness (HGI group: 59.9 ± 15.5 mm; LGI group: 
60.3 ± 14.9 mm, 11--0.9) differed between the two groups. 
184 
Chapter 5: The Effect of a 4-Month Dietary Glycaernic Index Manipulation on Weight Maintenance 
Following Weight Loss in Overweight and Obese Subjects: A Pilot Study 
5.8-6.5.2 Month 3 Maintenance 
Figures 5.4a and 5.4b show the mean daytime concentrations of hunger and fullness 
respectively of the two groups at month 3 of the maintenance phase. Complete VAS were 
provided by 16 subjects in the HGI group and 20 subjects in the LGI group. The 
concentrations of hunger and fullness differed throughout the day (P<0.001). However, 
there were no differences between the groups neither for hunger (P--0.8) nor for fullness 
(P--0.8). The whole day concentrations of hunger (HGI group: 38.1 ± 16.8 mm; LGI 
group: 29.4 ± 19.1 mm, P'-0.2) and fullness (HGI group: 60.1 ± 15.4 mm; LGI group: 61.2 
± 19.4 mrn, P--0.9) were not different between the groups. 
Figure 5.3a: Mean Daytime Concentration of Hunger of the High Glycaemic Index 
(GI) and the Low GI Groups at Month 1 of the Weight Maintenance 
Phase (Values are mean ± SEM) 
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Figure 5.3b: Mean Daytime Concentration of Fullness of the High Glycaemic Index 
(GI) and the Low GI Groups at Month 1 of the Weight Maintenance 
Phase (Values are mean ± SEM) 
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Figure 5.4a: Mean Daytime Concentration of Hunger of the High Glycaemic Index 
(GI) and the Low GI Groups at Month 3 of the Weight Maintenance 
Phase (Values are mean ± SEM) 
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Figure 5.4b: Mean Daytime Concentration of Fullness of the High Glycaemic Index 
(GI) and the Low GI Groups at Month 3 of the Weight Maintenance 
Phase (Values are mean ± SEMO 
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5.8.6.6 Fasting Blood Tests 
The cholesterol profile, TG and glucose concentrations of the two groups at randomisation, 
month 2 and month 4 maintenance and the changes from randomisation are shown in Table 
5.8. Because there was no difference in diet group x time interaction, the model was 
reduced to include only time and diet group. Total cholesterol, HDL and LDL cholesterol, 
and TG concentrations significantly increased over time (P<0.001 for the first 3 variables 
and P--0.007 for TG), there was no difference between groups however. The change in 
each of these variables was approximately 10% which is clinically relevant. Total 
cholesterol to HDL cholesterol ratio did not change over the time period (P--0.6) (reflecting 
the increase in both total cholesterol and HDL cholesterol) and was not different between 
groups (P--0.2). Fasting blood glucose concentration fell over time (P<0.001) but was not 
different between groups. 
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5.8.6.7 Postprandial Glucose Profile 
The postprandial glucose IAUC-30-180 of the two groups at randomisation and month 4 is 
shown in Figures 5.5a and 5.5b. Valid results were available from 13 out of 19 subjects in 
the HG1 group and 17 out of 23 subjects in the LGI group, because of either haemolysis or 
due to cannula failure during the postprandial assessment. A between-group comparison of 
IAUC by Mann-Whitney U test, showed no differences between groups at randomisation, 
month 4 or in the changes from randomisation. Repeated measures ANOVA showed a 
significant effect of time-3o-180 (P<0.001) but no differences between groups (P--0.8) or 
visits (P--0.8) and no interaction effect. At randomisation, glucose concentration peaked at 
30 minutes postprandially at 6.89 ± 1.26 mmol/I in the HGI group and at 6.80 ± 1.36 
mmol/I in the LGI group (P-48). At month 4, glucose concentration peaked at 30 minutes 
postprandially at 6.85: k 1.01 mmol/I in the HGI group and at 6.96 ± 1.54 mmol/I in the LGI 
group (P--0.8). 
5.8.6.8 Insulin Sensitivity and Postprandial Insulin Concentrations 
Fasting insulin concentrations, P-cell function (HOMA %P), insulin sensitivity (HOMA 
%S), insulin resistance (HOMA MR) and 3-hour postprandial insulin response are shown 
in Table 5.9 and Figures 5.6a and 5.6b. Valid results were available for 18 out of 19 
subjects in the HGI group and 22 out of 23 subjects in the LGI group. Samples from 2 
subjects were haemolysed. There were no differences between the groups in any of the 
parameters at randomisation, month 4 or in the changes from baseline tested by Mann- 
Whitney U test. Plasma samples taken at -15,0, +30,60,120 and 180 minutes only were 
analysed for insulin. Samples taken at other time points were not analysed due to cost 
constraints. Repeated measures ANOVA of IAUC. 15-180 showed a significant effect of time 
(P<0.001) but no significant effect of group (P'-0.2) or visit (P--0.5) and no interaction 
effects. At randomisation, insulin concentration peaked at 30 minutes postprandially at 
548.7 ± 439.2 pmol/1 in the HGI group and at 60 minutes postprandially at 580.8 1302.6 
pmol/1 in the LGI group (PL--0.8). At month 4, insulin peaked at 30 minutes postprandially 
at 590.5 ± 459.8 pmol/1 in the HGI group and at 769.4 ý: 393.8 pmol/1 in the LGI group 
(P--0.3). 
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Table 5.9: Fasting Insulin and Homeostasis Model Assessment Results of the High 
Glycaemic Index (HGI) Group and the Low GI (LGI) Group at 
Randomisation, Month 4 Maintenance and Changes from 
Randomisation (Values are median [IQR]) 
HGI group LGI group P value 
(n= 18) (n--22) 
Fasting insulin (pmol/1) 
Randomisation 42.4 [27.8 - 56.3] 47.2 (38.5 - 58.3] 0.6 
Month 4 39.2 [25.7 - 63.2] 53.1 [33.7 - 79.2] 0.2 
A from mndomisation -2.6 [-16.7 - 12.8] 8.3 [-9.4 -21.9] 0.2 
HONIA %p 
Randomisation 95.4 [70.1 - 117.8] 102.5 [78.1 - 124.9] 0.4 
Month 4 82.1 [71.8 - 115.3] 109.8 [70.5 - 140.4] 0.2 
A from mndomisation -1.1 [41.5 - 7.8] 0.05 [-17.4 - 25.3] 0.5 
HONIA %S 
Randomisation 124.1 [96.9 - 185.7] 113.3 [97.7 - 138.1] 0.6 
Month 4 133.0 [85.9 - 199.8] 104.9 [68.3 - 155.1] 0.2 
A from randomisation 11.1 [-28.6 - 40.5] -16.3 [40.3 - 18.8] 0.2 
HONIA IR 
Randomisation 0.8 [0.5 - 1.0] 0.9 [0.7 - 1.0] 0.2 
Month 4 0.8 [0.5 - 1.2] 1.0 [0.6 - 1.5] 0.2 
A from randomisation -0.06 [-0.03 - 0.2] 0.1 [-0.2 - 0.4] 0.6 
HGI High Glycaemic Index, LGI = Low Glycaernic index, A= Change, HOMA = Homeostasis Model Assessment, % 
P= cell function, %S= insulin sensitivity, IR = insulin resistance. P value of between group comparison done by 
Mann-Whitney U tests for non-normally distributed data or data that one of the groups was non-normally distributed and 
could not be log-transformed. 
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Figure 5.5a: Fasting and 3-Hour Postprandial Glucose Response of the High 
Glycaernic Index (HGI) and the Low GI (LGI) Groups to a Standard 
Meal at Randornisation and at Month 4 of the Weight Maintenance 
Phase (Values are mean ± SEM) 
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HGI = High Glycaemic Index, LGI = Low Glycaemic Index, Rand = randomisation, m4 = month 4 maintenance. 
Repeated measures ANOVA revealed significant effect of time-30-180 (P<0.001), no difference between visits 
(P-- 1.0) or groups (P--O. 8) and no interaction effects. 
Figure 5.5b: 3-Hour IAUC Glucose of the High Glycaemic Index (HGI) and the Low 
G1 (LGI) Groups at Randomisation and at Month 4 of the Weight 
Maintenance Phase (Bars represent SEM) 
L=A HGlgroup(n-13) I- I LGIgroup(n-17) 
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HGI = High Glycaernic Index, LGI = Low Glycaernic Index, Between-group comparison of IAUCO. 18o glucose by 
Mann-Whitney U test revealed no significant difference at randomisation (P--0.8) or at month 4 (P-0.6). 
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Figure 5.6a: Fasting and 3-hour Postprandial Insulin Response of the High 
Glyeaemic Index (HGI) and the Low GI (LGI) Groups to a Standard 
Meal at Randomisation and at Month 4 of the Weight Maintenance 
Phase (Values are mean ± SEM) 
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HGI = High Glycaemic Index, LGI = Low Glycaemic Index, Rand = randomisation, m4 = month 4 maintenance. 
Repeated measures ANOVA revealed significant effect of time-15-igo (P<0.001), no difference between visits 
(P--0.5) or groups (P--0.2) and no interaction effects. 
Figure 5.6b: 3-hour IAUC Insulin of the High Glycaemic Index (HGI) and the Low 
GI (LGI) Groups at Randomisation and at Month 4 of the Weight 
Maintenance Phase (Bars represent SEM) 
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HGI = High Glycaernic Index, LGI = Low Glycaemic Index. Between group comparison of IAUCO-180 insulin by 
Mann-Whitney U test revealed no significant difference at randomisation (P--0.7) or at month 4 (P--0.4). 
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5.8.6.9 Sources of Glycaemic Index Calculations 
Table 5.10 shows the percentage contribution of different sources i. e. published or 
estimated to GI calculations during the study. The GI values assigned from the 
International Tables (Foster-Powell et al 2002) and the University of Sydney GI website 
(University of Sydney. 2007) were sub-divided into those obtained from a mean of 2 or 
more GI values and those GI values obtained from only one tested food (single value). For 
all GI calculations, 3.1% of CHO intake was not assigned a GI value due to its 
insignificant CHO contribution. This incorporates foods such as cheese, sauces and most 
vegetables. 16.2% of the CHO was assigned a GI value from estimated sources and 80.7% 
of CHO was assigned a GI value from published sources. The percentage of CHO 
assigned a GI value from published or estimated sources was similar between the groups 
and at different time points over the study period. 
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5.9 Discussion 
This pilot randomised intervention trial of the effect of diet GI manipulation on weight loss 
maintenance, showed that in the setting of a healthy eating, high CHO, moderate in fat and 
protein diet, changing the type of CHOs consumed does not affect weight maintenance. 
The difference in body weight between the two groups was 1.2 % resulting from a 0.8 ± 
3.4 % weight loss in the LGI group and a 0.3 ± 2.4 % weight gain in the HGI group. A 
power calculation based on this difference showed that 78 subjects would be required in 
each group for the study to be powered at the 0.80 concentration, i. e. a total of 156 
subjects. 
5.9.1 Weight Loss Phase 
In this study, the weight loss phase was only a prerequisite for being randomised to the 
weight maintenance phase. During this phase, subjects achieved a median weight loss of 
6.1 (IQR: 5.2-7.1)% through reducing their energy intake by 654 ± 456 kcal/day. The 
weight loss diet was high in CHO (most of which was sugar due to the lactose content of 
Slinifaste drinks), low fat and moderately high in protein. The ideal dietary composition 
for weight loss is still under debate and this is outside the scope of this thesis. Since the 
diet was milk-based, it had a LGI (the GI of Shinfasto drinks is 33, the GI of semi- 
skimmed milk is 29). However, milk products are insulinotropic as judged from Mold to 
6-fold higher insulinemic indices than expected (Ostman et al. 2001) and thus may not 
have the same metabolic benefits as other LGI foods (Jenkins et al 1987b). Diet GL was 
also lower during the weight loss phase as both GI and CHO intake were reduced. During 
this phase, subjects also increased their activity concentration and improved their physical 
status. As expected, the weight reduction and the increase in activity, led to significant 
improvements in both cholesterol and glucose profiles. 
5.9.2 Weight Maintenance Phase 
5.9.2.1 Dietary Composition 
Following weight loss, subjects were randomised to a LGI or HGI diet consumed to 
appetite for 4 months to assess weight maintenance. The two groups differed in both diet 
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GI (P<0.001 at month 2 and at month 4) and diet GL (P=0.044 at month 2 and P=0.002 at 
month 4 of the weight maintenance phase). CHO intake did not differ suggesting that the 
difference in diet GL between the groups was only attributed to the difference in GI i. e. the 
type, and not the amount of CHO consumed. As discussed above, however, all subjects 
consumed a LGI diet during the weight loss phase. Compared with the weight loss phase, 
the HGI group experienced an increase in diet GI during the weight maintenance phase of 
19.4 ± 10.9 units (P<0.001 month 4 maintenance vs, month I weight loss). The LGI group, 
also experienced a small increase in diet GI during the weight maintenance phase of 4.0 ± 
7.1 units (P=0.028 month 4 maintenance vs month 1 weight loss). Thus, in practice, the 
HGI group increased their GI when they were randomised to this dietary intervention 
whereas the LGI group consumed a LGI diet both during the weight loss and the weight 
maintenance phase. Nevertheless, as discussed above, the metabolic effects of a milk- 
based diet (i. e. Slimfasto) on glucose and insulin concentrations may be different from 
those where all CHOs and especially polysaccharides are manipulated. This is further 
discussed in Chapter 6, Section 6.2.1. Nevertheless, the question of whether the metabolic 
benefits of diet GI manipulation would be different if the weight loss diet had a different 
dietary composition and GI remains unanswered. Comparison of the diet GI during the 
weight maintenance phase to the subjects' baseline diet, showed that the HGI group had an 
significant increase in diet GI of 7.1 ± 10.6 units (P<0.01 month 4 maintenance vs habitual 
diet) and the LGI group had a significant reduction of 4.9 ± 5.1 units (P<0.01 month 4 
maintenance vs habitual diet). 
At month 4 maintenance, the LGI group consumed more fibre per 1000 kcal, however, this 
difference did not persist when fibre was expressed as actual intake per day. This is 
important since in some previous studies such as Jenkins et al (1985), fibre intake was not 
equal in the two groups, making it difficult to differentiate between the effects of lowering 
diet GI from those of increasing fibre and especially soluble fibre intake. In the present 
study, the CHO intake of the two groups did not differ during the weight maintenance 
period, however, the LGI group was reported to consume a lower percentage of starch than 
the HGI group with no difference in percentage sugar intake. This may be explained by the 
percentage CHO coded as 'unidentified' i. e. unable to be classified as starch or sugar by the 
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DietPlan dietary analysis program (this was not shown in the macronutrient breakdown). 
No other macronutrient difference was seen between the groups. 
5.9.2.2 Body Weight and Composition 
No differences in body weight or composition were seen between the groups during the 
weight maintenance phase. The groups did not differ in activity and fitness concentrations. 
The application of GI to weight regulation is a vigorously debated issue since evidence is 
still controversial (Pawlak et al 2002; Raben 2002). Similar to the present findings, a 10- 
week ad libitum intake of LGI or HGI diets also did not find significant differences in body 
weight between the groups. However, both groups lost weight but there was a tendency 
for the LGI group to do better, leading the authors to speculate that a longer study period or 
a bigger sample size could have resulted in some differences (Sloth et al 2004). A previous 
study showed that a LGI diet led to more weight loss in hyperinsulinaemic women than a 
HGI diet (Slabber et al 1994) and a recent study showed that subjects who had a higher 
insulin response to an oral glucose tolerance test lost more weight on a low GL than a low 
fat diet than those who had a normal response (Ebbeling et al 2007). However, both 
studies focused on weight loss rather than maintenance. Also, the latter study and some 
other recent studies have focused on lowering diet GL rather than GI only (Millan-Price et 
al 2006; Das et al 2007; Ebbeling et al 2007; Maki et al 2007). This was achieved mainly 
by limiting the total CHO intake and also by consuming low GI CHOs. Thus the 
metabolic benefits of a low CHO diet (which by definition would also be altered in other 
macronutrients), cannot be separated from those of manipulating the type of CHO 
consumed. 
In the present study, a within-group analysis showed that the LGI group only had a 
significant reduction in percentage body fat. In a study comparing energy-restricted HGI 
and LGI diets, fat tissue was oxidised to a lesser degree and muscle to a greater degree on 
the HGI diet (Agus et al 2000). Moreover, in men, a 5-week period on a LGI diet led to a 
700g reduction in total fat mass accompanied by a decrease in lipoprotein lipase and 
hormone-sensitive lipase RNA in subcutaneous abdominal adipose tissue (Bouche et al 
2002). Additionally, studies in rats showed that HGI diets increased fatty acid synthase 
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enzyme and lipogenesis; (Kabir et al 1998), body fat (Pawlak et al. 2004) and leptin 
concentrations (Pawlak et al 2001) while LGI diets decreased epididymal adipocyte 
diameter (Kabir et al 1998) and epididymal fat mass (Pawlak et al 2001). 
It should be noted that the reproducibility of the body fat analyser reported by the company 
was about 0.5% of body fat (Biospace 1999) which agrees with the reproducibility findings 
of the present study. The RCs of waist measurement showed that they were highly 
reproducible. 
5.9.2.3 Energy Intake 
During the weight maintenance phase, the LGI group reported consumption of less energy 
(EI) than that estimated to require (E,, q) using Schofield (Schofield 1985) equations and 
PAL concentrations in order to maintain weight. Energy balance is achieved when energy 
intake and energy expenditure are equal. It is of note, however, that throughout the weight 
maintenance period, both groups had a low EI: Ereqg thus this result should be assessed with 
caution. The low EI: Ereq could be due to the following: Firstly, all subjects were 
overweight or obese and as previously discussed, underreporting and/or misreporting of 
food intake is common in this group. Twelve subjects (29%) were identified as under- 
reporters at baseline based on the Goldberg Index. Therefore, it comes to no surprise that 
the reported EI: Ereq ratios were so low during the weight maintenance phase. Secondly, 
energy intake was only measured for 6 days during the 4-month period. Measurement of 
intake at more regular intervals (e. g. every month) may have given a more accurate picture. 
Thirdly, the estimated energy requirements were based on Schofield (Schofield 1985) 
equations and assignment of PALs, both of which are generic and thus prone to error when 
applied to individuals. A more accurate assessment of individual total energy expenditure 
could have been carried out using doubly labelled water but this was not done due to cost 
constraints and practical issues. 
Nevertheless, the lower EI: Emq of the LGI group may be a suggestion of LGI foods being 
more satiating than HGI foods. Two reviews on GI and appetite including 16 (Ludwig 
2000) and 20 studies (Roberts 2000), reported that most studies showed LGI foods to have 
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a short term effect of suppressing hunger and energy intake, of increasing satiety or both. 
In contrast, another review found contradictory results and concluded that short-term 
human intervention data do not provide convincing evidence that LGI meals have a more 
positive effect on satiety and hunger than HGI meals (Raben 2002). This review, though, 
has been criticised for not including relevant and adequately powered papers (Pawlak et al. 
2003). It may be that HGI CHOs are associated with a reduction in appetite and food 
intake in the short-term (e. g. one hour) and the satiating effects of lower GI CHOs are 
delayed (e. g. 2-3 hours) (Anderson & Woodend 2003). 
5.9.2.4 Appetite 
In the present study, appetite was assessed by VAS under free-living conditions. The VAS 
assessed hunger and fullness before and after meals, however no differences were found 
between the groups. VAS have been extensively used in appetite research. An 8-day study 
of LGI or HGI food consumption also found no differences in appetite between groups 
assessed by VAS (Alfenas et al 2005). In another study, although no differences in hunger 
ratings were found, food was requested sooner after a HGI meal than a LGI meal in time- 
blinded subjects (Ball et al. 2003). The lack of captured differences could be due to the 
physiologic, learned and cognitive components to hunger, which make appetite assessment 
very difficult. It may have been more appropriate to use a repeated measures design 
whereby within-subject's changes from baseline were assessed, as this would have been 
more more powerful and reliable, as well as sensitive to capture changes. In the present 
study, further limitations were the small sample size and the use of a parametric test for 
data analysis which further reduce the possibility of finding any changes. Another 
limitation was the fact that questions were asked mostly around meal times except for the 
rwben get up' and 'before sleep' time and the 'whole day' question. Furthermore, 
although VAS use in appetite has been validated, their use in free-living subjects has not 
been validated. Nevertheless, a recent study comparing the regular Weight Watchers diet 
with a revised programme incorporating LGI foods in a free-living population using VAS, 
found a generally lower intensity of hunger and desire to eat in the LGI group particularly 
in the afternoon (Bellisle et al. 2007). Moreover, a study comparing a low GL with a low 
fat energy-restricted diet found that subjects in the low GL group reported less hunger over 
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the previous 24 hours than those in the low fat group (Pereira et al 2004b). Thirdly, VAS 
are limited as they are only a subjective measurement of appetite and may not be sensitive 
enough to pick up the effect of diet manipulation. An objective appetite assessment would 
have been measurement of anorexigenic gut peptides such as PYY3-36 and/or the orexigenic 
ghrelin hormone. To my knowledge, this has not been done up to now. 
5.9.2.5 Fasting and Postprandial Glucose and Insulin Profiles 
No differences were seen between the groups in fasting or postprandial glucose and insulin 
concentrations, insulin sensitivity or P cell function over the 4-month period. Results of 
previous studies vary with some studies finding no differences in glucose profiles between 
LGI and HGI diets (Brynes et al 2003a) and some finding differences (Millan-Price et al 
2006). Previous studies either matched the long term diet with the test food provided (e. g. 
if a LGI diet was provided, a LGI test meal was also provided) (Millan-Price et al 2006; 
Wolever & Mehling 2003b) or used an oral glucose tolerance test (Frost et al 1996) rather 
than a standard meal. In this study, a standard test meal was chosen to test the long term 
manipulation of diet GI on the body's metabolic response. A comparison of the changes in 
glucose-insulin dynamics (rather than only the actual values) was carried out in order to 
reduce between-subject variation, nevertheless, other factors such as changes in weight, 
body fat and fitness concentrations may have influenced the results. Previous studies 
(Millan-Price et al 2006) finding differences in postprandial glucose profiles between HGI 
and LGI diets used capillary rather than venous blood. Use of capillary blood is the 
standard methodology employed in GI testing (Joint FAO/WHO Expert Consultation 
1998) since venous blood samples have a higher CV (Hatonen et al. 2006). This factor 
may have also influenced the results. 
Although concentrations of fasting and postprandial glucose and insulin and those of 
insulin sensitivity were not measured before weight loss, it is possible that all subjects 
experienced improvements in these metabolic parameters; a well-known metabolic benefit 
of weight reduction. It is speculated that weight loss and subsequent maintenance overrode 
any benefits of a LGI diet on insulin sensitivity and P cell function seen in previous studies 
(Frost et al 1998; Laaksonen et al 2005; Wolever & Mehling 2002). Evidence for this 
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comes from three recent studies. Raatz et al (2005), assessed insulin sensitivity by HOMA 
and found improvements during the weight loss phase in subjects following LGI, HGI and 
low fat diets, however, no differences were observed between the diets during a 24-week 
follow-up free-living phase. Pittas et al (2006) in a 6-month study of energy-restricted 
high or low GL diets found that glucose-insulin dynamics (fasting and post-load insulin 
and insulin resistance) improved in both groups but no differences were observed between 
the groups after adjustment for weight change. McMillan-Price et al (2006), who 
compared four weight loss diets of varying glycaemic load also found no differences in 
HOMA results while changes in fat mass correlated with changes in fasting insulin 
concentration and HOMA IFL These studies highlight the importance of absolute weight 
change and body composition on glucose-insulin dynamics over the dietary macronutrient 
composition used to achieve it. 
5.9.2.6 Blood Lipid Profile 
Lastly, during the weight maintenance phase, blood lipid concentrations increased in both 
groups compared to the weight loss phase. This was most probably due to the increase in 
intake of total fat, from 22.6% of energy (for all subjects) to approximately 31-32% (for the 
two groups) and saturated fat from 5.9% to approximately 8-9% during the weight 
maintenance period causing a rebound effect in blood lipid concentrations. No difference 
in blood lipid profiles or TG concentrations were seen between the groups over the weight 
maintenance phase. This agrees with a Cochrane Review showing that a LGI diet reduces 
total cholesterol slightly but does not affect LDL cholesterol, HDL cholesterol or TG 
concentrations (Kelly et al 2004). 
5.9.3 Strengths and Limitations 
This study was carried out under entirely free-living conditions. Meals or key foods were 
not provided to subjects as in some previous studies (Brynes et al 2003a; Millan-Price et al 
2006; Sloth et al 2004). This has both advantages and limitations. The major advantage is 
that it is a true test of whether diet GI manipulation can be achieved in free-living subjects. 
Both at month 2 and month 4 of the weight maintenance phase, for which 3-day diaries 
were provided, the groups differed significantly in diet GI. Moreover, both groups 
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achieved a significant change in GI from habitual diet. The LGI group achieved a GI of 
49.9 at month 2 and 49.7 at month 4 which compares well to a weight loss study were key 
foods were provided, where a GI of 45 was achieved (Millan-Price et al 2006). Although 
there is no exact cut-off point, foods with a GI :5 55 are generally considered LGI (Foster- 
Powell et al 2002). Therefore, this provides strong evidence that diet GI can be 
manipulated and that a LGI diet can be maintained for a long period of time under free 
living conditions. A limitation is that compliance to the diet relies completely on the 
subjects and compliance checks rely on the subjects' reporting of intake. Moreover, a food 
GI may vary according to country of origin, cooking and storage amongst other factors. 
Ideally, an objective assessment of dietary GI compliance should be devised (see Chapter 
6, Section 6.2.3). 1 
With regards to the accuracy of the diet GI, published GI values were used for 81% of the 
CHO, nevertheless, 12% of CHO was assigned an estimated GI value. Estimations were 
based on standard recipes (e. g. apple pie) or on mixed meals (e. g. bean salad), or on similar 
foods based on the known factors affecting a food's GI (Chapter 1, Section 1.2.2) (e. g. 
garlic bread was based on white bread with butter). However, they are still estimations and 
thus may compromise the accuracy of the GI calculations. Nevertheless, a food was 
assigned the same GI value throughout the study period therefore any errors in estimations 
would be systematic and would still allow fair comparisons of diet GI between groups. 
The study is limited in that most subjects were women and thus it is not possible to know 
whether men would have behaved in a different way. Although the study's advertisement 
invited both men and women to participate, only 13 men (out of 111 subjects) were 
recruited and only 3 (out of 42 subjects) completed the study. It may be speculated that a 
study where weight loss is achieved using meal replacement drinks and followed by weight 
maintenance, might be more attractive to women. A recent evaluation of two hospital 
weight loss clinics (Hickson, 2007 in press) showed that 70% of patients referred to the 
clinics were women, despite obesity rates being roughly equal in both genders. Thus, this 
tendency for more women to attempt weight loss is not restricted to research and reflects 
the routine situation. 
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Another limitation of this study is the high attrition rate during the weight loss phase of 
44% which is higher than the 16% dropout rate at 3 months reported in a meta-analysis of 
partial meal replacement diets (Heyrnsfield et al 2003). This was probably due to the fact 
that the attrition rate included subjects failing to lose enough weight, who were dismissed 
from the study. Attrition rates are highly variable, however, ranging from 7.5-67% in 
commercial weight loss programs (Tsai & Wadden 2005), and are affected by many factors 
such as time issues, initial weight, psychological and social factors (Teixeira et al. 2004). 
In this study, completers were older than non-completers, which might relate to more 
health concerns, differences in previous weight loss attempts and/or more commitment to 
the study. The 14% drop out during the 4-month weight maintenance period is similar to 
the 10% seen in a comparison of diets of different GI and protein content for 12 weeks (i. e. 
3 months) (Millan-Price et al 2006). 
5.10 Conclusion 
In conclusion, it was shown that dietary GI can be manipulated and this dietary change can 
be maintained in free-living subjects. In the setting of a healthy eating diet, composed of 
approximately 50% CHO and moderate in fat and protein, manipulating diet GI does not 
provide a further benefit for weight maintenance following weight loss. Nevertheless, the 
LGI group consumed less energy than estimated to require in order to maintain body 
weight, a finding which may be related to the satiating effects or other metabolic benefits 
of LGI foods. Since this was a pilot study, further data collection is warranted to reach a 
definite conclusion. 
203 
Chapter 6: Discussion 
Chapter 6: Discussion 
204 
Chapter 6: Discussion 
6.1 Summary of Findings 
The aim of this thesis was to investigate the effect of dietary GI manipulation provided in 
addition to healthy eating and weight loss advice on CHD risk, with the hypothesis that a 
LGI compared to a HGI diet would reduce heart disease risks over and above the reduction 
achieved by healthy eating and weight loss alone. Additionally the effect of dietary GI 
manipulation on weight maintenance following weight loss was assessed, with the 
hypothesis that a LGI diet would facilitate better weight maintenance than a HGI diet. 
Three investigations presented in Chapters 3-5, were designed to answer-these questions. 
This Chapter aims to summarise the main findings, answer the thesis hypothesis, discuss 
the strengths and limitations of this work and provide suggestions for future research. 
The investigation in Chapter 3 showed that a 12-week LGI diet resulted in a lower 24-hour 
and overnight free-living glucose profile than a HGI diet in middle-aged subjects at risk of 
heart disease. Both diets were provided in addition to healthy eating and weight loss 
advice that would normally be given to subjects at risk of heart disease. It was also shown 
that although both groups reduced their energy intake, only the LGI group had a significant 
reduction in weight. A possible explanation may lie in the proposed satiating effects of 
LGI foods or the adverse postprandial metabolic profile induced after consumption of a 
HG1 diet (Ludwig 2002; Pawlak et al 2002). Following on from this investigation, the 
same dietary intervention was employed to examine its effect on arterial compliance and 
24-hour BP, fasting lipid profile, insulin sensitivity and postprandial insulin and glucose 
profiles in middle-aged men at risk of heart disease. Although the study was not 
completed due to recruitment difficulties, preliminary results showed that both groups lost 
weight and had improvements in most arterial compliance measurements. Additionally, 
the LGI group had a bigger reduction in total cholesterol than the HGI group, a fmding 
which is in agreement with a Cochrane Review on the effect of LGI diets on heart disease 
(Kelly et al 2004), and a within-group analysis showed that only the LGI group had 
significant reductions in LDL cholesterol and TG concentrations. Importantly, by month 
6, the fasting insulin concentrations and insulin resistance were lower in the LGI than those 
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of the HGI group. The study also provided preliminary evidence that a LGI diet may have 
benefits on BP. 
The pilot investigation in Chapter 5 was designed to answer a central question in obesity 
management i. e. that of weight maintenance following weight loss. Subjects were 
randomised to a 4-month LGI or HGI diet for weight loss maintenance. It was shown that 
in the setting of a healthy eating diet, changing the type of CHOs consumed does not affect 
weight maintenance following weight loss. 
The results of studies in Chapters 3 and 4 suggest that a LGI diet is more beneficial in 
reducing the risk of heart disease than a HGI diet; even in the setting of a healthy eating, 
weight loss diet. Nevertheless, because the available evidence comes from a pilot study 
and from an as yet incomplete investigation, it still remains unclear whether a LGI diet has 
a holistic beneficial effect on CHD risk factors. Furthermore, as discussed in Chapter 1, 
Sections 1.2.2 and 1.2.4, there are many different types of LGI foods and these exert their 
effects through a variety of mechanisms which are not all equally beneficial on health. 
The study in Chapter 5, suggests that when a healthy diet of approximately 50% CHO and 
moderate in fat and protein is consumed, manipulating the type of CHO does not have an 
effect on weight maintenance. ' However, since it was a pilot investigation, further data 
need to be collected in order to have a definitive answer to the hypothesis. Therefore, the 
overall thesis hypothesis can neither be proven nor rejected; nevertheless at this stage 
available data suggests that in the setting of a healthy eating diet, a LGI diet is more 
beneficial for CHD risk reduction but provides no extra benefit for weight maintenance 
following weight loss. 
6.2 Strengths and Limitations 
One of the strengths of this thesis was that it employed medium to long-term research 
designs, which are more valuable in assessing the metabolic effects of a dietary 
intervention. Moreover, subjects were free-living which allowed assessment of diet 
implementation in the real world, although this inevitably introduces more confounding 
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factors such as holiday periods, periods of illness, eating out, etc. The use of two pieces of 
equipment, the MiniMed CGMS and the Diasys Integra 11 ABPM system which enabled 
assessment of 24-hour glucose profiles and 24-hour BP respectively in free-living subjects, 
was also valuable. By using these machines, information was gathered for the whole day 
while subjects were in their own environment and continued to carry out their routine 
activities. A far more representative picture of their metabolism was obtained than that 
acquired using only results obtained under laboratory conditions. However, for data 
analysis and presentation, the collected data had to be averaged over previously set blocks 
of time. 
A limitation applying to all studies was that neither the investigators (myself for all 
anthropometric, BP, arterial compliance and blood glucose analysis assessments and 
Candace Bovill-Taylor for the arterial compliance measurements), nor the subjects were 
blinded to the interventions. It should be noted that the analysis of blood lipids and insulin 
was done by blinded technicians. The investigators may have been biased because of the 
many studies supporting the benefits of LGI diets while the subjects may have been biased 
because of the, occasionally misinformed, publicity on the benefits of LGI diets. The fact 
that subjects in the HGI group increased their GI in all three studies, however, disproves 
that subjects were biased against the HGI diet. In order to avoid assumptions on which 
diet was more beneficial, subjects were not informed of the study's hypothesis. Blinding 
of both the subjects and the investigators in a dietary intervention study is difficult but 
could have been carried out by randomisation by an independent investigator and provision 
of key foods labelled by codes. Providing foods however would have prevented 
assessment of diet implementation in free-living subjects. Alternatively, other 
investigators who were blind to the intervention could have been employed to carry out 
assessments of weight, waist circumference, arterial compliance etc. However, this was 
not feasible due to resource limitations. 
Another limitation was that diet acceptability was not assessed. Previous studies rated the 
satisfaction and easiness of diet implementation and assessed palatability of diet and faecal 
patterns as an attempt to evaluate diet acceptability (Bellisle et al 2007; Maki et al 2007; 
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Sloth et al 2004). Thus it is suggested that future research should incorporate a 
questionnaire aiming to rate the acceptability of the diets. 
6.2.1 Metabolic Effects of Glycaernic Index Manipulation 
In the studies presented in this thesis, there was a significant difference in diet GI between 
the two groups, however, the change in GI within individual subjects was small and a 
bigger change may have led to more substantial metabolic benefits such as in postprandial 
glucose and insulin concentrations. In Chapters 3 and 4, there was only a small within- 
group reduction in GI in the LGI group and in Chapter 5, weight loss was achieved by 
consuming a LGI food i. e. SlimfastO, after which the LGI group continued to consume a 
LGI diet for weight maintenance while the HGI group increased diet GI. The metabolic 
effects of the dietary intervention may have differed if the diet GI during the weight loss 
phase was higher. 
Furthermore, it is possible that no changes were seen in postprandial glucose and insulin 
profiles due to adaptation to the diet, which led the short-term beneficial effect of a LGI 
diet on glucose and insulin responses to be diminished over the long-term (Kiens & Richter 
1996). Other possible reasons may be related to different responses between individuals to 
dietary changes resulting in a net effect of no change in outcome. For example, 
epidemiological research showed that an increased risk of CHD and/or high fasting TG in 
women consuming a high GL diet was determined by their BMI (Liu et al 2000; Liu et al 
2001) suggesting that the effects of the same diet can vary depending on adipocity which is 
related to insulin sensitivity (Willett et al. 2002). 
Additionally, the effect of a LGI diet may vary depending on the type of LGI foods 
consumed, for example high fibre LGI foods, some mono- and disaccharides and dairy 
products, all have a LGI but their metabolic effects are different as discussed in Chapter 1, 
Section 1.2.4. Epidemiological research in both men (Salmeron et al 1997a) and women 
(Salmeron et al 1997b) showed that risk of development of Type II diabetes was higher in 
those consuming a high GL, low cereal fibre diet compared to those consuming a low GL, 
high cereal fibre diet. The biological mechanisms by which LGI foods that are also high in 
208 
Chapter 6: Discussion 
fibre exert their effects, and in particular whole grains, pulses and legumes (Chapter 1, 
Section 1.5.5.3) make them superior to LGI foods such as dairy products. Other CHOs 
such as sucrose, lactose and fructose have a low GI because of their fructose and galactose 
moieties which do not raise blood glucose (Wolever 2006). Dairy products have a low GI 
because of their high insulin response induced by the proteins they contain (Nilsson et al 
2004). Thus it may be useful in a future intervention study to classify LGI foods according 
to their source e. g. wholegrain products, legumes, pasta, fruit, dairy products before 
assessing their effects. 
Furthermore, another classification of LGI foods could be based on fibre content and type. 
In this thesis, there was no difference in fibre intake per day between the two groups. This 
is not surprising since as discussed in Chapter 1, Section 1.2.2, the GI of a food is 
determined by many different factors and fibre content was estimated to explain only 21% 
of the variation in GI (Wolever 1990). Trout et al (1993) also found that the method of 
preparation and the characteristics of starch and starch granules were more important in 
predicting GI among 18 starchy foods than their fibre, phytic acid, protein or fat content. 
Dietary fibre has different physiological effects depending on its type (e. g. water soluble 
and insoluble), origin (e. g. cereal, fruit, vegetable) and processing (e. g. refined/unrefined). 
All of these factors suggest that in addition to classifying foods by their source, it would be 
valuable to also classify fibre intake according to type, source and processing in order to 
ascertain whether lowering diet GI per se leads to metabolic benefits or whether this 
manipulation needs to be combined with increasing fibre intake. Moreover, in a future 
intervention study, the effects of LGI diets varying in fibre content needs to be studied. 
6.2.2 Overall Dietary Assessment 
in all three intervention studies, dietary assessment was carried out by food diaries kept for 
3-7 days. Use of biomarkers such as the urinary nitrogen technique found that weighed 
food records are the most valid way of dietary assessment, followed by the estimated 7-day 
records (Bingham et al. 1995). Although weighed food records may be the most accurate 
way of measuring actual food intake, they may not reflect habitual intake since weighing 
food takes time and effort, potentially leading subjects to adjust their intake towards 
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consuming more easily reported foods. It is of note that at present, no dietary assessment 
methodology is without error, either random or systematic. Random errors, which may be 
due to day-to-day variation in food intake or errors in food composition analysis or GI 
calculations, can be reduced by increasing the number of days of dietary reporting or 
increasing the sample size. In order to reduce this type of error, subjects were asked to 
keep diet records at regular intervals. Systematic errors result from consistent under- or 
over- reporting of intake or from errors in food composition databases or GI values 
(Beaton 1994). Some of the subjects were found to under-report their intake, an 
unsurprising finding since this phenomenon is common in overweight subjects (Hoidrup et 
al 2002). Under-reporting may be due to an intentional change in food intake to become 
'healthier' in an attempt to be socially desirable or to please the health professional; or due 
to subconsciously changing intake; or a result of underestimation of food portion sizes or 
added fats and sauces to foods. It is obvious that errors in dietary assessment have 
implications on GI calculations and potentially study results. Ideally, biomarkers need to 
be developed for an objective assessment of intake of the main dietary components of 
interest Le CHO and dietary GI (for further discussion see Section 6.2.3). 
6.2.3 Dietary Glycaemic Index Manipulation and Compliance 
Assessment 
The methodology of diet GI manipulation employed in this thesis was by providing one-to- 
one spoken and written instructions on altering CHO-containing foods to LGI or HGL 
This was chosen in order to assess the feasibility of changing diet GI and maintaining this 
change over a medium to long-term period in free-living subjects. However, this 
methodology is limited by the lack of an objective way of assessing diet GI. Other 
investigators used different ways of assessing compliance. For example, Bellisle et al 
(2007), assessed compliance using a food checklist which included starch and cereals, 
fruits, nuts and bakery products varying in GI. Subjects filled in the checklist over 3 days 
and compliance to the diet was presumed to be good when at least 3 LGI or HGI foods 
were consumed each day. However, this methodology does not allow estimation of the 
overall diet GI, fails to take into account the effect of consuming foods with the opposite 
GI e. g. HGI foods by subjects randomised to a LGI diet, and again relies completely on the 
210 
Chapter 6: Discussion 
information obtained from the subjects. Sloth et al (2004) assessed dietary compliance by 
incorporating lithium chloride, a salt completely excreted in urine into bread varying in GI 
which was provided to subjects. Subjects were required to provide 24-hr urine samples 
which were analysed for lithium by flame atomic absorption spectrometry to evaluate 
compliance with the test food. This method was not employed in this thesis firstly because 
all CHO-containing foods rather than just one were manipulated, and also since it requires 
provision of a key food which has the disadvantages previously discussed. 
Alternatively, an objective assessment of dietary compliance in free-living subjects could 
have been carried out if a biomarker of CHO quality and quantity was to be employed. 
The emerging science of metabolomics, which is the global analysis of metabolites i. e. 
6small molecules generated by metabolism representing all metabolic pathways with a 
focus on the identification of each pathway and its role' (German et al. 2005), may be used. 
The main analytical tools used for metabolic profiling are nuclear magnetic resonance 
spectroscopy and mass spectroscopy which capture a comprehensive snapshot of 
metabolism (German et al 2005; Goodacre 2007). For example, in a study examining the 
plasma samples of women before and after consumption of 60g of soy, changes were 
observed in plasma lipoproteins, amino acids and CHO profiles (Solanky et al. 2003). 
Similarly, metabolomics may be used to assess changes in high-resolution spectra of 
plasma or urine samples or changes in colonic microflora before and after consumption of 
a LGI diet. The information would not only be valuable for assessing dietary compliance 
but also for identifying lack of response to dietary change perhaps due to genetic variation 
and for identifying unexpected metabolic effects. Currently, the ongoing project 
HUSERMET (HUSERMET 2007) aims to develop novel methods for the analysis of 
human metabolites. 
6.2.4 Dietary Glycaernic Index Calculation 
Calculation of diet GI was based on assigning published or estimated GI values to foods. 
Most of CHO (70-80%) was assigned a GI value from published sources; nevertheless, 
inaccuracies in calculations may have occurred since GI values are affected by many 
factors such as preparation, duration of cooking, food variety or ripeness (see Chapter 1, 
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Section 1.2.2). Additionally, the formulation and baking conditions of foods such as 
breakfast cereals and breads may differ between countries (Foster-Powell et al 2002). 
Moreover, big variations in GI may arise due to differences in origin or variety of a food. 
For example, the published GI values of rice range from 45-112 (Foster-Powell et al 2002). 
In assigning a GI value for rice, the closest corresponding variety was chosen if this was 
known, or else, the mean GI of several tested rice varieties was assigned in order to reduce 
variability. Another factor which may affect GI variability is that GI testing is done by 
different centres (Brand-Miller & Holt 2004), although in an interlaboratory study of four 
foods, GI values did not vary significantly between different centres (Wolever et al. 
2003a). In this thesis, in order to improve the accuracy of GI calculations, subjects were 
asked to provide detailed information on the preparation methods and rice variety. In 
future studies, more information should be collected on food preparation and addition of 
fats, cooling and re-heating of foods, brand names of products such as bread, ripeness of 
fruit and any other factors which are known to affect a food's GI, aiming to increase the 
precision of assigned GI values. Even so, it is expected that some variation between foods 
will always exist as occurs for macro and micronutrients. 
Approximately 20-30% of CHO was assigned an estimated GI value. In comparison to 
this, a study reporting on the accuracy of GI calculations from 24-hour dietary recalls 
(Olendzki et al. 2006) found that 22.4% of CHO used in GI calculations could be directly 
matched to published values, while the rest was either closely matched by breaking down 
the foods to ingredients or assigned an average GI value for the group of foods (e. g. 
cookies). A direct comparison to the investigations in this thesis is difficult, since the 
methodology used was different, but the study confn-ms that assigning GI values is not an 
exact science at present. In another study also calculating GI values from 24-hour recalls, 
44% of foods were assigned a GI value from published sources, 33% of foods were best 
matched and 23% of foods' GI values were estimated (Davis et al. 2004). This study did 
not report the percentage of CHO for which a GI value was estimated. 
The fact that a considerable amount of foods need to be assigned an estimated GI value has 
several implications. Firstly, it emphasises the need of further testing and publication of 
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GI values (especially of UK products) to increase the accuracy of diet GI calculations. 
Foods that are of particular interest are potatoes, cooked using a variety of methods, and 
confectionary. Although it is probably impossible to know the GI of every available 
product, recent work has assigned GI values to some commercially available products 
(Henry et al 2005) and this has added to the accuracy of GI calculations in this thesis. It is 
also encouraging that since the GI calculations were done, a few new publications of GI 
values have been made available (Aston et al. 2007; Henry et al. 2007). In order to allow 
direct comparison of diet GI between studies, it is important that the same GI values are 
used in estimations and this may be achieved by publication of estimated GI values. 
The methodology employed for diet GI calculation in this thesis is nevertheless far more 
accurate than that used in epidemiological research where calculation of diet GI is based on 
assigning a GI value (either published or estimated) to a group of similar foods (rather than 
individual foods) then multiplying this by the CHO content of the portion consumed 
(which is an estimation) and then dividing it by the total CHO consumed (which is also an 
estimation) (Liu et al 2001; Salmeron et al 1997a). This shows that direct comparison of 
GI values reported in intervention studies and epidemiological studies may not be accurate. 
6.3 Future Work 
In Chapter 4, a high fat meal was provided with the intention of assessing postprandial lipid 
metabolism before and after diet GI manipulation. This analysis will be carried out in the 
future when all the data is collected. Postprandial hypertriglyceridaernia, resulting from 
accumulation of both hepatically derived (i. e. endogenous) triacylglycerol-rich lipoproteins 
(TRL) (VLDL and LDL) and intestinally derived (i. e. exogenous) ones (chylomicrons and 
remnants), might reveal a state of fat intolerance linked to an elevated CHD risk which 
cannot be detected by measurement of fasting plasma TG (Karpe 1999). Previous studies 
showed that postprandial accumulation of TRL positively correlates with visceral obesity 
and plasma insulin concentrations while the amplitude of postprandial lipaernia may 
correlate with the severity of insulin resistance (Couillard et al. 1998; Jeppesen et al. 1995; 
Mekki et al. 1999). The postprandial increase in plasma TG concentration is 
predominantly due to exogenous (apoB-48) TRL (Cohn et al. 1993). Harbis et al (2001) 
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measured glucose, insulin and TRL concentrations after providing meals of different GIs 
and found a strong positive correlation during the 6-hour postprandial period between 
apoB-48 concentration and plasma insulin concentration. In a later study, the same 
investigators showed that LGI meals reduce the postprandial accumulation of both 
hepatically and intestinally derived TRL in obese, insulin-resistant subjects (Harbis et al 
2004). 
It is hypothesised that a LGI diet will lead to a faster clearance of TRL, particularly of 
intestinal origin, and a reduction in postprandial FFA concentrations through improvements 
in visceral fat accumulation and insulin resistance. Measuring the effect of diet GI 
manipulation on postprandial lipid and lipoprotein concentrations would provide an 
understanding of the effect of this dietary change on postprandial metabolism and draw a 
clearer picture of the mechanisms linking lipoprotein metabolism, insulin resistance and 
reduced arterial compliance. 
In Chapter 5, measurement of gut peptides in the fasted and postprandial states such as the 
anorexigenic PYY3-36 and the orexigenic ghrelin, would provide an objective assessment of 
appetite and an insight into any mechanisms linking diet GI and appetite. Both PYY3-36 
and ghrelin are implicated in meal-time hunger and meal initiation and ultimately energy 
balance (Cummings & Shannon 2003). The effect of weight loss on PYY concentrations is 
still under investigation. In obese adults, weight loss caused a reduction in fasting PYY 
concentrations (Pfluger et al. 2006) while gastric bypass surgery caused postprandial PYY 
concentrations to rise which may partly mediate the weight loss effects of this surgery 
(Chan et al. 2006). It may be that the changes in PYY concentrations are determined by 
the way (i. e. dietary, exercise, surgical), weight loss is achieved. Caloric restriction and 
weight loss, led to a significant increase in plasma ghrelin concentrations which was 
positively correlated with the extent of weight loss (Cummings et al 2002; Hansen et al. 
2002) suggesting a mechanism for the rebound weight gain following dieting. There are 
suggestions that a low-fat, high-CHO diet might cause weight loss without affecting 
ghrelin concentrations (Monteleone et al. 2003; Weigle et al. 2003). Interestingly, it has 
also been shown that ghrelin concentrations fall rapidly and dose-dependently to CHO 
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intake (Blom et al. 2005). Nevertheless, the effect of diet GI manipulation on either of 
these peptides has not been explored up to now and would be valuable to do so in the 
future. It may be that the reduction in energy intake in the LGI group seen in Chapter 5 
was a result of changes in fasting and postprandial release of anorexigenic and orexigenic 
gut peptides. This could be studied by a comparison of the gut peptide concentrations 
before and after manipulating diet GI. 
Another issue for future consideration is the way of assessing insulin sensitivity, which is 
central in the effects of a LGI diet on CHD risk factors. The study in Chapter 4, assessed 
many CHD risk factors but did not employ a gold standard methodology e. g. 
hyperinsulinaemic-euglycaemic or hyperglycaernic clamp to measure insulin sensitivity. 
The multi-centre study by Reading, Imperial, Surrey, Cambridge and Kings (RISCK), uses 
the intravenous glucose tolerance test to assess insulin sensitivity, and is investigating the 
effect of altering the type and amount of fat and CHO by four dietary interventions (low fat 
high GI, low fat low GI, high MUFA high GI and high MUFA low GI) on a number of 
CVD risk factors in individuals at high risk of CVD. 
In a future dietary GI intervention study blood samples for genetic assessment aiming to 
identify gene-nutrient interactions, could be collected. Nutrigenomics, a newly emerging 
scientific area, enables understanding of discrepancies in individual responses to dietary 
changes and disease outcomes (Trujillo et al. 2006). For example, the DiOGenes program 
(Diet, Obesity and Genes), a multi-centre, randomised, 6-12 month research program 
focusing on the whole family, is being carried out across Europe and aims to determine the 
efficacy of altering GI and protein intake on preventing weight gain and re-gain (Saris & 
Harper 2005). Genetic variation and gene expression in adipose tissue will be studied to 
try to identify how different genes affect the individual's response to dietary intervention. 
Lastly, the investigations in this thesis aimed at reducing CHD risks and maintaining body 
weight and evaluation was carried out for a period of 3-6 months. A future project may 
address the issue of a longer follow-up period to provide information on whether dietary 
changes can be maintained and measure on one hand changes in variables and on the other 
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hand disease occurrence, to establish whether improvement in risk factors actually 
translated in disease prevention. Two examples of projects where dietary changes were 
seen to translate to improvement in disease outcome are the Trials of Hypertension 
Prevention (Cook et al. 2007) and the Diabetes Prevention Program (Hamman et al. 2006) 
which assessed the efficacy of interventions on CVD and diabetes development 
respectively. 
6.4 Contribution of this Thesis to Research in the 
Field 
This project has contributed to the field of GI research in a number of ways. It has 
provided the results of the first study assessing the effect of GI manipulation on arterial 
compliance and 24-hour BP. Previous diet GI intervention studies only assessed BP by a 
sphygmomanometer at a hospital or research centre (Ebbeling et al 2005; Maki et al 2007; 
Sloth et al 2004) but none carried out a 24-hour assessment. Also, this thesis provided the 
first direct comparison of HGI and LGI diets for weight maintenance. Additionally, this 
thesis added to previous evidence in Type 11 diabetic subjects and in healthy young adults 
(Brynes et al 2003b; Brynes et al 2005), that a LGI diet leads to reductions in 24-hour and 
overnight glucose profiles. Furthermore, work in this thesis provided evidence that diet GI 
can be manipulated in free-living subjects and a LGI diet can be consumed over a 4-6 
month period. In Chapters 4 and 5, the 3-hour and 6 -hour postprandial metabolic 
assessments provided insights into the medium to long term effect of diet GI manipulation 
on postprandial glucose and insulin concentrations. 
Additionally, this work contributed to the establishment of a standardised methodology at 
the Hammersmith Hospital for assigning GI values and sources of GI calculations and 
standardisation of mixed-meat calculation using recipes. 
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Appendix 1: Prescreening Questionnaire 
Name: 
Gender: 
Date of Birth: 
Ethnicity: 
Telephone Number: 
Address: 
GP name & address: 
Weight: 
Height: 
Please list all health problems that you have - past and present: 
Please list any medicines you are taking at the moment: 
If you are female, are you pregnant or is there any chance you may be pregnant? 
Are you participating in any other research study? 
Are you a blood donor? 
Do you have high blood cholesterol? 
Do you have high blood pressure9 
Do you smoke? 
Which days and dates would you be available for about one hour visit? 
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DIETARY RFCORD 
(]-day example) 
NAME: 
DATE: 
This record is designed to obtain accurate information about 
the type and quantity of food that you eat. 
Please read the instructions carefully before completing the 
Food Record. 
Please complete this record three days before seeing the 
dietitian, one of which should be a weekend day i. e. 
Saturday or Sunday. 
Please return to: Elena Philippou 
Nutrition & Dietetic Department 
Hammersmith Hospital 
Du Cane Road 
LONDON W12 OHS 
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FOODRECORD 
Read through these instructions carefully once or twice before you start. 
We would like you to record, as accurately as possible, what you eat and 
drink for 3 days, one of which should be a weekend day (Saturday/Sunday). 
Please record ALL food and drink consumed. Record at the time of eating 
and NOT from memory at the end of the day. Keep this record sheet with 
you throughout the day. 
You should include all meals and snacks, plus sweets, drinks etc. When 
recording food eaten at meals, please include any sauces, dressing or extras 
eg: gravy, salad dressing, pickles, as well as the main food. 
If you do not eat a particular meal or snack simply draw a line across the page 
at this point. 
Guidelines for describina food & drink: 
1. Please give details of method of cooking eg: grilled, boiled, roasted. 
2. Give as many details as possible about the type of food you eat: 
a) State brand name where applicable 
eg: 'Princes' sardines in tomato sauce OR 
'Sainsburys'half-fat Edam cheese. 
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b) Name the type of biscuit, cake or cereal 
eg: Rich Tea, Madeira, Branflakes. 
c) Name the type of cheese, fish or meat 
eg: Cheshire cheese, haddock fillet, pork chop. 
3. Suggestions for recording quantity of food and drink: 
a) For many foods such as vegetables, cereals and some fruit a household 
measure is adequate, state the number of teaspoons (tsp) or tablespoons 
(tbsp) or cups, and whether concentration, rounded or heaped. 
Level 
Rounded 
Heaped 
b) All convenience foods have their weight on the packaging and this can 
be quoted 
eg: 150g carton Ski raspberry yoghurt OR 
1/2 15 oz can baked beans. 
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c) Bread, fruit loaves etc. Indicate the size of the loaf and the thickness of 
the slice 
eg: 1 thick slice granary bread, small loaf 
d) Cheese, fish, meat. When possible, please weigh your portions of these 
foods. Otherwise describe as well as you can. 
eg: 2 large thin slices ham OR 
2 small lamb chops (no fat eaten) OR 
Medium fillet of cod grilled with 1 tsp flora OR 
Cube of cheddar cheese the size of a matchbox. 
Remember to include everything you eat and drink including snacks and 
nibbles. 
Please do not change what you normally eat just because you are filling in this 
record - Be Honest! 
THANK YOU VERY MUCH FOR YOUR HELP 
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DIETARY RECORD SHEET - EXAMPLE 
Record ALL food and drink consumed during the day including snacks, 
nibbles, sauces and dressings. 
Record method of cooking, type and quantity of food 
eg: 6 tbsp boiled wholemeal spaghetti 
2 egg sized roast potatoes. 
DAY: ExaMple DATE: 1 st June 2003 
MEAL/ QUANTITY DETAILS OF FOOD & Leave 
SNACK EATEN DRINK Blank 
Early 1 cup (200ml) Tea with 
Morning 2 concentration Skimmed milk 
tbsp 
Breakfast 3 heaped tbsp Branflakes (Kellogg's) 
I handful Raisins 
1/4pint Skimmed milk for cereal 
1 medium slice Wholemeal toast (large loaf) 
1 rounded tsp Flora light margarine 
During I mug (large- Coffee with 
Morning 300ml) Skimmed milk 
2 concentration Apple (eaten with skin) 
tbsp 
1 medium 
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Midday 2 medium slices Sandwiches: 
2 concentration Wholemeal bread (Allinsons) 
tsp large loaf, sliced 
4 wafer thin slices Flora light margarine 
1/2 small Ham, smoked, prepackaged 
4 leaves (no fat) 
3 thin slices Tomato, sliced 
I large Cucumber 
I can (330ml) Banana 
Diet Coke 
During I glass (200ml) Low Calorie squash made with 
Afternoon made with 30ml concentrated squash 
25g pkt KP roasted salted peanuts 
Evening I medium sized Chicken breast, no fat, no skin, 
Meal I apple sized grilled 
I concentration Jacket potato, eaten with skin 
tbsp Butter, spreadable 
3 florets Broccoli, boiled 
1 heaped tbsp Carrots, old, boiled 
Ix 150g tub Low fat raspberry yoghurt 
I glass (1/2 pint) Orange juice, unsweetened 
I cup (200ml) Tea with 
2 concentration Skimmed milk 
tbsp 
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During 2 Digestive biscuits, plain 
Evening 1 small mug coffee, decaffeinated 
(200ml) skimmed milk 
2 tbsp 
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DAY 1: DATE: 
MEAL/ 
SNACK 
QUANTITY 
EATEN 
DETAILS OF FOOD & 
DRINK 
Leave 
Blank 
Early 
Morning 
Breakfast 
During 
Morning 
Midday 
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DAY 1: DATE: 
MEAL/ QUANTITY DETAILS OF FOOD & Leave 
SNACK EATEN DRINK Blank 
During 
Afternoon 
Evening 
Meal 
During 
Evening 
Bedtime 
Snack 
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LOW GLYCAEMIC INDEX 
Ensure you have one of the following foods with each of Your meals: 
BREAKFAST 
Porridge, All-Bran, Muesli, Sultana bran 
Fruit 
Yoghurt 
Pumpernickel bread, wholegrain (granary) bread, 
bread with bits (grains/seeds), brown pitta bread 
A void. - Corqflakes, Brai? 17akes, Weelabix, Rice Krispic-ýV, 
Pqffed wheat, White bread, Wholemeal bread, French 
bread 
SNACKS 
Fruit 
Salted popcom 
Muesli bars 
Dried fi7uit and unsalted nuts 
A void. - Biscuits and cakes 
Melon, watermelon, pineapple, dates, raisins 
LUNCH & SUPPER 
Sandwich using the bread alternatives above 
Baked beans, other beans & lentils 
Pasta, noodles 
Basmati rice (not easy cook), rice mixed with peas, 
wild rice 
Split pea soup, lentil soup 
Lasagne 
New or waxy potatoes, sweet potato 
Yam, plantain 
Bulgur wheat, barley 
Avoid: Baked, mashed or fried potatoes and rice other 
than shown above 
DESSERTS 
Fruit compote 
Fruit crumble and custard 
Baked apples and custard 
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HIGH GLYCAEMIC INDEX 
Ensure you have one of the following foods with each of your meals: 
BREAKFAST 
Wholemeal or white bread, French bread, 
crumpets, bagel 
Cornflakes, Branflakes, Weetabix, Coco-Pops, 
Rice Krispies, Puffed wheat 
A void: 
Porridge, muesli, All Bran 
Bread with bits (granarylseeded), ge bread, 
pitta bread 
SNACKS 
Water biscuits, Rice cakes, ryvita 
Pretzels 
Watermelon, melon, pineapple, canned apricot, 
dates, raisins 
A voi& 
Oatcakes and other fi-uit 
Biscuits and cakes 
Nuts and dried fi-uit 
-moo 
F, 
mWow-' "I 
7ilb 
LUNCH & SUPPER 
Wholemeal/ white bread sandwich 
Bagels 
Potatoes (mashed, roasted, baked) 
Jasmine rice, arborio (risotto) rice, 
pudding rice, overcooked 'fluffy rice' 
Cous cous 
A void: 
Pasta, noodles, basmati 
m icrowave- cooked rice 
Beans and lentils 
Newpotatoes 
rice, brown rice or 
DESSERTS 
Tapioca pudding 
Bread and butter pudding 
Waffles 
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BAECKE QUESTIONNAIRE 
NAME: 
1. What is your main occupation? 
2. At work I sit.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
3. At work I stand.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
4. At work I walk.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
5. At work I lift heavy loads.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
6. After work I am tired.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
7. At work I sweat.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
8. In comparison with others of my own age I think my work is physically.... 
much lighter lighter as heavy heavier much heavier 
9. Do you play sport? YES NO 
If yes: 
Which sport do you play most frequently? 
How many hours a week? <1 / 1-2 / 2-3 / 3-4 / >4 
How many months a year? >1 / 1-3 / 4-6 / 7-9 / >9 
If you play a second sport: 
Which sport is it? 
How many hours a week? <1/1-2/2-3/3-4/>4 
How many months a year? >1/1-3/4-6/7-9/>9 
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10. In comparison with others of your own age I think my activity during leisure 
time is.... 
much less less the same more much more 
11. During leisure time I sweat.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
12. During leisure time I play sport.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
13. During leisure time I watch television.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
14. During leisure time I walk.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
15. During leisure time I cycle.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
16. How many minutes per day do you walk and/or cycle to and from work, 
school, shopping? 
<5 / 5-15 / 15-30 / 30-45 / >45 
17. During leisure time I do do-it-yourself activities.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
18. During leisure time I work in the garden.... 
NEVER SELDOM SOMETIMES OFTEN ALWAYS 
19. How many hours per day do you sleep on average? 
<5 /6/7/8/ >9 
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VISUA 
ANA OGUE 
SCA ES 
(I-DAYEX4MPLE) 
NAME 
SUBJECT No: 
DATE: 
281 
Appendix 5: Visual Analogue Scales 
Day 1 
DATE TO FILL .................... WITEN GET UP TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
IIIIIIIII ýý 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
IIIIIIiIIII 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTHING A LARGE AMOUNT 
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Day 1 
DATE TO FILL .................... BEFORE BREAKFAST TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT 13E TO EAT RIGHT NOW? 
IIIIIII i---T---- I 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTHNG A LARGE AMOUNT 
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Day 1 
DATE TO FILL .................... AVrER BREAKFAST TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
IIIIIII-III 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
IIIIIIII113 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
IIIIII-I 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTHING A LARGE AMOUNT 
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Day 1 
DATE TO FILL .................... BEFORE LUNCH TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
IIIIIII -- II 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
IIIIIIIII ýý 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTI-DNG A LARGE AMOUNT 
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Day I 
DATE TO FILL .................... AVrER LUNCH TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
IIiIIIIIII 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
IIIIiIIIII 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTIUNG A LARGE AMOUNT 
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Day I 
DATE TO FILL .................... BEFORE EVENING MEAL TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
I r----- I--IIII ýý 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
IIIIIIIII:: ýý 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTHING A LARGE AMOUNT 
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Day 1 
DATE TO FILL .................... AFlrER EVENING MEAT, TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
NOT AT ALL HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
EXTREMELY HUNGRY 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTBING A LARGE AMOUNT 
288 
Appendix 5: Visual Analogue Scales 
Day I 
DATE TO FILL .................... .1 
1/2 TIOURS AFrER EVENING MEAL 
HOW HUNGRY DID YOU FEEL TODAY? 
NOT AT ALL HUNGRY 
HOW FULL DID YOU FEEL TODAY? 
NOT AT ALL FULL 
EXTREMELY HUNGRY 
EXTREMELY FULL 
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Day I 
DATE TO FILL .................... BEFORE GOING TO BED TIME ............ 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
NOT AT ALL HUNGRY EXTREMELY HUNGRY 
HOW FULL DO YOU FEEL RIGHT NOW? 
NOT AT ALL FULL EXTREMELY FULL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
NOT AT ALL PLEASANT EXTREMELY PLEASANT 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTHNG A LARGE AMOUNT 
290 
Appendix 6: Chapter 3 Study Information Sheet 
Information Sheet for Research Participants 
You will be given a copy of this Information Sheet 
Study of the effect of slowly absorbed starchy foods (low glycaemic index) on blood 
glucose, insulin, lipids and gut hormones in healthy volunteers at risk of heart disease 
We would like to invite you to participate in a research project. You should not take part 
in the study if you do not wish to do so. If you do decide to take part, please let us know 
beforehand if you have been involved in any other study during the last year. You are free 
to withdraw at any time without explanation and your subsequent treatment will not be 
affected. 
We will be happy to let you have a copy of the leaflet entitled 'Medical Research and You' 
published by Consumers for Ethics in Research (CERES). This leaflet gives more 
information about medical research and looks at some questions you may want to ask. 
What is the purpose of the study? 
We are hoping to find a way through diet to prevent heart problems in currently healthy 
people. From studies we carried out in the past we believe that slowly absorbed (low 
glycaemic index) starchy foods can affect blood fat concentrations, insulin and glucose 
concentrations reducing the possibility of having heart disease. Low glycaemic starch 
may also affect the hormones produced by the gut before and after eating. We hope this 
study will give an indication of the importance of starchy foods in helping to reduce the 
risk of heart disease in people without any current heart problems. 
Why have I been chosen? 
We have asked you to take part in this study because we are keen to discover more about 
the effects of a low glycaemic diet on blood fat concentrations, insulin, glucose and gut 
hormones in healthy people. We recently did a similar study in people with previous 
coronary heart disease and found that the cholesterol lowering drugs that these people were 
on, masked the effects of the diet. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
What wiH happen to me if I take part? 
Should you decide to take part you will be randomised to follow one of two diets for 12 
weeks. This means that the computer will decide by chance which diet to follow and you 
will not have a choice. One of the diets is based on healthy eating which consists of low 
fat foods and eating more starchy foods, and the other is a combination of healthy eating 
and slowly absorbed (low glycaemic index) starch. 
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At the first appointment you will undergo a medical examination, the study will be 
explained to you and you will be asked to consent to the study. You will be given at least 
24 hours to think about this. If you decide you want to go ahead with the study you will be 
asked to fill in a record of what you eat for 7 days. 
Once this is completed we will ask you to return to the hospital to fit a monitor under your 
skin in your tummy area which can sense blood sugar every five minutes for 3 days. This 
allows us to determine closely the effect of the diet on your blood sugar when you are at 
home. In order to make sure the monitor is working correctly, we will need to do a few 
finger pricks after the monitor is fitted. We will also ask you to do four finger pricks 
every 24 hours over the 3 days that you will be wearing the monitor. During these three 
days, you should refrain from drinking any alcohol. You will be asked to come back after 
three days to remove the monitor. 
On the first day of the first week of the study, you will need to come in the morning after 
an overnight fast i. e. not eating or drinking anything other than water after 9: 00 pm. You 
should also refrain from drinking any alcohol and undertaking strenuous exercise 24 hours 
before. We will measure your weight, height and waist circumference. Your body fat will 
be measured by a machine which passes a small electric current through the body. From 
resistance to this current, the machine can work out body fat. This is a non-invasive 
method and without any radiation. 
The doctor will then insert a plastic cannula into your arm to enable us to collect blood 
samples. You may feel a little discomfort when the cannula is inserted. Three fasting 
blood samples will be taken to measure your blood sugar, insulin and lipids. You will then 
be given a meal and blood samples will be taken periodically for 3 hours after the meal. 
The total amount of blood taken on each study day is approximately II Omls, which is 
about a fifth of the amount taken during a normal blood donation. During this time, you 
can relax by reading or watching TV. The same tests will be repeated once at the end of 
the trial for comparison. 
You will then be told which diet to follow as chosen by the computer and you will be given 
advice and practical tips on how to follow the diet by a dietitian. The dietitian will phone 
you at week 3 and week 9 to see how you are getting on with your diet. We will ask you to 
keep a 7-day record of what you eat on Week 5 and Week 11 (i. e. the weeks before you 
come back to the hospital). 
We will ask you to come back to the hospital on week 6 after fasting and avoiding alcohol 
and exercise as on Week 1. We will again measure your weight, waist circumference and 
your body fat. We will take one 10 ml blood sample to check the concentrations of blood 
sugar, insulin and lipids. 
On Week 12, you should come in again fasted and after avoiding alcohol and exercise for 
24 hours before. We will repeat the same measurements as Week I to check the effect of 
the diet. We will place the glucose monitor under your skin again for 3 days, during which 
you should avoid alcohol consumption. 
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Your travel expenses will be reimbursed. 
What do I have to do? 
If you decide to take part, you would have to attend the hospital for blood tests as 
explained before. The days before the blood tests (Weeks 1,6 and 12) you should refrain 
from drinking any alcohol and strenuous exercise. While you are wearing the glucose 
monitor you should also refrain from drinking any alcohol. 
During the study, you will be asked to follow the diet that the computer chose for you. The 
dietitian will give you advice on this and if you are overweight on how to reduce your 
weight. The diet will either based on healthy eating which means eating low fat foods and 
more of starchy foods or a combination of healthy eating and slowly absorbed starchy 
foods (this is called a low glycaemic index diet). Foods with a low glycaemic index are 
pasta, granary bread, beans and fruit. All food used in the study can be purchased from 
any supermarket, and we will also provide you with a slowly absorbed bread to replace 
your normal bread. 
In order for us to assess your diet, you will asked to keep a 7-day food diary on Weeks 5 
and II and provide your supermarket/shop receipts and empty food packages and food 
labels. 
What is the drug or procedure that is being tested? 
We are testing the effect of a slowly absorbed starch diet followed for 12 weeks on certain 
factors that we know increase the possibility of heart disease like blood sugar, insulin and 
blood lipids. We also want to test the effect of this diet on hormones that are produced 
naturally in the body before and after eating. 
Are there any risks in taking part? 
There are no risks other than a small amount of discomfort when the plastic tube is placed 
in your arm for taking blood at the beginning and end of the study. This will be placed by 
a doctor. We will also take a single blood sample at the screening visit and in the middle 
of the study. You may have a small amount of discomfort when the glucose monitor is 
placed. 
What are the possible benefits of taking part? 
We hope that the information from this study will help to find the best advice for 
preventing heart problems in healthy people. 
What happens when the research study stops? 
We will give all people who took part in the study a copy of the results. 
What if something goes wrong? 
In the event of your suffering any adverse effects as a consequence of your participation in 
this study, you will be compensated through the Imperial College School of Medicine's 
"No Fault" Compensation Scheme. 
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Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. We will seek 
your permission to tell your GP about the study at the end of the research project. 
What will happen to the results of the research study? 
The results of the study will be published in a peer-reviewed journal. In addition they will 
be available to everyone who took part in the study within six months of the study 
finishing. Individuals will not be identified in any report/publication. 
Who is organising and funding the research? 
The research is organised by the Department of Nutrition and Dietetics. 
Who has reviewed the study? 
The Hammersmith Hospitals Trust Research Ethics Committee has reviewed the study. 
Contact for Further Information 
If you wish to talk the study through or wish to raise a concern please write or ring Dr 
Gary Frost or Dr Audrey Brynes at the Department of Nutrition & Dietetics, 
Hammersmith Hospital, Du Cane Road, London W12 OHS. Telephone 020 8383 3048. 
Thank you for volunteering to take part in this study! 
Volunteers will be given a patient information sheet and a signed consent form to keep. 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL 2007 
Signed (REC Chairman) Date 
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Participant Consent Form 
Title of Proiect: 
Study of the effect of slowly absorbed starchy foods (low glycaemic index) on blood glucose, 
insulin, lipids and gut hormones in healthy volunteers at risk of heart disease 
The participant should complete the whole of this sheet him or herselE 
(please tick each statement if it applies to you) 
I have read the Information Sheet for Patients and 
Volunteers Health . y 
I have been given the opportunity to ask questions and 
discuss this study. 
I have received satisfactory answers to all my questions. 
I have received enough information about the study. 
The study has been explained to me by: 
Prof/Dr/Mr/Mrs/Ms 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting my future medical care. 
I agree to take part in this study. 
SignecL ................................................................................ 
Date ................................. 
(NAME IN BLOCK 
CAPITALS) .............................................................................................................. 
Investigator's signature ....................................................... 
Date: .............................. 
(NAME IN BLOCK 
CAPITALS) .............................................................................................................. 
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Information Sheet for Research Participants 
You will be given a copy of this Information Sheet 
The effect of a 6-month low glycaemic index diet on arterial compliance, blood 
pressure and postprandial metabolic and gut hormone response in middle aged men 
at risk of heart disease 
We would like to invite you to participate in a research project. You should not take part 
in the study if you do not wish to do so. If you do decide to take part, please let us know 
beforehand if you have been involved in any other study during the last year. You are free 
to withdraw at any time without explanation and your subsequent treatment will not be 
affected. 
We will be happy to let you have a copy of the leaflet entitled 'Medical Research and You' 
published by Consumers for Ethics in Research (CERES). This leaflet gives more 
information about medical research and looks at some questions you may want to ask. 
What is the purpose of the study? 
We are hoping to find a way through diet to prevent heart problems in currently healthy 
people. From studies we carried out in the past we believe that low glycaemic index foods 
i. e. slowly absorbed foods can affect blood fat concentrations and insulin and glucose 
concentrations, reducing the possibility of having heart disease. Low glycaemic index 
foods may also affect the hormones produced by the gut before and after eating. We are 
also interested to find out if this type of starch has any effect on blood pressure and the 
stiffness of arteries. Stiffer (less elastic) arteries are associated with ageing, high blood 
pressure and a greater strain on the heart. We hope this study will show if some diets are 
better for the heart than others. 
Why have I been chosen? 
We have approached you to take part in this study because you are healthy but have some 
risks for heart disease. We are keen to discover more about the effects of low glycaemic 
index foods on the stiffness of arteries (blood vessels), blood pressure, blood fat 
concentrations, insulin, glucose and gut hormones in healthy people. We recently did a 
similar study in people with previous coronary heart disease and found that the cholesterol 
lowering drugs that these people were on, masked the effects of the diet. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
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What wiH happen to me if I take part? 
Should you decide to take part you will be randomised to follow one of two diets for 6 
months. This means that the computer will decide by chance which diet to follow and you 
will not have a choice. One of the diets is based on healthy eating which consists of low 
fat foods and eating more starchy foods, and the other is a combination of healthy eating 
and slowly absorbed (low glycaemic index) foods. We will also provide you with three 
bread rolls a day to eat. 
At the first appointment you will undergo a medical examination, a blood test and a breath 
test. The latter involves breathing into a small plastic tube for a few seconds to measure 
the amount of hydrogen (a gas) in your breath. The study will be explained to you and you 
will be asked to consent to the study. You will be given at least 24 hours to think about 
this. If you decide you want to go ahead with the study you will be asked to fill in a record 
of what you eat for 7 days. 
If you are fit to take part, you will need to attend the hospital ten times over a6 month 
period. 
At the beginning of the study, you will need to come in to the hospital using the same 
method of transport each time so that the conditions under which the tests are done are 
constant. You should avoid alcohol and exercise for 24 hours before your appointment. 
We will perform arterial compliance tests, which cause no discomfort, to determine the 
elasticity of your arteries. This involves 2 measurements: (1) To check the stiffness of the 
central arteries in the body, (2) To check the stiffness of the arteries in the arms and legs. 
The first will be measured using a hand held plastic probe placed on the skin of your wrist 
and a probe placed on the skin on the side of the neck. This procedure will take 
approximately 10 minutes. The second will be measured using a probe placed on the skin 
on the side of the neck and the groin. This procedure will take approximately 20 minutes. 
Neither test uses needles or is painful, although a slight pressure may be felt at the site of 
the probes. An ECG will be performed to record how healthy your heart is. 
On the same day, we will also ask you to wear a blood pressure monitor for 24 hours. This 
will record blood pressures at 30-minute intervals during the day and at 60 minute intervals 
during the night. This process is not painful. The machine will also give information 
about your arteries at the same time. 
A day after, you will be asked to attend for approximately a 7-hr visit. You will need to 
come in the morning after an overnight fast i. e. not eating or drinking anything other than 
water for 12 hours before your appointment time. You should also refrain from drinking 
any alcohol and undertaking strenuous exercise 24 hours before. We will measure your 
weight, height and waist circumference. Your body fat will be measured by a machine 
which passes a small electric current through the body. From resistance to this current, the 
machine can work out body fat. This is a non-invasive method and without any radiation. 
We will also repeat the breath test. 
297 
Appendix 7: Chapter 4 Study Information Sheet 
A trained doctor, nurse or dietitian will then insert a plastic cannulae into your arm to 
enable us to collect blood samples. You may feel a little discomfort when the cannulae is 
inserted. Three fasting blood samples will be taken to measure your blood sugar, insulin 
and lipids. You will then be given a meal and blood samples will be taken periodically for 
6 hours after the meal. The total amount of blood taken on this study day is approximately 
110mls, which is about a fifth of the amount taken during a normal blood donation. 
During this time, you can relax by reading or watching TV. The same tests will be 
repeated once at the end of the trial for comparison. 
You will then be told which diet to follow as chosen by the computer and you will be given 
advice and practical tips on how to follow the diet by a dietitian. You will be asked to 
attend the hospital every month to see the dietitian to discuss your progress and set ftirther 
dietary targets. Your weight and waist circumference will be recorded on each visit and 
your body fat will be measured as before on months 3 and 6 of the study. Breath 
measurements will be taken at each visit to check compliance to the diet. You will be 
asked to keep a 3-day record of what you eat before each visit. These will be collected and 
analysed. You will be also asked to return the empty packages of the bread rolls provided. 
Three months after the beginning of the study, we will repeat the arterial compliance 
measurements and ECG. We will also take a blood sample to measure your blood fat 
concentrations, glucose, insulin and some hormones that affect appetite. You should not 
eat or drink anything other than water for 12 hours before your appointment and avoid 
alcohol and exercise for 24 hours before. 
On month 6, in addition to the measurements done on month 3, we will also fit the blood 
pressure monitor in the same way as at the beginning of the study. We will ask you to 
come back two days later in the morning. You should not eat or drink anything other than 
water for 12 hours before your appointment and avoid alcohol and exercise for 24 hours 
before. We will check your body's response to a meal in the same way as at the beginning 
of the study. 
Your travel expenses will be reimbursed. 
What do I have to do? 
If you decide to take part, you would have to attend the hospital ten times as explained 
before. The days before the arterial compliance and blood tests (beginning and months 3 
and 6) you should refrain from drinking any alcohol and strenuous exercise. The days 
before the blood tests you should also not eat or drink anything other than water for 12 
hours before (i. e. overnight). 
During the study, you will be asked to follow the diet that the computer chose for you. The 
dietitian will give you advice on this and on how to lose weight if you are overweight. The 
diet will be based on either healthy eating which means eating low fat foods and more 
starchy foods or a combination of healthy eating and low glycaemic index foods. All 
food used in the study can be purchased from any supermarket, and we will also provide 
you with three bread rolls a day to eat. 
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In order for us to assess your diet, you will be asked to keep a 3-day food diary each month 
before your appointment with the dietitian and provide empty food packages and food 
labels. 
What is the drug or procedure that is being tested? 
We are testing the effect of a slowly absorbed diet followed for 6 months on certain factors 
that we know increase the possibility of heart disease such as arterial compliance, blood 
pressure, blood sugar, insulin and blood lipids. We also want to test the effect of this diet 
on hormones that are produced naturally in the body before and after eating. 
Are there any risks in taking part? 
There are no risks other than a small amount of discomfort when the plastic tube is placed 
in your arm for taking blood at the beginning and end of the study. This will be placed by 
a trained member of staff (doctor, nurse or dietitian). We will also take a single blood 
sample at the screening visit and three months after the beginning of the study. 
What are the possible benefits of taking part? 
We hope that the information from this study will help to find the best advice for 
preventing heart problems in healthy people. 
What happens when the research study stops? 
We will give all people who took part in the study a copy of the results. 
What if something goes wrong? 
In the unlikely event of your suffering any adverse effects as a consequence of your 
participation in this study, you will be compensated through the Imperial College School of 
Medicine's "No Fault" Compensation Scheme. 
Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. We will seek 
your permission to tell your GP about the study at the beginning and end of the research 
project. 
What will happen to the results of the research study? 
The results of the study will be published in a peer-reviewed journal. In addition they will 
be available to everyone who took part in the study within six months of the study 
finishing. Individuals will not be identified in any report/publication. 
Who is organising and funding the research? 
The research is organised by the Department of Nutrition and Dietetics. 
Who has reviewed the study? 
The Hammersmith Hospitals Trust Research Ethics Committee has reviewed the study. 
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Contact for Further Information 
If you wish to talk the study through or wish to raise a concern please write or ring Dr 
Gary Frost or Dr Audrey Brynes at the Department of Nutrition & Dietetics, 
Hammersmith Hospital, Du Cane Road, London W12 OHS. Telephone 020 8383 3048. 
Thank you for volunteering to take part in this study! 
Volunteers will be given a patient information sheet and a signed consent form to keep. 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL: 2008 
Signed (REC Chairman) Date 
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Participant Consent Form 
Title of proiect: 
The effect of a 6-month low glycaemic index diet on arterial compliance, blood 
pressure and postprandial metabolic and gut hormone response in middle aged men 
at risk of heart disease 
The participant should complete the whole of this sheet him or herself. 
(please tick each statement if it applies to you) 
I have read the Information Sheet for Patients and 
Healthy Volunteers. 
I have been given the opportunity to ask questions and 
discuss this study. 
I have received satisfactory answers to all my questions. 
I have received enough information about the study. 
The study has been explained to me by: Elena Philippou 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting my future medical care. 
I agree to take part in this study. 
Signed ................................................................................. 
Date ................................. 
(NAME IN BLOCK 
CAPITALS) .............................................................................................................. 
Investigator's signature ....................................................... 
Date: .............................. 
(NAME IN BLOCK 
CAPITALS) .............................................................................................................. 
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Information Sheet for Research Participants 
You will be given a copy of this Information Sheet 
The effect of low glycaemic diet on four months weight maintenance following a 
two-month weight reduction program in overweight volunteers 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
We will be happy to let you have a copy of the leaflet entitled 'Medical Research and 
You' published by Consumers for Ethics in Research (CERES). This leaflet gives more 
information about medical research and looks at some questions you may want to ask. 
Thank you for reading this. 
What is the purpose of the study? 
Obesity is a very common problem and losing weight can be difficult. Once you have 
lost weight, keeping your weight down successfully is an under-recognized problem. 
This study consists of two stages: a two-month weight reduction program using formula 
drinks and meals (Slimfast) and a four-month weight maintenance program. The total 
time of the study is 6 months. 
Once you have lost weight in the first part of the study, we are interested to test if the 
glycaemic index (GI) of your diet has an effect on how successfully you can keep your 
weight off. Glycaemic Index is simply ranking of the foods according to the 
concentration of the blood sugar after their consumption. 
Why have I been chosen? 
To take part in this study, you need to be overweight and aged between 18 to 65 years 
old. You should not be on any weight loss medication or suffer from any serious disease 
except Type II diabetes. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
302 
Appendix 8: Chapter 5 Study Information Sheet 
What will happen to me if I take part? 
Screening 
If you agree to take part, you will be examined by one of the doctors and have a blood 
test taken. You will be interviewed by a dietitian and you will be asked to complete a 
questionnaire about your activity concentrations. You will also be given a food and 
activity diary to record your food intake as accurately as possible for 7 days. You will be 
asked to fill in a visual analogue scale to record your hunger, appetite and satiety for 3 
days. These should be returned back to the department for analysis to determine your 
current energy and nutrient intake. 
The first part of the study consists of two months weight reduction program. During this 
period, you will be instructed to take formula drinks and meals (Slimfast) in place of 
your normal meals. These will be provided and a dietitian will advise you on the amount 
that you require to lose weight. 
Slimfast is an over the counter formula diet, which is being used for weight reduction. 
You will be asked to come to the department every month for approximately an hour. 
We will measure your weight and waist circumference. Your height will be measured 
only at the beginning of the study. At the start of the study, we will take a 20 ml (i. e. 4 
teaspoonfuls) fasting blood sample to measure your cholesterol, glucose concentrations 
and hormones that affect appetite and body weight. Before this visit you will need to fast 
for 12 hours, drinking only water and avoiding alcohol and vigorous physical activity for 
24 hours beforehand. 
At the start and again after 2 months we will also measure your body fat and fitness 
concentration. Your body fat will be measured by a machine which passes a small 
electric current through the body. From resistance to this current, the machine can work 
out body fat. Your fitness concentration will be measured by a walking test. This 
involves walking a 10 metre distance within a set time interval which becomes 
progressively shorter. All are non-invasive methods. A dietitian will review your 
progress, discuss any problems with you and advise you. 
If you lose at least 5% of your initial weight, you will be eligible to take part in the 
second part of the study. 
The second part of the study consists of four months weight maintenance. You will be 
asked to continue to come to the department every month. Your weight and waist 
circumference will be measured. Also, at month 4 and 6 of the study, we will measure 
your body fat and fitness concentration as before. 
Study visits: 
At the beginning of the weight maintenance part of the study (month 2) and end (month 
6) we will assess your body's response to a meal. Each study day will last approximately 
4 hours. - During these you will sit or lie on a couch or bed and may read or watch 
television. A plastic cannulae will be placed into a vein in one arm to take blood 
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samples. You may feel a little discomfort when the cannulae is inserted. We will take 3 
baseline samples to measure your blood glucose, insulin, lipids, C-reactive protein and 
gut hormones. If you have diabetes, we will also measure your HbAlc, fructosamine and 
C-peptide. After this you will be given a meal. Once you finish eating, we will take 8 
blood samples over a3 hour period to assess your body's response to the meal. 
At your visit during the 4th month of the study we will take one fasting blood sample to 
check the glucose, lipids and some proteins in your blood. If you have diabetes, we will 
repeat the extra tests of HbAlc, fructosamine and C-peptide. 
The total amount of blood taken overall on the study will be approximately 300 ml, this 
is about half the amount taken during a normal blood donation session. 
Before these visits you will need to fast for 12 hours, drinking only water and avoiding 
alcohol and vigorous physical activity for 24 hours beforehand. 
You will be asked to keep a 3-day food diary and 3-day visual analogue scales before 
visits at month 3 and 6 and bring it with you to the visits. 
We will reimburse your travel expenses during the study. 
What do I have to do? 
In the first part of the study (two months), you will need to eat and drink formula meals 
and drinks (Slimfast) in replacement of your normal meals. A dietitian will advise you 
on the amount you need to take, in order to lose weight. You will also be advised on 
increasing your activity concentration for the whole duration of the study. 
The second part of the study is a randomised parallel trial. This means that those taking 
part will be chosen in a matched random way and put into two groups. One group will 
follow a normal glycaemic diet, and the other group will follow a low glycaemic diet. 
The results of these two groups will then be compared. You will be allocated to a group 
by chance by a computer and so have no choice on which group you will be in. 
At the beginning of this part of the study, the dietitian will give you advice on how to 
follow the diet of the group you were randomised to i. e. low glycaemic index or normal 
glycaemic index. You will need to attend the hospital every month for the duration of 
the study to discuss your progress with the dietitian and make any changes if necessary. 
You will need to fill in a 3-day food diary and 3-day visual analogue scales before visits 
at months 3 and 6. For this part, you will have a controlled diet program (including 
alcohol intake) based on how much energy you need to maintain your weight. 
You can continue to take your regular medications while you participate in the study. If 
you become pregnant you will be withdrawn from the study. 
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What is the drug or procedure that is being tested? 
There is no drug prescription here. We will advise you to change your diet to a low or 
normal glycaemic index diet. We are not going to test any new device or technique in 
this study. 
What are the alternatives for diagnosis or treatment? 
In this study we are not going to substitute your diagnosis or treatment procedures with 
other procedures. 
What are the side effects of any treatment received when taking part? 
There are no side effects in this study. In the first part of the study, we expect all 
volunteers to lose weight. 
What are the possible disadvantages and risks of taking part? 
There will be no disadvantage and risks of taking part in this study. You will be asked to 
make some changes to your normal dietary intake to change its glycaemic index. The 
foods used will be the same as those available to the general population. 
What are the possible benefits of taking part? 
We believe that overall, by taking part in this study you will be able to lose weight and 
maintain the weight that you have lost. However, this cannot be guaranteed. The 
information we get from this study may help us treat future overweight patients better. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatment that is being studied. If this happens, your research doctor or dietitian 
will tell you about it and discuss with you whether you want to continue in the study. If 
you decide to withdraw, your research doctor or dietitian will make arrangements for 
your care to continue. If you decide to continue in the study you will be asked to sign an 
updated consent form. Also, on receiving new information your research doctor or 
dietitian might consider it to be in your best interests to withdraw you from the study. 
He/she will explain the reasons and arrange for your care to continue. 
What happens when the research study stops? 
If you wish, you can continue the diet therapy after the study stops under supervision of 
your doctor. If you wish you can obtain a copy of the results of the study about a year 
after the study. All results will be anonymous i. e. no subject will be identified in any 
publication. 
What if something goes wrong? 
In the event of your suffering any adverse effects as a consequence of your participation 
in this study, you will be compensated through the Imperial College School of 
Medicine's "No Fault" Compensation Scheme. 
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Will my taking part in this study be kept confidential? 
All information, which is collected, about you, during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will have 
your mine and address removed so that you cannot be recognised from it. Normally we 
would inform your GP or your medical practitioner of your participation in this study. 
However, if you would prefer us not to inform your GP or medical practitioner, we will 
not do so. 
What will happen to the results of the research study? 
We will interpret the results of the study and they will be published in the journals. The 
results are likely to be published 6 months after the study. You will not be identified in 
any report or publication. 
Who is organising and funding the research? 
This research is organised and funded by the Department of Nutrition and Dietetics, 
Hammersmith Hospital. This study has been reviewed by the Hammersmith, Queen 
Charlotte's & Chelsea and Acton Hospitals Research Ethics Committee. 
Contact for Further Information 
If you need further information about this study you can phone or write to 
Dr Gary Frost or Dr Audrey Brynes at the Department of Nutrition & Dietetics, 
Hammersmith Hospital, Du Cane Road, London W12 OHS. Telephone 020 8383 3048. 
Thank you for your interest in this study, and taking the time to read this. 
Version date 21/07/2004 
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Participant Consent Form 
Title of project: 
The effect of low glycaemic diet on four months weight maintenance following a 
two-month weight reduction program in overweight volunteers 
The participant should complete the whole of this sheet him or herself 
(please tick each statement if it applies to you) 
I have read the Information Sheet for Patients and 
Healthy Volunteers. 
I have been given the opportunity to ask questions and 
discuss this study. 
I have received satisfactory answers to all my questions. 
I have received enough information about the study. 
The study has been explained to me by: Elena Philippou 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting my future medical care. 
I agree to take part in this study. 
Signed ................................................................................. Date ................................. 
(NAME IN BLOCK 
CAPITALS) .............................................................................................................. 
Investigator's signature ....................................................... 
Date: .............................. 
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it, 7.1 1 28.9 2-Sig/day kP-N%i tor OR IoW GI xr, up. 
I'IlVrL inthuta%ting 
41utosL And 111yid profiles livalle., at baýoifli, nor at svcvI, 12. 
(, : 1119( ted CGxfS rvsu Its tor t)dNulirlv and %, t 0,12 %vvre 
Lollettt-d for It kolunivers as fliv Ncn%or failLit iii it%(, 
%OILI I it k CIN, [*IlVrV %N( rV 11(b ddIUtVlltC% tilt tWO 
grillljlý lit OIL CkNIS at tI. ANOUR ifigUn 1 1. 
Rs- sstvk 12, thtý 4, w 0 group had a stgrlifi, aiitlý lower 2-1, li 
AtV Ciio k7.115 81.1-1) %, % SS-11 fg-124 9ft-161mmol 101 
W, 015i and oýcrmght Sit AUC C-121) t2123 2-141 \s 
3WO 12HOS M721mmol-hil W<O. Otl glumse proMe as 
mtj%urttl Ilk ( (; \IS. Ihowe%ur. thert wtru no differcriLv% 
tkt%%uul tilt gnmps whi'n tharigLý trimi bj%thmv in thc 
91LAIIA ; lftlfft', %Vt'rL' C0111141ILLI. 
Discussion 
-1 his 11 :! 'It ItUllý' J111led ill ýMe%l tilt Utfl, I It , ljýjylgif Ig I Ile 
diet GI MI 11L. Art diwas. t. n%k Littors will the 24,1) gILKOW 
jin, filt. in -ýubjvus at risk it( litart t1r-, t aw. Sm(t it is it pilLpt 
St LlLI% , it %it 
I is %h0IIId IV JSNt-%SCd Wit III. Alt it ill. COI )%it It II It! tV It 
of a Im% C1 thet led to a II)%ver 24-h and ~rnight gluwst 
prit, filt, onfirynini; a IFfOlt 1 d.. 2()(Ai. 'This 
migt it suggest all i it II irovt ink I it it II it-patIL II ISU I ill sell ýit 1% 1ts 
r"tiltizig ill a detre-ase iii hupatit glu, ow output tollAming 
invak ClIvOIurn vt at., 100.1i. Wholu Ix3d s ýIutt^& tatillia 
tioll haN lkvfl shown to ifliproNe 11: 1 a low 0 dict as assessed 
by eug I% L acrint A)i, pent isti II nat-mit. damp ifZukafla el it., 
21K)4i. 1"his I% himally rtlcvant as rai%ecl poNtprandi. al 
gl%lilt'F1113 %VOLIIJ imrtaw LardimaslUlar risk even ill the 
11011MI1 gilLILOSA. t(Oltrilght rajliý, ffifto ? Mly tv 
coTltot1fIdc,, 1 hy. other heart discaw fisi, tactort, (Coutinho 
a it.. 10911; Thv DLCODL Study Grttip. 2MI ). (; Iuctse may 
lead III through oxidati%v stress tGugfi. afso 
a. d., 11)(16iand 11011 CIl/yIIIJtILgIl? Ldti0f% Of LDI-holustaul 
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